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A B S T R A C T
Background
Several options exist for managing overactive bladder (OAB), including electrical stimulation (ES) with non-implanted devices, con-
servative treatment and drugs. Electrical stimulation with non-implanted devices aims to inhibit contractions of the detrusor muscle,
potentially reducing urinary frequency and urgency.
Objectives
To assess the effects of ES with non-implanted electrodes for OAB, with or without urgency urinary incontinence, compared with:
placebo or any other active treatment; ES added to another intervention compared with the other intervention alone; different methods
of ES compared with each other.
Search methods
We searched the Cochrane Incontinence Specialised Register, which contains trials identified from the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, ClinicalTrials.gov, WHO ICTRP and handsearching of journals
and conference proceedings (searched 10 December 2015). We searched the reference lists of relevant articles and contacted specialists
in the field. We imposed no language restrictions.
Selection criteria
We included randomised or quasi-randomised controlled trials of ESwith non-implanted devices comparedwith any other treatment for
OAB in adults. Eligible trials included adults with OABwith or without urgency urinary incontinence (UUI). Trials whose participants
had stress urinary incontinence (SUI) were excluded.
Data collection and analysis
Two review authors independently screened search results, extracted data from eligible trials and assessed risk of bias, using the Cochrane
’Risk of bias’ tool.
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Main results
We identified 63 eligible trials (4424 randomised participants). Forty-four trials did not report the primary outcomes of perception of
cure or improvement in OAB. The majority of trials were deemed to be at low or unclear risk of selection and attrition bias and unclear
risk of performance and detection bias. Lack of clarity with regard to risk of bias was largely due to poor reporting.
For perception of improvement in OAB symptoms, moderate-quality evidence indicated that ES was better than pelvic floor muscle
training (PFMT) (risk ratio (RR) 1.60, 95% confidence interval (CI) 1.19 to 2.14; n = 195), drug treatment (RR 1.20, 95% 1.04 to
1.38; n = 439). and placebo or sham treatment (RR 2.26, 95% CI 1.85 to 2.77, n = 677) but it was unclear if ES was more effective
than placebo/sham for urgency urinary incontinence (UUI) (RR 5.03, 95% CI 0.28 to 89.88; n = 242). Drug treatments included
in the trials were oestrogen cream, oxybutynin, propantheline bromide, probanthine, solifenacin succinate, terodiline, tolterodine and
trospium chloride.
Low- or very low-quality evidence suggested no evidence of a difference in perception of improvement of UUI when ES was compared
to PFMT with or without biofeedback.
Low-quality evidence indicated that OAB symptoms were more likely to improve with ES than with no active treatment (RR 1.85,
95% CI 1.34 to 2.55; n = 121).
Low-quality evidence suggested participants receiving ES plus PFMT, compared to those receiving PFMT only, were more than twice
as likely to report improvement in UUI (RR 2.82, 95% CI 1.44 to 5.52; n = 51).
There was inconclusive evidence, which was either low- or very low-quality, for OAB-related quality of life when ES was compared to
no active treatment, placebo/sham or biofeedback-assisted PFMT, or when ES was added to PFMT compared to PFMT-only. There
was very low-quality evidence from a single trial to suggest that ES may be better than PFMT in terms of OAB-related quality of life.
There was a lower risk of adverse effects with ES than tolterodine (RR 0.12, 95% CI 0.05 to 0.27; n = 200) (moderate-quality evidence)
and oxybutynin (RR 0.11, 95% CI 0.01 to 0.84; n = 79) (low-quality evidence).
Due to the very low-quality evidence available, we could not be certain whether there were fewer adverse effects with ES compared to
placebo/sham treatment, magnetic stimulation or solifenacin succinate. We were also very uncertain whether adding ES to PFMT or
to drug therapy resulted in fewer adverse effects than PFMT or drug therapy alone Nor could we tell if there was any difference in risk
of adverse effects between different types of ES.
There was insufficient evidence to determine if one type of ES was more effective than another or if the benefits of ES persisted after
the active treatment period stopped.
Authors’ conclusions
Electrical stimulation shows promise in treating OAB, compared to no active treatment, placebo/sham treatment, PFMT and drug
treatment. It is possible that adding ES to other treatments such as PFMT may be beneficial. However, the low quality of the evidence
base overall means that we cannot have full confidence in these conclusions until adequately powered trials have been carried out,
measuring subjective outcomes and adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Non-invasive electrical stimulation for overactive bladder in adults
Background
People with overactive bladder (OAB) have a frequent and compelling desire to urinate, which has a significant impact on quality of
life. Many people with OAB also have urinary incontinence. OAB affects around 17% of the world’s population and is particularly
common in elderly people. Treatment for OAB includes pelvic floor muscle training, drug therapy and electrical stimulation.
Non-invasive electrical stimulation works by passing an electrical current through the bladder muscles, via a vaginal or anal probe, or
through a fine needle inserted into the tibial nerve around the ankle. The current is intended to reduce (inhibit) contractions of the
detrusor muscle (the bladder muscle which squeezes out urine); this should reduce the number of times a person will need to urinate.
Invasive electrical stimulation involves implanting electrodes within the body and requires a surgical procedure.
Aim
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We investigated whether electrical stimulation was better than no treatment at all or better than any other treatment available for OAB.
We also investigated which type of electrical stimulation was better for OAB and whether or not electrical stimulation was safe.
Results
We identified 63 studies (4424 people altogether) comparing electrical stimulation to no treatment or any other available treatment.
We found that electrical stimulation is probably better than sham electrical stimulation or pelvic floor muscle training at reducing the
main symptoms of OAB.
Electrical stimulation may be better than no active treatment or drug treatment at reducing OAB symptoms but we are less certain
about these results because the available evidence was less reliable.
Similarly, there was not enough evidence to tell if adding electrical stimulation to pelvic floor muscle training or to drug treatment
helped to reduce OAB symptoms. Nor could we tell which type of electrical stimulation was better.
We did not find enough information to know whether or not electrical stimulation was safer than other treatments, or if one type of
electrical stimulation was safer than others.
Many of the studies we identified did not report whether or not the treatment improved OAB symptoms or whether there were any
side effects caused by any of the treatments.
Finally, we could not tell from the evidence whether or not any benefits of electrical stimulation continued after the course of electrical
stimulation stopped.
The evidence in this review is current up to December 2015.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Electrical stimulation versus no active treatment
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospitals (Brazil and UK)
Intervention: Electrical st imulat ion
Comparison: No act ive treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with no active
treatment
Risk with electrical
stimulation
Part icipants cured or
improved
Follow-up: range 12
weeks to 12 months
Study populat ion RR 1.85
(1.34 to 2.55)
121
(2 RCTs)
⊕⊕©©
LOW 12
424 per 1000 784 per 1000
(568 to 1000)
Part icipants with im-
provement in urgency
urinary incont inence
See comment See comment Not est imable (0 studies) - Not reported
OAB-related quality of
lif e
(higher score indicates
better quality of lif e)
Follow-up: range 5
weeks to 12 weeks
In one trial part icipants in the intervent ion group
had lower ICI-Q scores (unclear if this was an
important dif f erence). In another no evidence of
a dif ference was found between groups in of
improvement in a range of QoL scores
- 148 (2 RCT) ⊕⊕©©
LOW 3
Adverse ef fects See comment See comment Not est imable (0 studies) - Not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (high likelihood of select ion bias).
2 Downgraded one level due to serious imprecision (small number of trials, small sample sizes).
3 Downgraded two levels due to very serious imprecision (two trials with small sample sizes).
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B A C K G R O U N D
Description of the condition
Overactive bladder (OAB) is a chronic disorder with an overall
prevalence in the adult population of over 10%, but that may ex-
ceed 40% in elderly groups (Irwin 2006). According to the Inter-
national Continence Society, OAB is characterised by symptoms
of urinary urgency (a strong compelling desire to urinate that is
difficult to overcome), with or without urinary incontinence. If
there is urinary incontinence accompanied by urgency, the leakage
is called urgency urinary incontinence (UUI). Overactive bladder
is usually accompanied by daytime frequency (increased need to
urinate) and nocturia (waking during the night to urinate), but
without urinary infection or other bladder pathologies (Abrams
2003). Overactive bladder with urinary incontinence is known as
’overactive bladder wet’; OAB without incontinence is known as
’overactive bladder dry’.
Overactive bladder hasmany potential causes, such as urinary tract
infections, neurogenic diseases and pelvic organ prolapse. Urgency
symptoms are often associated with involuntary contractions of
the detrusor muscle in the bladder: this is termed detrusor overac-
tivity if it is diagnosed using urodynamics. This overactivity can
be related to neurogenic, myogenic, or idiopathic origins (Shaw
2011). However, currently its aetiology is unclear.
Urinary incontinence has many psychosocial implications. It ap-
pears that OAB has a greater psychological impact than stress uri-
nary incontinence (SUI), with 60% of people with OAB reporting
a history of depression compared with 14% of people with SUI
(Zorn 1999).
Additionally, the financial impact ofOAB can be substantial. Costs
to health services and to patients are likely to be considerable
given the relatively high prevalence of OAB, particularly in elderly
people. The overall annual economic burden of OAB in the US
in 2007 was estimated to be USD 65.9 billion, with the average
annual per capita costs estimated to be USD 1925 (Gantz 2010).
WIth the worldwide problems of increasingly constrained budgets
and an aging population, it is imperative to ensure the efficient
allocation of available resources; therefore value formoney inOAB
treatments must be considered.
Description of the intervention
Conservative management, such as bladder training (Wallace
2004) or pelvic floor muscle training, has been recommended as
a first-line treatment for OAB (Abrams 2003).
The main type of medical treatment for OAB is pharmacotherapy
with anticholinergics, which have proven to be effective in several
randomised controlled trials (RCTs) (Madhuvrata 2012). How-
ever, common side effects such as dry mouth and constipation
limit long-term compliance, with discontinuation rates of 70%
to 90% within one year (D’Souza 2008). Intravesical botulinum
toxin injections may be an effective and safe option to treat refrac-
tory OAB (Duthie 2011); in the UK, bladder wall injections with
botulinum toxinA are recommended forwomenwithOABcaused
by proven detrusor overactivity if conservative or drug treatments
have failed (NICE 2013). This is considered to be a surgical in-
tervention in this review.
In people for whom conservative or drug treatment is not suffi-
cient, neuromodulation is an alternative. It is thought that neu-
romodulation with electrical stimulation (ES) can target specific
nerves in the sacral plexus that control pelvic floor function.
ES can be used to treat OAB via different routes, such as
implantable or internal (sacral neuromodulation) and non-im-
plantable external electrodes. Stimulation with non-implanted
electrodes can be delivered invasively (percutaneous stimulation),
semi-invasively (typically vaginal or anal probes) or non-invasively
(transcutaneous stimulation).
ES can be used on its own or in association with pelvic floormuscle
training, often indicated in SUI and OAB. There is currently little
consensus regarding the optimum treatment regimen, the number
and duration of sessions and the parameters used, such as electrical
frequency and pulse width.
This review includes non-implanted electrodes only; implanted
devices are included in another Cochrane systematic review
(Herbison 2009).
Routes of administration
Intravaginal electrical stimulation
Intravaginal ES for treating urinary incontinence was first reported
in the literature in the 1960s (Cadwell 1963). Subsequently, it has
been shown to achieve satisfactory results with frequencies below
12 Hertz (Hz) stimulating the pudendal nerve, which is thought
to inhibit the detrusor muscle, reduce involuntary contractions
and, consequently, reduce the number of micturitions (Messelink
1999). ES also works in a passive way, helping people with OAB
become conscious of their perineal (pelvic floor) muscle contrac-
tions and this may, in turn, help to inhibit involuntary detrusor
contractions (Amaro 2003).
The contraindications to intravaginal ES are pregnancy, vaginal
infection or lesion, a reduced perception of vaginal sensation,men-
struation, and metallic implants (Richardson 1996).
Rectal (anal) electrical stimulation
Transcutaneous electrical nerve stimulation (TENS) delivers an
electrical current through an electrode placed in the ischiorectal
area. Electrodes inserted in the rectal canal may inhibit detrusor
contractions through contact with the pudendal nerve afferent
fibres and thus may be effective in the treatment of UUI andOAB.
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Posterior tibial nerve stimulation
Percutaneous tibial nerve stimulation is a form of neuromodula-
tion that delivers retrograde stimulation to the sacral nerve plexus
via a needle electrode inserted into the ankle, cephalad to the me-
dial malleolus, an anatomical area recognised as the bladder cen-
tre. Transcutaneous tibial nerve stimulation is less invasive than
percutaneous stimulation and can be delivered over the peroneal
region of the ankle through surface electrodes (ICI 2013).
How the intervention might work
ES is thought to inhibit detrusor contractions, thus decreasing the
number of micturitions and potentially increasing bladder capac-
ity (Wang 2006). Electrodes can be located in the vaginal or rectal
canals in such a way as to obtain direct contact with a significant
quantity of afferent nerve fibres of the pudendal nerve. This stimu-
lation of the pudendal nerve activates the skeletal pelvic floor mus-
cles and inhibits detrusor contraction. Partial or total innervation
of the pudendal nerve is necessary so that nerve stimulation can
occur (Messelink 1999). The anal electrode can be used for men
to stimulate the pudendal nerve, or in women where the vaginal
approach is contraindicated.
There are two main mechanisms whereby ES is thought to work.
• ES in the form of neurostimulation aims to stimulate motor
efferent fibres of the pudendal nerve, which elicits a direct
response from the effector organ, for instance a contraction of
the pelvic floor muscles (Fall 1991; Scheepens 2003).
• ES in the form of neuromodulation aims to remodel reflex
loops, for instance the detrusor inhibition reflex, by stimulating
afferent nerve fibres of the pudendal nerve that influence these
reflex loops via the spinal cord (Vodusek 1986; Weil 2000).
The different sites for non-implanted ES, for instance direct in-
travaginal stimulation or peripheral transcutaneous tibial nerve
stimulation, may involve different mechanisms and therefore may
have different degrees of effectiveness.
Why it is important to do this review
Numerous treatment options exist forOAB, includingbehavioural
therapies such as pelvic floor muscle rehabilitation, bladder train-
ing, and dietary modification, as well as pharmacological ther-
apy and neuromodulation. Overall, behavioural therapies are con-
sidered the mainstay of treatment for urinary incontinence. It is
known that OAB can be improved through behavioural therapy
or drug treatment, but it is not known whether non-invasive ES
achieves better clinical outcomes. This review aims to present an
overview of current evidence related to ES in the treatment of
OAB.
This systematic review aims to investigate the effects of non-im-
planted ES in people with OAB with or without urgency incon-
tinence. It also aims to compare specific subgroups to investigate
whether ES might be more beneficial for some populations than
for others.
O B J E C T I V E S
To assess the effects of electrical stimulation (ES) with non-im-
planted electrodes for OAB, with or without urgency urinary in-
continence (UUI), compared with: placebo or any other active
treatment; ES added to another intervention compared with the
other intervention alone; different methods of ES compared with
each other.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), quasi-RCTs
(RCTs in which allocation to treatment was based on methods
such as alternatemedical records, date of birth, or other predictable
methods) and randomised cross-over trials.
Types of participants
Eligible studies included adults (≥18 years old, or according to
study authors’ definitions of adult) with either of the following:
• symptomatic diagnosis of overactive bladder (OAB),
urgency urinary incontinence (UUI), or mixed urinary
incontinence;
• urodynamic diagnosis of detrusor overactivity in addition
to OAB symptoms (urgency, frequency or episodes of urgency
incontinence).
Studies including participants with stress urinary incontinence
(SUI), with or without OAB symptoms were included if data were
reported separately for SUI and participants with OAB, or if the
majority (> 50%) of the population had OAB/UUI-predominant
symptoms.
Types of interventions
Eligible comparators were any intervention intended to decrease
urinary frequency and included placebo, sham treatment, conser-
vative treatment (including complementary therapies), drugs and
surgery. We also included studies comparing different electrical
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stimulation (ES) methods with each other. There were no restric-
tions by type of device, stimulation parameters (such as contin-
uous, interrupted, or duration of stimulation), duration of treat-
ment, route of administration (e.g. vaginal, rectal, skin, pretib-
ial area), or other similar factors. We excluded trials of different
combinations of treatments even if one of those was ES, where
it was not possible to identify the effect of this treatment alone
(e.g. ES plus another treatment versus ES plus other combined
treatments).
We investigated the following comparisons:
1. ES versus no active treatment
2. ES versus placebo or sham treatment
3. ES versus other conservative treatments (e.g. bladder
training, pelvic floor muscle training, biofeedback, magnetic
stimulation)
4. ES versus drug therapy (e.g. anticholinergics)
5. ES versus surgery (including botulinum toxin)
6. ES plus another treatment versus other treatment alone
7. One type of electrical stimulation versus another.
Types of outcome measures
We considered the following outcomes. Where outcome data were
reported at more than one follow-up point, we extracted the data
from the end of treatment and from the longest available follow-
up period.
Primary outcomes
• Perception of cure (number of participants without OAB
symptoms; number of participants without self-reported UUI)
• Perception of improvement (number of participants with
improvement in OAB symptoms; number of participants with
improvement in self-reported UUI)
• Condition-related quality-of-life measures (however defined
by authors or by any validated measurement scales such as the
International Consultation on Incontinence Questionnaire
(ICIQ))
Secondary outcomes
• Quantification of symptoms
◦ Number of incontinence episodes (per 24 hours)
◦ Number of urgency episodes (per 24 hours)
◦ Number of micturitions (per 24 hours)
◦ Number of nocturia episodes (per night)
◦ Number of pads used per 24 hours
• Economic data
◦ Costs of interventions
◦ Cost-effectiveness of interventions
◦ Resource implications
• Procedure outcome measures
◦ Duration of procedure
◦ Length of hospital stay
◦ Time to return to normal activity level
• Adverse effects
◦ Skin damage
◦ Pain or discomfort
◦ Vascular, visceral or nerve injury
◦ Voiding dysfunction
◦ Other complications
We also included other outcomes that were not pre-specified but
were deemed important during the course of data analysis.
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) outcomes
We included the following outcomes in ’Summary of findings’
tables (Guyatt 2008).
• Number of participants with improvement in OAB
symptoms or urgency symptoms
• Number of participants with improvement in self-reported
UUI
• OAB-related quality of life
• Number of participants with adverse effects (pain or
discomfort due to treatment)
• Cost-effectiveness of interventions
Search methods for identification of studies
We did not impose any restrictions, for example language or pub-
lication status, on the searches described below.
Electronic searches
This review drew on the search strategy developed for Cochrane
Incontinence. We identified relevant trials from the Cochrane
Incontinence Specialised Trials Register. For more details of the
search methods used to build the Specialised Register please see
the Group’s module in the Cochrane Library. The Register con-
tains trials identified from the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Pro-
cess, ClinicalTrials.gov, WHO International Clinical Trials Reg-
istry Platform (WHO ICTRP), UK Clinical Research Network
Portfolio and handsearching of journals and conference proceed-
ings. Most of the trials in the Cochrane Incontinence Specialised
Register are also contained in CENTRAL. The date of the last
search was 10 December 2015. The terms used to search the
Cochrane Incontinence Specialised Register are given in Appendix
1.
Some of the review authors (OLFG, RE, MOG, AK, JLA) also
searched the following databases; the search terms used are given
in Appendix 1
8Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• PubMed (inception to December 2015) was searched on 12
December 2015;
• CENTRAL (The Cochrane Library 2015, Issue 12 ) was
searched on 12 December 2015;
• Embase on OvidSP (covering from 1980 onwards) and the
Latin-American and Caribbean Center on Health Sciencies
Information (LILACS) (on the Virtual Health Library/Bireme)
(covering from 1982 to December 2015) were both searched on
12 December 2015. The highly sensitive Embase and LILACS
strategies for identification of RCTs (Castro 1997; Castro 1999;
Lefebvre 2011) were combined with search terms relating to the
condition and interventions;
• Information about ongoing clinical trials was sought by
searching the clinical trials registration sites ClinicalTrials.gov
and WHO ICTRP on 12 December 2015.
Searching other resources
Reference lists
The review authors scrutinised the reference lists of the identified
relevant studies for additional citations.
Personal contact
We consulted clinical specialists and contacted authors of included
trials where appropriate to obtain unpublished data.
Data collection and analysis
Selection of studies
Two review authors independently screened the trials identified by
the literature search.We resolved any disagreements by consulting
a third review author.
Data extraction and management
One review author extracted data, which was checked by a sec-
ond reviewer, with discrepancies resolved by discussion. We used
a pre-standardised data extraction form to extract data pertaining
to study characteristics (design, methods of randomisation), par-
ticipants, interventions and outcomes.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias in included
trials using the Cochrane tool for assessing risk of bias (Higgins
2011), considering the following four domains: random sequence
generation, allocation concealment, blinding, and incomplete out-
come data. We resolved any disagreements by consulting a third
review author.
Measures of treatment effect
We analysed included trial data as described in theCochraneHand-
book for Systematic Reviews of Interventions (Deeks 2011).
Binary outcomes
For dichotomous data, we calculated risk ratios (RRs) with 95%
confidence intervals (CIs).
Continuous outcomes
For continuous data, we have presented mean differences (MDs)
with 95% CIs.
Unit of analysis issues
The unit of analysis is each participant recruited into the trials.
We analysed studies with non-standard designs as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Deeks
2011). We analysed studies with multiple treatment groups by
treating each pair of arms as a separate comparison, as appropri-
ate. For randomised cross-over studies we used data from the first
period of treatment only.
Dealing with missing data
We analysed data on an intention-to-treat (ITT) basis, as far as
possible, whereby all participants must be analysed according to
the groups to which they were randomised. Where participants
were excluded after allocation or withdrew from the trial, we have
reported any details provided in full.Where data from randomised
cross-over trials were incomplete we have included data from the
first period of randomisation only.
We made all reasonable attempts to contact study authors for
clarification of missing data. Where trials reported mean values
without standard deviations (SDs) but with P values or 95% CIs,
we used Review Manager’s (RevMan) calculator to estimate the
SDs (RevMan 2014). Where trials reported mean values only, we
assumed the outcome to have a SD equal to the highest SD from
the other trials within the same analysis.
Assessment of heterogeneity
We assessed clinical heterogeneity by examination of the study
details and tested for statistical heterogeneity between trial results
using the Chi2 test (Deeks 2011) and the I2 statistic (Higgins
2003), using the following I2 values:
• less than 30% heterogeneity may not be important;
• 30% to 50% may represent moderate heterogeneity;
• more than 50% may represent substantial or considerable
heterogeneity.
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Assessment of reporting biases
We intended to assess the likelihood of potential publication bias
using funnel plots but insufficient data were available.
Data synthesis
We used Cochrane’s statistical software, Review Manager 5
(RevMan) (RevMan 2014), for data analysis. We used the fixed-
effect model to analyse data. Where we identified significant het-
erogeneity (for example I2 higher than 50%), we computed pooled
estimates of the treatment effect for each outcome under a ran-
dom-effects model (with two or more studies).
Where outcomes were reported which were similar to, but not
precisely the same, as pre-specified ones, we used ’surrogate’ out-
comes to substitute formissing data. For example, if a trial reported
episodes of urinary incontinence without specifying the type of
incontinence (e.g. SUI or UUI), we used the data as a substitute
for UUI. Similarly, we used ’improvement in urgency symptoms’
as a substitute for ’improvement in OAB symptoms’. Finally, if
a subjective outcome (such as OAB symptoms) was reported as
combined with an objective outcome (such as detrusor overactiv-
ity) without reporting them separately, we used that outcome as a
surrogate for the subjective outcome.
In comparing ES to drug therapy we have presented subgroups
for each drug but this is for presentation purposes only and is not
intended to act as an indirect comparison between drugs. When
comparing ES to drug therapy, in terms of adverse effects, we did
not use a pooled estimate of effect because of the variation between
drugs in the range of possible side effects.
Subgroup analysis and investigation of heterogeneity
In the case of substantial heterogeneity (I2 > 50%), we investigated
the causes of heterogeneity and, where data permitted, carried out
the following subgroup analyses:
• participants with idiopathic OAB versus those with
neurogenic OAB;
• approaches of electrodes (transcutaneous (e.g. perineal skin,
sacral, posterior pretibial nerve), endocavitary (vaginal, rectal,
urethral), and percutaneous (posterior pretibial nerve).
In some cases, we have presented forest plots with subgroups for
illustrative purposes only, for instance in comparison 2 (electri-
cal stimulation compared to other conservative treatments), we
wanted to demonstrate the various comparators in the trials so we
conveyed this information in the names of the subgroups. Simi-
larly, we used the same approach in comparison 4 (electrical stim-
ulation plus another treatment compared to the other treatment
alone), to demonstrate the various other treatments.
Sensitivity analysis
We intended to perform a sensitivity analysis comparing trials with
low risk of selection bias to those with high risk of bias but there
were insufficient numbers of eligible trials.
’Summary of findings’ tables
We applied the principles of the GRADE system to assess the
quality of the body of evidence associated with specific outcomes
(perception of cure, perception of improvement and OAB-related
quality of life) (Guyatt 2008). The GRADE approach appraises
the quality of a body of evidence based on the extent to which one
can be confident that an estimate of effect or association reflects the
item being assessed. The quality of a body of evidence considers
within-study risk of bias (methodological quality), the directness
of the evidence, heterogeneity of the data, precision of effect esti-
mates, and risk of publication bias. We constructed ’Summary of
findings’ tables using theGRADEproGDT software (GRADEpro
GDT 2015).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search strategy identified 3862 records; after removal of du-
plicate references there was a total of 3428 titles and abstracts to
screen. Following assessment of 230 full-text articles, we consid-
ered 84 reports of 63 studies that met the minimal methodologi-
cal requirements for inclusion in this review. Figure 1 details the
screening process.
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Figure 1. PRISMA study flow diagram
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Thirteen reports of 13 ongoing studies were identified
and have been added to the list of ongoing studies (
NTR2192; NCT01783392; NCT02456441; NCT02583529;
NCT02377765; NCT01940367; NCT02582151;
NCT01464372; NCT01912885; NCT02452593;
NCT02110680; NCT02311634; NCT02511717) (see:
Characteristics of ongoing studies).
Included studies
The individual trials are described in the Characteristics of
included studies table.
Sixty-three trials (84 reports) met the inclusion criteria and were
included in this review. A total of 4224 participants were ran-
domised across the included trials.
Design
All but five of the included studies were reported as RCTs. We in-
cluded three randomised cross-over trials (Gonzalez 2015; Soomro
2001; Vecchioli-Scaldazza 2013) and two quasi-RCTs (Svihra
2002; Wise 1992).
Sample size
Thirty-seven of the included studies did not report any details
relating to sample size calculation. Sample sizes ranged from 22 to
315 (median 51).
Setting
The trials took place in a variety of countries:
• 12 trials took place in Brazil (Alves 2015; Amaro 2006;
Arruda 2008; Barroso 2002; Boaretto 2011; Bellette 2009;
Marques 2008; Monteiro 2014; Schmidt 2009; Schreiner 2010;
Schreiner 2014; Souto 2014);
• 10 in the UK (Booth 2013; Monga 2011; Oldham 2013;
Seth 2014; Shepherd 1984; Shepherd 1985; Slovak 2015; Vohra
2002; Wise 1992; Wise 1993);
• nine in the USA (Brubaker 1997; Firra 2013; Kennelly
2011; Lobel 1998; Peters 2009; Peters 2010; Phillips 2012;
Smith 1996; Sotelo 2011);
• three each in Australia (Bower 1998; Lo 2003; Soomro
2001), Italy (Finazzi-Agrò 2005; Finazzi-Agrò 2010;
Vecchioli-Scaldazza 2013) and Taiwan (Wang 2004; Wang 2006;
Wang 2009);
• two each in Chile (Gonzalez 2015; Manriquez 2013),
China (Chen 2015; Lin 2004), Japan (Yamanishi 2000a;
Yamanishi 2000b) the Netherlands (Berghmans 2002; Spruijt
2003);
• one each in Belgium (Gaspard 2014), Egypt (Abdelbary
2015), Finland (Vahtera 1997), Iran (Eftekhar 2014), Russia
(Kosilov 2013), Slovakia (Svihra 2002), Spain (Olmo Carmona
2013) and Sweden (Franzén 2010); and Turkey (Sancaktar 2010)
• one in Austria and Germany (Preyer 2015).
Five studies did not report the country or any details on study
setting (Aaronson 1995; Lima 2011; Orhan 2015; Preyer 2007;
Walsh 2001).
Very few details were reported regarding study settings; exceptions
were one trial carried out in residential care homes and sheltered
accommodation (Booth 2013) and trials investigating types of ES
suitable for home or portable use (Barroso 2002; Kennelly 2011;
Monga 2011; Oldham 2013; Phillips 2012; Seth 2014; Shepherd
1985; Soomro 2001; Sotelo 2011; Wise 1992; Wise 1993).
Participants
The trials included a variety of participant groups.
Sex
Fourteen trials were open to men and women (Booth 2013; Olmo
Carmona 2013; Gaspard 2014; Kennelly 2011; Monga 2011;
Peters 2009; Peters 2010; Phillips 2012; Slovak 2015; Soomro
2001; Vahtera 1997; Walsh 2001;Yamanishi 2000a; Yamanishi
2000b), one was open only to men (Monteiro 2014), and six did
not report the participants’ sex (Gonzalez 2015; Lin 2004; Orhan
2015; Seth 2014; Sotelo 2011; Vohra 2002). All other trials were
open to women only.
Age
One trial included only participants over 65 years (Booth 2013).
Two trials included only participants over 60 years (Alves 2015;
Schreiner 2014) and another imposed a lower age limit of 40
(Abdelbary 2015). The Olmo Carmona 2013 trial included par-
ticipants aged 45 to 75 (mean 60 years). Fourteen trials did not
report participants’ mean age (Alves 2015; Lima 2011;Manriquez
2013; Marques 2008; Monga 2011; Orhan 2015; Phillips 2012;
Preyer 2015; Seth 2014; Shepherd 1984; Shepherd 1985; Wang
2006; Wise 1992; Wise 1993). Across the remaining trials, the
mean age of participants in the trials ranged from 46 to 70 years.
Diagnosis
The participants had a variety of diagnoses of the causes of their
overactive bladder (OAB).
• Fourteen trials based their inclusion criteria on urodynamic
diagnosis (Aaronson 1995; Arruda 2008; Berghmans 2002;
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Bower 1998; Brubaker 1997; Finazzi-Agrò 2010; Lobel 1998;
Shepherd 1985; Smith 1996; Walsh 2001; Wise 1992; Wise
1993; Yamanishi 2000a; Yamanishi 2000b).
• Six trials included only participants with neurogenic OAB
or detrusor overactivity (Chen 2015; Eftekhar 2014; Gaspard
2014; Monteiro 2014; Seth 2014; Vahtera 1997).
• All other trials reported inclusion criteria based on
symptomatic diagnosis of OAB, urgency urinary incontinence
(UUI), or any kind of incontinence or bladder dysfunction.
Eleven trials included participants with mixed urinary inconti-
nence (MUI and stress urinary incontinence (SUI)) (Barroso 2002;
Booth 2013; Brubaker 1997; Firra 2013; Lo 2003; Oldham 2013;
Schmidt 2009; Shepherd 1984; Shepherd 1985; Smith 1996;
Spruijt 2003). All other trials included participants with OAB and
UUI only.
Duration of trials
Treatment duration ranged from a single one-off session to four
months. Fifteen trials followed up participants beyond the end
of the treatment period (Abdelbary 2015; Amaro 2006; Arruda
2008; Barroso 2002; Gaspard 2014; Kosilov 2013; Lobel 1998;
Monteiro 2014; Peters 2010; Schmidt 2009; Schreiner 2010;
Slovak 2015; Souto 2014; Vahtera 1997; Vecchioli-Scaldazza
2013). The duration of post-treatment follow-up ranged fromone
month to two years. Four trials did not report treatment duration
or follow-up.
Types of interventions
The parameters and components of the active electrical stimula-
tion (ES) interventions varied widely and are summarised in Table
1.
Control/comparator interventions included the following.
• No active treatment (Berghmans 2002; Marques 2008;
Monteiro 2014; Oldham 2013; Slovak 2015: Svihra 2002;
Vahtera 1997)
• Sham ES (Amaro 2006; Barroso 2002; Bellette 2009;
Booth 2013; Bower 1998; Brubaker 1997; Finazzi-Agrò 2010;
Kennelly 2011; Peters 2010; Shepherd 1984; Shepherd 1985;
Vohra 2002; Walsh 2001; Yamanishi 2000a)
• Placebo (Kosilov 2013; Wang 2006; Wang 2009)
• Pelvic floor muscle training (PFMT) (Arruda 2008;
Berghmans 2002; Boaretto 2011; Firra 2013; Gaspard 2014;
Lima 2011; Lo 2003; Schmidt 2009; Schreiner 2010; Spruijt
2003; Wang 2004)
• PFMT plus biofeedback (Gaspard 2014; Schmidt 2009;
Wang 2004)
• Bladder training and PFMT (Schreiner 2014)
• Behavioural therapy (Gonzalez 2015)
• Electro-acupunture (Olmo Carmona 2013)
• Laseropuncture (Kosilov 2013)
• Functional magnetic stimulation (Yamanishi 2000b)
• Drug treatment (oestrogen cream, oxybutynin,
propantheline bromide, probanthine, solifenacin succinate,
terodiline, tolterodine and trospium chloride) (Aaronson 1995;
Abdelbary 2015; Arruda 2008; Boaretto 2011; Chen 2015;
Franzén 2010; Kosilov 2013; Lin 2004; Manriquez 2013; Orhan
2015; Peters 2009; Preyer 2007; Preyer 2015Sancaktar 2010;
Smith 1996; Soomro 2001; Souto 2014; Svihra 2002;
Vecchioli-Scaldazza 2013; Wang 2006; Wang 2006; Wang 2009;
Wise 1992; Wise 1993)
• Different ES regimens (Alves 2015; Lobel 1998; Monga
2011; Phillips 2012; Seth 2014; Slovak 2015; Sotelo 2011)
In one trial (Marques 2008) it was unclear whether the comparator
was no active treatment or sham treatment; the description was
“the same protocol but without electrical stimulation.”
Types of outcomes
Nineteen trials reported the primary outcomes of perception of
cure or improvement of OAB symptoms (Aaronson 1995; Bellette
2009; Booth 2013; Kennelly 2011; Lin 2004; Lo 2003; Lobel
1998; Monteiro 2014; Peters 2009; Peters 2010; Schmidt 2009;
Shepherd 1985; Smith 1996; Soomro 2001; Spruijt 2003; Vohra
2002; Wang 2004; Wang 2006; Wang 2009).
A validated measure of quality of life (QoL) was reported in 22
trials (Alves 2015; Bellette 2009; Olmo Carmona 2013; Chen
2015; Finazzi-Agrò 2010; Firra 2013; Gaspard 2014; Gonzalez
2015; Oldham 2013; Orhan 2015; Peters 2010; Phillips 2012;
Sancaktar 2010; Schmidt 2009; Schreiner 2010; Schreiner 2014;
Seth 2014; Souto 2014; Svihra 2002; Vecchioli-Scaldazza 2013;
Wang 2004; Wang 2009). Two trials reported QoL, but did not
state the instrument used (Abdelbary 2015; Preyer 2007), and an-
other trial used an in-house QoL instrument (Yamanishi 2000a).
Thirteen trials did not report any of the primary outcomes
(Berghmans 2002; Bower 1998; Eftekhar 2014; Kosilov 2013;
Manriquez 2013; Monga 2011; Preyer 2015; Sancaktar 2010;
Slovak 2015; Sotelo 2011; Vahtera 1997; Wise 1993; Yamanishi
2000b).
Five trials reported urodynamic outcomes only (Berghmans 2002;
Bower 1998; Vahtera 1997; Walsh 2001; Yamanishi 2000b).
Twenty trials reported data relating to adverse effects (Chen
2015; Finazzi-Agrò 2005; Franzén 2010; Gaspard 2014; Kennelly
2011; Lin 2004; Lobel 1998; Oldham 2013; Peters 2010; Phillips
2012; Preyer 2007; Preyer 2015; Sancaktar 2010; Schreiner 2010;
Soomro 2001; Sotelo 2011; Svihra 2002; Wise 1993; Yamanishi
2000a; Yamanishi 2000b).
None of the trials reported any data relating to procedure outcome
measures.
Excluded studies
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After full-text screening, we excluded 132 reports of 128 studies
from the review. The main reasons for exclusion were ineligible
study design (non-RCTs), ineligible population (participants did
not have OAB or UUI), and ineligible interventions such as sacral
neuromodulationwith implanted devices ormagnetic stimulation.
See the table ’Characteristics of excluded studies’ for full details of
the excluded studies.
Studies awaiting classification
One report of one study is awaiting translation (Zhao 2000).
Ongoing studies
We identified 13 reports of 13ongoing trials thatmet our inclusion
criteria (Characteristics of ongoing studies).
The following comparisons are being investigated in the ongoing
trials.
• ES versus sham ES (NCT02456441; NCT02583529;
NCT01464372; NCT02582151; NCT02110680;
NCT02511717)
• ES versus conservative treatment (bladder training:
NTR2192; PFMT: NCT02452593)
• Different types of ES (NCT01783392; NCT02377765;
NCT01940367; NCT01912885; NCT02311634)
Risk of bias in included studies
See Figure 2 Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
Random sequence generation
Two trials were judged to be at high risk of bias for random se-
quence generation (Monteiro 2014; Svihra 2002) because their
methods of sequence generation did not appear to be truly ran-
dom. Twenty-three trials were judged to be at low risk of bias
for randomisation (Abdelbary 2015; Arruda 2008; Barroso 2002;
Bellette 2009; Berghmans 2002; Booth 2013; Brubaker 1997;
Olmo Carmona 2013; Eftekhar 2014; Finazzi-Agrò 2010; Firra
2013; Franzén 2010; Gonzalez 2015; Oldham 2013; Peters 2009;
Preyer 2015; Sancaktar 2010; Schreiner 2010; Slovak 2015; Souto
2014; Spruijt 2003; Vohra 2002; Wang 2009). The remaining
trials did not report their methods in sufficient detail to judge
whether allocation to groups was fully randomised and therefore
were at unclear risk of bias.
Allocation concealment
Nine trials reported adequate methods of concealment of allo-
cation and so were at low risk of bias (Berghmans 2002; Olmo
Carmona 2013; Firra 2013; Franzén 2010; Preyer 2015, Shepherd
1984; Slovak 2015; Wang 2004; Wang 2006), none were judged
to be at high risk and the remainder did not report sufficient detail
regarding their methods of allocation concealment and we there-
fore judged them to have an unclear risk of bias.
Blinding
Blinding of participants and personnel (performance bias)
Four trials (Arruda 2008; Bellette 2009; Eftekhar 2014; Preyer
2015) were judged to be at high risk of performance bias because
treatment was carried out by personnel who were aware of treat-
ment group allocation, whichmay have influenced their treatment
methods.
Fifteen trials had adequate blinding methods to be judged at low
risk of performance bias (Alves 2015; Amaro 2006; Barroso 2002;
Berghmans 2002; Booth 2013; Bower 1998; Brubaker 1997;
Finazzi-Agrò 2010; Kennelly 2011; Peters 2010; Shepherd 1985;
Slovak 2015; Wang 2006; Wang 2009; Yamanishi 2000a) and the
remainder were unclear.
For some comparisons, blinding of participants would not be pos-
sible, for instance ES versus drug treatment, versus surgery or ver-
sus conservative treatment. Trials investigating those comparisons
were judged to be at unclear risk of performance bias because
knowledge of the treatment received may have had an influence
on self-reported outcomes but there was no means of avoiding it.
Blinding of outcome assessment (detection bias)
Four trials (Firra 2013; Bellette 2009; Eftekhar 2014; Preyer 2015)
were at high risk of detection bias because the outcome assessors
were not blinded to group allocation.
Eighteen trials were judged to be at low risk of detection bias (
Alves 2015; Amaro 2006; Arruda 2008; Barroso 2002; Berghmans
2002; Brubaker 1997; Olmo Carmona 2013; Finazzi-Agrò 2010;
Gaspard 2014; Kennelly 2011; Lo 2003; Oldham 2013; Schmidt
2009; Shepherd 1984; Slovak 2015; Vecchioli-Scaldazza 2013;
Wang 2004; Wang 2006) and the remainder were unclear.
Incomplete outcome data
Four trials were at high risk of attrition bias.
• Gonzalez 2015 and Seth 2014 reported differential attrition
with no adequate explanation and did not report whether the
analysis included all participants who were randomised.
• Schreiner 2014 reported 12 month follow-up data for a
proportion of the intervention group and no 12 month data for
the comparator group.
• Wise 1993 experienced differential withdrawal for reasons
attributable to the comparator.
Twenty-eight trials were judged to be at low risk of attrition
bias (Alves 2015; Arruda 2008; Bellette 2009; Berghmans 2002;
Booth 2013; Olmo Carmona 2013; Chen 2015; Finazzi-Agrò
2010; Franzén 2010; Gaspard 2014; Kennelly 2011; Lin 2004;
Lobel 1998; Monteiro 2014; Peters 2009; Peters 2010; Preyer
2007; Preyer 2015; Schmidt 2009; Schreiner 2010; Spruijt 2003;
Vecchioli-Scaldazza 2013; Vohra 2002; Walsh 2001; Wang 2004;
Wang 2009; Yamanishi 2000a; Yamanishi 2000b) and the remain-
der were unclear.
Effects of interventions
See: Summary of findings for the main comparison Electrical
stimulation versus no active treatment; Summary of findings 2
Electrical stimulation versusplaceboor sham treatment;Summary
of findings 3 Electrical stimulation versus pelvic floor muscle
training (PFMT); Summary of findings 4 Electrical stimulation
versus pelvic floor muscle training (PFMT) plus biofeedback;
Summary of findings 5 Electrical stimulation versus magnetic
stimulation; Summary of findings 6 Electrical stimulation
versus laseropuncture/electro-acupuncture; Summary of findings
7 Electrical stimulation versus drug therapy; Summary of
findings 8 Electrical stimulation plus pelvic floor muscle training
(PFMT) versus PFMT alone; Summary of findings 9 Electrical
stimulation plus behavioural therapy versus behavioural therapy
alone; Summary of findings 10 Electrical stimulation plus drug
therapy versus drug therapy alone; Summary of findings 11
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Electrical stimulation (ES) once a week versus ES twice a week;
Summary of findings 12 Electrical stimulation (ES) once a week
versus ES three times a week; Summary of findings 13 Sensory
threshold electrical stimulation (ES) versus motor threshold ES
1. Electrical stimulation versus no active treatment
Five trials with 336 participants compared ES with no active treat-
ment (Berghmans 2002; Monteiro 2014; Oldham 2013; Svihra
2002; Vahtera 1997).
Primary outcomes
Perception of cure or improvement of OAB symptoms
Two trials reported subjective cure or improvement (Monteiro
2014; Oldham 2013). Low-quality evidence indicated that par-
ticipants receiving ES were more likely to report cure or improve-
ment in symptoms than those receiving no active treatment (RR
1.85, 95% CI 1.34 to 2.55; n = 121) (Analysis 1.1; Summary of
findings for the main comparison).
Number of participants satisfied with treatment
Not reported
Improvement in urgency urinary incontinence (UUI)
Not reported
OAB-related quality of life
Two trials (Oldham 2013, Svihra 2002) reported QoL measured
by the following instruments:
• International Consultation on Incontinence Questionnaire
(ICI-Q);
• Incontinence Quality of Life Questionnaire (I-QoL);
• Behavioural Urge Score (BUS); and
• International Prostate Symptom Score (IPSS)
Low quality evidence indicated no evidence of a difference in qual-
ity of life between those undergoing ES and those who received no
active treatment (Summary of findings for the main comparison;
Table 2).
Secondary outcomes
Quantification of symptoms
One trial reported a statistically significant effect in favour of ES
in terms of nocturia and daytime frequency (Marques 2008) but
without giving any raw data (Table 2).
One trial reported symptom outcomes at two different time points
(Monteiro 2014), which suggested that the effectiveness of ES did
not diminish over time (Table 2).
Economic data
Not reported
Procedure outcomes
Not reported
Adverse effects
Not reported
2. Electrical stimulation versus placebo or sham
treatment
Eighteen trials with 1569 participants compared ES to placebo or
sham treatment: drug placebo: Kosilov 2013; Wang 2006; Wang
2009; and sham ES: Amaro 2006; Barroso 2002; Bellette 2009;
Booth 2013; Bower 1998; Brubaker 1997; Finazzi-Agrò 2010;
Kennelly 2011; Peters 2010; Shepherd 1984; Shepherd 1985;
Slovak 2015; Vohra 2002; Walsh 2001; Yamanishi 2000a.
Primary outcomes
Perception of cure or improvement of OAB symptoms
Based on four trials (Bellette 2009; Wang 2006; Wang 2009;
Yamanishi 2000a), participants receiving ES were almost three
times more likely than those in the placebo or sham treatment
groups to be cured, according to subjective assessment (RR 2.69,
95% CI 1.39 to 5.21; n = 189) (Analysis 2.1).
Moderate-quality evidence, based on 10 trials, suggested that par-
ticipants receiving ES were more than twice as likely as those in
the placebo or sham treatment groups to report cure or improve-
ment of OAB symptoms (RR 2.26, 95% CI 1.85 to 2.77; n =
677) (Analysis 2.2; Summary of findings 2) (Bellette 2009; Booth
2013; Finazzi-Agrò 2010; Kennelly 2011; Peters 2010; Slovak
2015; Vohra 2002; Wang 2006; Wang 2009; Yamanishi 2000a).
Heterogeneity was high (I2 = 66%) but the estimate of effect re-
mained statistically significant with a random-effects model (RR
2.46, 95% CI 1.60 to 3.80).
Moderate-quality evidence relating to subjective cure or improve-
ment showed that percutaneous tibial nerve stimulation was more
effective than sham or placebo treatment (RR 3.19, 95% CI 2.22
to 4.58; n = 304) (Booth 2013; Finazzi-Agrò 2010; Peters 2010;
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Vohra 2002), while intravaginal ES showed an even greater effect
(RR 5.46, 95% CI 2.33 to 12.81; n = 94) (Wang 2006; Wang
2009) (Analysis 2.3).
Number of participants satisfied with treatment
Two small trials (Amaro 2006; Yamanishi 2000a) showed that
participants undergoing ES were more likely to report satisfaction
with treatment than those receiving sham ES (RR 1.44, 95% CI
1.02 to 2.04; n = 98) (Analysis 2.4).
Improvement in urgency urinary incontinence
Moderate-quality evidence supported the use of ES in terms of
improvement in UUI when compared to placebo or sham treat-
ment (RR 2.23, 95% CI 1.46 to 3.40), however, heterogeneity
was high (I2 = 78%), probably due to the large differences in effect
sizes between the trials (Finazzi-Agrò 2010; Peters 2010). A ran-
dom-effects model still favoured ES but the result was no longer
statistically significant (RR 5.03, 95% CI 0.28 to 89.88; n = 242)
(Analysis 2.5; Summary of findings 2).
OAB-related quality of life
Seven trials reported a measure of QoL related to OAB or in-
continence. One trial used an instrument that was not validated
(Yamanishi 2000a); the other instruments used were:
• International Consultation on Incontinence Questionnaire
- Urinary Incontinence (ICIQ-UI) (Booth 2013; Oldham 2013);
• Overactive Bladder Questionnaire (OAB-Q) (Bellette 2009;
Peters 2010); and
• Incontinence Quality of Life (I-QOL) (Finazzi-Agrò 2010;
Svihra 2002).
Three trials reported statistically significant differences in favour
of ES inQoL scores (Bellette 2009; Peters 2010; Yamanishi 2000a)
but the other trials found no evidence of a difference (Table 3);
these results were based on very low-quality evidence (Summary
of findings 2).
Secondary outcomes
Quantification of symptoms
ES was found to be more effective than placebo or sham treatment
for the following outcomes.
• Incontinence episodes (per 24 hours): MD -1.43, 95% CI -
1.92 to 0.95; n = 143) (Analysis 2.7) (Barroso 2002; Kosilov
2013).
• Nocturia episodes (per night): MD -0.37, 95% CI -0.73 to
-0.02; n = 245 (Analysis 2.8) (Bellette 2009; Peters 2010).
• Micturitions (per 24 hours): MD -1.09, 95% CI -1.70 TO
-0.47; n = 285 (Analysis 2.9) (Amaro 2006; Bellette 2009; Peters
2010).
One trial (Kosilov 2013) measured the number of incontinence
episodes at two time points. At the end of six months’ treatment
there was no evidence of a difference betweenES and placebo (MD
-0.50, 95%CI -1.18 to 0.18) but at 12 months after baseline there
were significantly fewer incontinence episodes in the ES group
than the placebo group (MD -1.10, 95% CI-1.82 to -0.38; n
= 107). The pooled estimate of effect reported above used the
12-month data from Kosilov 2013 but the result did not change
substantially if the six-month data were used (pooled MD -1.13,
95% CI -1.59 to -0.66).
One trial (Yamanishi 2000a) found no evidence of a difference
between groups in the number of pads used per 24 hours (Table
3).
Economic data
Not reported
Procedure outcomes
Not reported
Adverse effects
Low-quality evidence indicated no evidence of a difference be-
tween ES and placebo or sham treatment in the number of ad-
verse effects (RR 1.24, 95% CI 0.84 to 1.83; n = 450) (Analysis
2.10) (Kennelly 2011; Peters 2010; Yamanishi 2000a) (Summary
of findings 2). Adverse effects reported by participants included
skin irritation, urinary tract infection, vaginal pain, discomfort
and tingling.
3. Electrical stimulation versus other conservative
treatments
Eleven trials with 882 participants compared ES to other conser-
vative treatments (Arruda 2008; Berghmans 2002; Boaretto 2011;
OlmoCarmona 2013; Kosilov 2013; Lima 2011; Schreiner 2010;
Schreiner 2014; Spruijt 2003; Wang 2004; Yamanishi 2000b).
i) ES versus pelvic floor muscle training (PFMT)
Seven trials (n = 519) compared ES to PFMT (Arruda 2008;
Berghmans 2002; Boaretto 2011; Lima 2011; Schreiner 2014;
Spruijt 2003; Wang 2004).
18Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Primary outcomes
Perception of cure or improvement of OAB symptoms
One small trial (n = 22) reported the number of participants cured
and found no significant difference between ES and PFMT (Table
4) (Arruda 2008).
Based on three trials, moderate-quality evidence indicated that ES
was better than PFMT in terms of cure or improvement of OAB
symptoms (RR 1.60, 95% CI 1.19 to 2.14; n = 195) (Analysis
3.1) (Arruda 2008; Schreiner 2014; Wang 2004) (Summary of
findings 3).
Number of participants satisfied with treatment
Data from two trials, one of which was a three-arm trial with two
different ES groups, suggested that participants were significantly
more likely to be satisfied with PFMT treatment with ES (RR
0.76, 95% CI 0.60 to 0.96; n = 102) (Analysis 3.2) (Arruda 2008;
Boaretto 2011).
Improvement in urgency urinary incontinence (UUI)
Very low-quality evidence from a single trial (Wang 2004) found
no evidence of a difference between ES and PFMT in terms of
improvement in UUI (RR 1.62, 95% CI 0.51 to 5.12) (Table 4,
Summary of findings 3).
OAB-related quality of life (QoL)
Very low-quality evidence, froma single trial, suggested betterQoL
in the ES group than the PFMT group (Wang 2004) (Summary
of findings 3).
Secondary outcomes
Quantification of symptoms
One small trial (Arruda 2008; n = 22) found no evidence of a
difference between ES and PFMT in incontinence episodes, daily
micturitions, pads per day or nocturia episodes (Table 4).
Economic data
Not reported
Procedure outcomes
Not reported
Adverse effects
Not reported
ii) ES versus PFMT plus biofeedback
One trial (n = 120) compared ES to biofeedback-assisted PFMT
(Wang 2004).
Primary outcomes
Perception of cure or improvement of OAB symptoms
Low-quality evidence from one trial (Wang 2004) found no evi-
dence of a difference between ES and PFMT plus biofeedback in
terms of improvement in UUI (RR 1.06, 95% CI 0.60 to 1.85)
(Summary of findings 4; Table 5).
Number of participants satisfied with treatment
Not reported
OAB-related quality of life (QoL)
Low-quality evidence from the same trial (Wang 2004) suggested
no evidence of a difference in OAB-related QoL measured by
the King’s Health Questionnaire (MD -5.78 (95% CI -88.99 to
77.43) (Summary of findings 4; Table 5).
Secondary outcomes
None of the secondary outcomes were reported.
iii) ES versus PFMT plus behavioural therapy
One trial compared ES to PFMT plus behavioural therapy
(Berghmans 2002) but none of the outcomes of interest were re-
ported.
iv) ES versus magnetic stimulation
Primary outcomes
One trial (Yamanishi 2000b) compared ES to magnetic stimula-
tion but did not report any of our primary outcomes.
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Secondary outcomes
Quantification of symptoms
Not reported
Economic data
Not reported
Procedure outcomes
Not reported
Adverse effects
Very low-quality evidence from one trial (n = 32) indicated no
evidence of a difference between ES and magnetic stimulation in
the numbers of participants with adverse effects (no adverse effects
in either group) (Yamanishi 2000b) (Summary of findings 5).
v) ES versus laseropuncture/electro-acupuncture
One trial compared ES to laseropuncture (Kosilov 2013; n = 229)
and another comparedES to electro-acupuncture (OlmoCarmona
2013; n = 22).
Primary outcomes
Perception of cure or improvement of OAB symptoms
Not reported
Number of participants satisfied with treatment
Not reported
OAB-related quality of life
Moderate-quality evidence, from one trial, reported significantly
better QoL scores (Olmo Carmona 2013;) in the ES group than
in the electro-acupuncture group (Summary of findings 6) (Table
6).
Secondary outcomes
Quantification of symptoms
Based on two trials, there were significantly fewer incontinence
episodes in the ES groups than in those receiving laseropuncture or
electro-acupuncture (MD-1.84, 95%CI -2.33 to -1.35; n = 136) (
Analysis 4.1 ) (OlmoCarmona 2013; Kosilov 2013). Kosilov 2013
(n = 114) reported the number of incontinence episodes at two
time points; after six months’ treatment there were significantly
fewer incontinence episodes in the ES group (MD - 1.60, 95%
CI -1.92 to -1.28) and after nine months’ follow-up the difference
increased to -1.80 (95% CI -2.30 to 1.30). The pooled results
reported above included the nine-month follow-up data from this
trial; replacing itwith the six-month data changed the result toMD
-1.62 (95%CI -1.93 to -1.30). Additionally, the other trial (Olmo
Carmona 2013; n = 22) reported mean numbers of micturitions
and nocturia episodes but found no evidence of a difference in
number of micturitions or nocturia episodes (Table 6).
Economic data
Not reported
Procedure outcomes
Not reported
Adverse effects
Not reported
4. Electrical stimulation versus drug therapy
Twenty-three trials with 1756 participants compared ES to the
following drug treatments.
• Oestrogen cream (Abdelbary 2015)
• Oxybutynin: immediate release (Arruda 2008; Boaretto
2011); extended-release (Manriquez 2013); not reported if
extended or immediate release (Soomro 2001; Souto 2014;
Svihra 2002; Wang 2006; Wang 2009; Wise 1993)
• Probantheline bromide (Smith 1996)
• Probanthine (Aaronson 1995)
• Solifenacin succinate (Chen 2015; Vecchioli-Scaldazza
2013)
• Terodiline (Wise 1992)
• Tolterodine, extended-release (Peters 2009)
• Tolterodine (not reported if extended or immediate release
(Franzén 2010; Lin 2004; Preyer 2007; Preyer 2015; Sancaktar
2010)
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• Trospium and solifenacin (Kosilov 2013)
• Unspecified anticholinergic agent (Orhan 2015)
Primary outcome
Perception of cure or improvement of OAB symptoms
Overall, there was no evidence of a difference between ES and
drug treatment in curing OAB (RR 0.98, 95% CI 0.69 to 1.41;
n = 388). Nor was there any evidence of a difference between
ES and individual drugs (tolterodine (Franzén 2010; Lin 2004;
Peters 2009), oxybutynin (Arruda 2008;Wang 2006;Wang 2009),
propantheline bromide (Smith 1996)) (Analysis 5.1).
Whenmeasuring cure or improvement together,moderate-quality
evidence suggested that ES was more effective than drug treatment
overall (RR 1.20, 95% 1.04 to 1.38; n = 439) but no evidence of
a difference was found when comparing ES to individual drugs
(tolterodine (Franzén 2010; Lin 2004; Peters 2009), oxybutynin
(Arruda 2008; Wang 2006; Wang 2009), propantheline bromide
(Smith 1996)) (Analysis 5.2). Another trial (Aaronson 1995) re-
ported data not suitable for meta-analysis but found that 69%
of participants receiving ES were cured or improved compared to
50% of participants taking probanthine (Summary of findings 7).
With regard to cure or improvement of OAB symptoms, a sub-
group analysis based on low-quality evidence found that ES deliv-
ered through intravaginal or transanal routes was more effective
than drug treatment (RR 1.28, 95% CI 1.03 to 1.59; n = 199)
(Analysis 5.3), but there was no evidence of a difference in cure or
improvement between transcutaneous posterior tibial nerve stim-
ulation and drug treatment (RR 0.51, 95% CI 0.23 to 1.13; n =
64).
There was no evidence of a difference in the number of people
satisfied with ES or drug therapy with oxybutynin (RR 0.90, 95%
CI 0.72 to 1.14; n = 125) (Arruda 2008; Boaretto 2011) (Analysis
5.4).
Number of participants satisfied with treatment
Not reported
Improvement in urgency urinary incontinence
None of the trials comparing ES to drug treatment reported im-
provement in UUI.
OAB-related quality of life
Based on low-quality evidence from two trials comparing ES to
solifenacin succinate (Chen 2015; Vecchioli-Scaldazza 2013) and
another trial comparing ES to vaginal oestrogen cream (Abdelbary
2015), there was no evidence of a difference between the groups
in terms of I-Qol, OAB-Q and PPIUS scores. However, statis-
tically significant differences in favour of ES over drug therapy
were reported, measured by an unspecified QoL instrument and
the Patient Globe Impression of Improvement tool (Summary of
findings 7; Table 7).
The Orhan 2015 trial reported that they found a statistically sig-
nificantly higher improvement in the ES group than in the an-
ticholinergic group according to three QoL measures; Urinary
Distress Inventory (UDI-6), Incontinence Impact Questionnaire
(IIQ-7), Over Active Bladder symptom scores (OABSS). How-
ever, no raw data were reported.
One trial reported QoL measured at three different time points;
at the end of treatment and at three and six months’ follow-up
(Abdelbary 2015). The data suggested better QoL of life in the
ES group initially but at six months there was no evidence of a
difference between ES and vaginal oestrogen cream.
Secondary outcomes
Quantification of symptoms
Overall, ES was more effective than drug treatment in terms of
incontinence episodes per 24 hours (MD 0.24, 95% CI 0.09
to 0.38; n = 477); however, heterogeneity was high (I2 = 96%)
and the result was no longer statistically significant in a ran-
dom-effects model (MD 0.25, 95% CI -1.11 to 1.60) (Analysis
5.5) (Abdelbary 2015; Arruda 2008; Kosilov 2013; Peters 2009;
Vecchioli-Scaldazza 2013).
Comparing ES to individual drugs, one trial reported significantly
more incontinence episodes in the ES group than the trospium
plus solifenacin group (MD 2.20, 95% CI 1.78 to 2.62; n = 110)
(Kosilov 2013) but there was no evidence of a difference between
ES and tolterodine (Peters 2009), oxybutynin (Arruda 2008) or
oestrogen cream (Abdelbary 2015) in incontinence episodes.
There was insufficient evidence of a difference between ES and
drug treatment for the following outcomes (Analysis 5.6; Analysis
5.7; Analysis 5.8 and Table 7).
• Urgency episodes
• Number of micturitions per 24 hours
• Nocturia episodes
• Number of people with nocturia
• Pads used per day
Economic data
One cost-effectiveness study (Chen 2012) found that percuta-
neous tibial nerve stimulation (PTNS) was not cost-effective com-
pared to extended release tolterodine (incremental cost-effective-
ness ratio (ICER) of USD 70,754 per quality-adjusted life year,
USD 20,754 above the USD 50,000 acceptable threshold). The
probability of cost-effectiveness at the USD 50,000 threshold was
21%.
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Procedure outcomes
Not reported
Adverse effects
The reported adverse effects included dry mouth, constipation,
headache, skin irritation, blurred vision, muscular pain, indiges-
tion, nausea and dizziness. Due to the variety of adverse effects
associated with different drugs, we did not pool the data to obtain
one overall estimate effect, as this may have led to a misleading
result.
ComparingES to individual drugs, low-quality evidence suggested
fewer adverse effects with ES thanwith oxybutynin (RR0.11, 95%
CI 0.01 to 0.84; n = 79) (Svihra 2002; Wise 1993). Moderate-
quality evidence indicated fewer adverse effects with ES than with
tolterodine (RR 0.12, 95% CI 0.05 to 0.27; n = 200) (Franzén
2010; Lin 2004; Preyer 2007; Preyer 2015) but there was no evi-
dence of a difference in adverse effects between ES and solifenacin
succinate (Chen 2015) (very low-quality evidence) (Analysis 5.9)
(Table 7).
5. Electrical stimulation versus surgery
No studies were identified that compared ES with surgery. How-
ever, one economic evaluation was identified (Robinson 2010),
which found that PTNS was more cost-effective than botulinum
toxin (ICER GBP 50,133 and GBP 111,953 respectively), al-
though neither treatment would be considered cost-effective ac-
cording to the thresholds used by the UK’s National Institute for
Health and Care Excellence.
6. Electrical stimulation plus another treatment
versus another treatment alone
i) ES plus PFMT versus PFMT alone
Five trials (203 participants) compared ES plus PFMT to PFMT
alone (Firra 2013; Gaspard 2014; Lo 2003; Schmidt 2009;
Schreiner 2010).
Primary outcome
Perception of cure or improvement of OAB symptoms
None of the trials comparing ES plus another treatment versus
another treatment alone reported cure or improvement.
Based on two small trials (Gaspard 2014; Schreiner 2010), sig-
nificantly more participants reported satisfaction with ES plus
PFMT than PFMT alone (RR 1.58, 95% CI 1.13 to 2.20; n =
82) (Analysis 6.1).
Number of participants satisfied with treatment
Not reported
Improvement in urgency urinary incontinence
Low-quality evidence from one small trial (Schreiner 2010) found
that participants receiving ES plus PFMT were more than twice
as likely to report improvement in UUI (RR 2.82, 95% CI 1.44
to 5.52; n = 51) (Table 8; Summary of findings 8)
OAB-related quality of life
Low-quality evidence from three trials suggested no evidence of
a difference between groups in QoL scores when measured with
SF-Qualiveen and York Incontinence Perception Scale but there
was better QoL in the ES plus PFMT group in one trial reporting
ICIQ-SF scores (Summary of findings 8; Table 8).
Secondary outcomes
Quantification of symptoms
Data from two trials suggested that adding ES to PFMT was more
effective than PFMTalone in terms of incontinence episodes (MD
-0.83, 95% CI -1.47 to -0.19; n = 119) (Firra 2013; Gaspard
2014). However, heterogeneity was high (I2 = 61%), probably due
to the differences between trials in direction of effect. A random-
effects analysis altered the result so that it was no longer statistically
significant (MD -0.60, 95% CI -1.84 to 0.64) (Analysis 6.2). In
terms of urgency episodes, two trials found that ES with PFMT
was better than PFMT alone (MD -2.49 (-2.74 to -2.24) but there
was unexplained heterogeneity (I2 = 87%) and a random-effects
analysis maintained a statistically significant result but with wider
confidence intervals (MD -2.33, 95 CI -3.11 to -1.54; n = 248)
(Analysis 6.3) (Firra 2013; Gaspard 2014). Data from two trials
showed no evidence of a difference inmicturitions per day between
ES plus PFMT and PFMT alone. One trial found that adding
ES to PFMT was more effective than PFMT alone in terms of
number of nocturia episodes (Schreiner 2010) (Table 8).
Economic data
Not reported
Procedure outcomes
Not reported
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Adverse effects
Very low-quality evidence from a single trial found no evidence
of a difference between ES plus PFMT and PFMT only in the
number of people with adverse effects (Summary of findings 8;
Table 8).
Other outcomes
Further data from a trial comparing ES plus PFMT to PFMT
alone (Firra 2013) are presented in Table 8. These data relate to
pelvic floor muscle strength and are inconclusive.
ii) ES plus behavioural therapy versus behavioural therapy
alone
One trial (Gonzalez 2015; n = 82) compared ES plus behavioural
therapy to behavioural therapy alone.
Primary outcome
Perception of cure or improvement of OAB symptoms
Not reported
Number of participants satisfied with treatment
Not reported
Improvement in urgency urinary incontinence
Not reported
OAB-related quality of life
Very low-quality evidence from a single trial (Gonzalez 2015) sug-
gested higher QoL when ES was added to behavioural therapy
(Summary of findings 9; Table 9).
Secondary outcomes
Not reported
iii) ES plus drug therapy versus drug therapy alone
Three trials compared ES plus drug therapy to drug therapy alone
(Abdelbary 2015; Orhan 2015; Souto 2014)
Primary outcome
Perception of cure or improvement of OAB symptoms
Not reported
Number of participants satisfied with treatment
Not reported
Improvement in urgency urinary incontinence
Not reported
OAB-related quality of life
Low-quality evidence, from two trials, suggested there may be no
difference inQoLwhenESwas added to drug therapy (tolterodine
or vaginal oestrogen cream) (SMD -1.50 (95%CI -3.72 to 0.72; n
= 248) (Analysis 7.1) (Summary of findings 10) (Abdelbary 2015;
Sancaktar 2010)
The trial by Abdelbary 2015 measuredQoL at three different time
points; at the end of treatment and at three and sixmonths’ follow-
up. There was a statistically significant difference in favour of ES
plus oestrogen cream at all time points (Table 10).
Secondary outcomes
Quantification of symptoms
Data from two trials suggested that adding ES to drug therapy
(tolterodine or oestrogen cream) resulted in significantly fewer in-
continence episodes than drug therapy alone (MD -0.53, 95%
CI -0.63 to -0.43; n = 248) (Abdelbary 2015; Sancaktar 2010)
(Analysis 7.2). However, heterogeneity was very high (I2 = 97%),
probably due to considerable differences in sample sizes. A ran-
dom-effects analysis altered the result slightly but it remained sta-
tistically significant (MD -0.60, 95% CI -1.18 to -0.02).
ES added to drug therapy (tolterodine or oestrogen cream) also re-
sulted in significantly fewer urgency episodes (MD -2.49, 95%CI
-2.74 to -2.24; 248) (Abdelbary 2015; Sancaktar 2010) (Analysis
7.3). Again, heterogeneity was high (I2 = 87%) and a random-
effects analysis altered the result only slightly (MD -2.33, 95% CI
-3.11 to -1.54).
However, no evidence of a difference was found in the following
outcomes when comparing ES plus drug therapy to drug therapy
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alone micturitions per 24 hours (Abdelbary 2015; Souto 2014; n
= 250) (tolterodine or oxybutynin) (Analysis 7.4)
The trial by Abdelbary 2015 (n = 210) measured symptoms at
three different time points; at the end of treatment and at three
and six months’ follow-up. In almost all cases, the result suggested
adding ES to oestrogen cream was more effective than oestrogen
cream alone.
Economic data
Not reported
Procedure outcomes
Not reported
Adverse effects
Very low-quality evidence from a single trial indicated no evidence
of a difference in adverse effects when ES was added to tolterodine
compared to tolterodine alone (Sancaktar 2010; n = 38) (Summary
of findings 10; Table 10). The reported adverse effects included
constipation, dry mouth, headache and skin irritation.
7. One type of electrical stimulation versus another
type of electrical stimulation
Ten trials with 533 participants compared one type of ES with
another (Alves 2015; Boaretto 2011; Bower 1998; Finazzi-Agrò
2005; Lobel 1998;Monga 2011; Phillips 2012; Seth 2014; Slovak
2015; Sotelo 2011).
Primary outcome
Perception of cure or improvement of OAB symptoms
Very low-quality evidence from a single trial (Lobel 1998; n =
37), comparing ES once a week versus ES twice a week, found
that all participants were improved after five weeks of treatment
and that 24% (9/37) were satisfied enough to request no further
treatment. However, these data were not reported separately for
the two treatment groups (Summary of findings 11); Table 11).
Finazzi-Agrò 2005 (n = 35), which compared one session of per-
cutaneous ES per week to three sessions per week, found little ev-
idence of a difference between the groups in terms of successful
treatment. Success was defined as greater than 50% reduction in
micturitions per 24 hours, or as greater than 50% reduction in
UUI episodes in participants who had UUI at baseline (Summary
of findings 12; Table 11). Again, the quality of evidence was very
low.
Number of participants satisfied with treatment
Not reported
OAB-related quality of life
Very low-quality evidence, from a single trial (Alves 2015; n = 28)
comparing sensory threshold ES to motor threshold ES, suggested
there was no evidence of a difference inQoLmeasured with ICIQ-
OAB (Summary of findings 13; Table 11). Similarly, very low-
quality evidence from another trial (Finazzi-Agrò 2005) suggested
little evidence of a difference in I-QoL scores when once a week
ES was compared to three times per week (Summary of findings
12).
Secondary outcomes
Quantification of symptoms
One trial (Monga 2011; n = 74), comparing ES patches placed
by investigators versus patches placed by participants, reported
various outcomes relating to quantification of symptoms but did
not separate the data according to treatment group.
Another small trial (Alves 2015; n = 28), comparing two different
kinds of tibial nerve stimulation found no evidence of a differ-
ence between treatments in the number of UUI episodes, urgency
episodes, micturitions or nocturia episodes (Table 11). Similarly,
the Finazzi-Agrò 2005 trial (n = 35) comparing ES delivered once
a week to ES three times per week, reported little evidence of a
difference between the groups in incontinence episodes and mic-
turitions per 24 hours (Table 11).
No other outcomes relating to quantification of symptoms were
reported by any of the identified trials.
Economic data
Not reported
Procedure outcomes
Not reported
Adverse effects
One trial (n = 37; Lobel 1998), comparing ES once a week versus
ES twice a week, reported the following adverse effects across all
participants but not separated by treatment group.
• Discomfort: 16% (6/37)
• Leg tremor: 8% (3/37)
• Urinary tract infection: 8% (3/37)
Another trial (n = 50; Sotelo 2011), comparing different ES patch
placements, reported one participant experiencing adverse effects
24Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
but did not report to which treatment group the participant be-
longed. Very low-quality evidence from Finazzi-Agrò 2005, com-
paring one ES session per week to three sessions per week, reported
no adverse effects in either group (Summary of findings 12).
Other outcomes
One trial (Boaretto 2011) compared two different pulse widths
(200 microseconds and 500 microseconds) and reported similar
satisfaction in both groups (RR for number of people not satisfied:
0.73, 95% CI 0.25 to 2.10; n = 38) (Table 11).
25Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Electrical stimulation versus placebo or sham treatment
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospitals (Brazil, Italy, Japan, Taiwan, USA, UK)
Intervention: Electrical st imulat ion
Comparison: Placebo or sham treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo or
sham treatment
Risk with electrical
stimulation
Part icipants cured or
improved
Follow-up: range 4
weeks to 12 weeks
Study populat ion RR 2.26
(1.85 to 2.77)
677
(10 RCTs)
⊕⊕⊕©
MODERATE 1
262 per 1000 593 per 1000
(485 to 726)
Part icipants with im-
provement in urgency
urinary incont inence
Follow-up: range 4
weeks to 13 weeks
Study populat ion RR 5.03 (0.28 to 89.88) 242
(2 RCTs)
⊕⊕©©
LOW 23
189 per 1000 948 per 1000
(53 to 1000)
OAB-related quality of
lif e
Follow-up: range 4
weeks to 13 weeks
3/ 7 trials reported signif icant ly higher quality of
lif e in the intervent ion groups. Others reported
no evidence of a dif ference between groups
- 627
(7 RCTs)
⊕⊕©©
LOW 24
Adverse ef fects
Follow-up: median 12
weeks
Study populat ion RR 1.24
(0.84 to 1.83)
450
(3 RCTs)
⊕⊕©©
LOW 25
139 per 1000 172 per 1000
(117 to 254)
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (high risk of performance and detect ion bias in one trial; unclear risk of
bias in many domains in other trials)
2 Downgraded one level due to serious imprecision (small sample sizes and events, wide conf idence interval of the pooled
ef fect est imate)
3 Downgraded one level due to serious risk of bias (unclear sequence generat ion and allocat ion concealment in the included
studies).
4 Downgraded one level due to serious risk of bias (unclear risk of bias in most domains)
5 Downgraded one level due to serious risk of bias (unclear risk of select ion bias)
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Electrical stimulation versus PFM T
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospitals (Brazil, Taiwan)
Intervention: Electrical st imulat ion
Comparison: PFMT
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with PFM T Risk with electrical
stimulation
Part icipants cured or
improved
Follow-up: median 12
months
Study populat ion RR 1.60
(1.19 to 2.14)
195
(3 RCTs)
⊕⊕⊕©
MODERATE 1
390 per 1000 625 per 1000
(465 to 836)
Part icipants with im-
provement in urgency
urinary incont inence
Follow-up: 6 weeks
Study populat ion RR 1.62
(0.51 to 5.12)
52
(1 RCT)
⊕©©©
VERY LOW 23
382 per 1000 619 per 1000
(195 to 1000)
OAB-related quality of
lif e
assessed with: King’s
Health Quest ionnaire
(lower scores indicate
better quality of lif e)
Follow-up: 6 weeks
The mean OAB-related quality of lif e in the inter-
vent ion group was 129.81 higher (47.83 higher
to 211.79 higher)
- 49
(1 RCT)
⊕©©©
VERY LOW 23
Adverse ef fects See comment See comment Not est imable (0 studies) - Not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io2
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Dowgraded one level due to serious risk of bias (some risk of performance and attrit ion bias)
2 Downgraded two levels due to very serious risk of bias (unclear risk of select ion and detect ion bias)
3 Downgraded two levels due to very serious imprecision (single trial, small sample size, wide conf idence interval)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Electrical stimulation versus PFM T plus biofeedback
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Taiwan)
Intervention: Electrical st imulat ion
Comparison: PFMT plus biofeedback
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with PFM T plus
biofeedback
Risk with electrical
stimulation
Part icipants cured or
improved
See comment See comment Not est imable (0 studies) - Not reported
Part icipants with im-
provement in urgency
urinary incont inence
Follow-up: 6 weeks
Study populat ion RR 1.06
(0.60 to 1.85)
51
(1 RCT)
⊕⊕©©
LOW 12
500 per 1000 530 per 1000
(300 to 925)
OAB-related quality of
lif e
Assessed with: King’s
Health Quest ionnaire
(lower scores indicate
better quality of lif e)
Follow-up: 6 weeks
The mean OAB-related quality of lif e in the inter-
vent ion group was 5.78 lower (88.99 lower to 77.
43 higher)
- 51
(1 RCT)
⊕⊕©©
LOW 12
No evidence of a dif fer-
ence between groups in
quality of lif e scores
Adverse ef fects See comment See comment Not est imable (0 studies) - Not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (unclear risk of select ion and performance bias)
2 Downgraded one level due to serious imprecision (single trial, small sample size)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Electrical stimulation versus magnetic stimulation
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Japan)
Intervention: Electrical st imulat ion
Comparison: Magnetic st imulat ion
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with magnetic
stimulation
Risk with electrical
stimulation
Part icipants cured or
improved
See comment See comment Not est imable (0 studies) - Not reported
Part icipants with im-
provement in urgency
urinary incont inence
See comment See comment Not est imable (0 studies) - Not reported
OAB-related quality of
lif e
See comment See comment Not est imable (0 studies) - Not reported
Adverse ef fects
Follow-up: 4 weeks
Not est imable 32
(1 RCT)
⊕©©©
VERY LOW 12
No events reported in
either group
0 per 1,00 0 per 1,00
(0 to 0)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent3
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Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded two levels due to very serious imprecision (single trial, small sample size)
2 Downgraded one level due to serious risk of bias (unclear risk of select ion and performance bias)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Electrical stimulation versus laseropuncture/ electro-acupuncture
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Spain)
Intervention: Electrical st imulat ion
Comparison: Laseropuncture/ electro-acupuncture
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with laseropunc-
ture/ electro-
acupuncture
Risk with electrical
stimulation
Part icipants cured or
improved
See comment See comment Not est imable (0 studies) - Not reported
Part icipants with im-
provement in urgency
urinary incont inence
See comment See comment Not est imable (0 studies) - Not reported
OAB-related quality of
lif e
Assessed with: Bladder
Self -Assessment Ques-
t ionnaire (lower scores
indicate better quality
of lif e)
Follow-up: 12 weeks
The mean OAB-related quality of lif e in the inter-
vent ion group was 2.09 lower (4.1 lower to 0.08
lower)
- 22
(1 RCT)
⊕⊕©©
LOW 1
Signif icant ly greater
quality of lif e in inter-
vent ion group
Adverse ef fects See comment See comment Not est imable (0 studies) - Not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded two levels due to very serious imprecision (single trial, small sample size)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Electrical stimulation versus drug therapy
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospitals (Brazil, China, Sweden, Taiwan)
Intervention: Electrical st imulat ion (ES)
Comparison: Drug therapy
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with drugs Risk with electrical
stimulation
Part icipants cured or
improved
Follow-up: range 4
weeks to 2 years
Study populat ion RR 1.20
(1.04 to 1.38)
439
(8 RCTs)
⊕⊕⊕©
MODERATE 1
585 per 1000 702 per 1000
(608 to 807)
OAB-related quality of
lif e
Follow-up: range 4
weeks to 6 months
One trial used OAB-Q, PGII and PPIUS and found
a signif icant result only in the PGII, which was
in favour of ES. Another trial f ound no evidence
of a dif ference between groups in I-QoL scores.
A third trial f ound higher QoL scores in the ES
group at the end of treatment and at 3 months’
follow-up but no evidence of a dif ference at 6
months’ follow-up
- 336
(3 RCTs)
⊕⊕©©
LOW 12
Adverse ef fects - ES
versus oxybutynin
Follow-up: 5 weeks
Study populat ion RR 0.11
(0.01 to 0.84)
79
(2 RCTs)
⊕⊕©©
LOW 23
214 per 1000 24 per 1000
(2 to 180)
Adverse ef fects - ES
versus tolterodine
Follow-up: range 4
weeks to 2 years
Study populat ion RR 0.12
(0.05 to 0.27)
200
(4 RCTs)
⊕⊕⊕©
MODERATE 1
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459 per 1000 55 per 1000
(23 to 124)
Adverse ef fects - ES
versus solif enacin suc-
cinate
Follow-up: 4 weeks
Study populat ion RR 0.09
(0.01 to 1.60)
100
(1 RCT)
⊕©©©
VERY LOW 14
100 per 1000 9 per 1000
(1 to 160)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (unclear risk of bias in most domains)
2 Downgraded one level due to serious imprecision (few trials, small sample sizes)
3 Downgraded one level due to serious risk of bias (high risk of select ion and attrit ion bias)
4 Downgraded two levels due to very serious imprecision (single trial, wide conf idence intervals)
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Electrical stimulation plus PFM T versus PFM T alone
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Belgium, Brazil, USA)
Intervention: Electrical st imulat ion plus PFMT
Comparison: PFMT alone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with PFM T alone Risk with electrical
stimulation plus PFM T
Part icipants cured or
improved
See comment See comment Not est imable (0 studies) - Not reported
Part icipants with im-
provement in urgency
urinary incont inence
Follow-up: 12 weeks
Study populat ion RR 2.82
(1.44 to 5.52)
51
(1 RCT)
⊕⊕©©
LOW 12
269 per 1000 759 per 1000
(388 to 1000)
Adverse ef fects
Follow-up: 12 weeks
Study populat ion Not est imable 51
(1 RCT)
⊕©©©
VERY LOW 34
No events reported in
treatment groups
0 per 1000 0 per 1000
(0 to 0)
OAB-related quality of
lif e
Follow-up: range 8
weeks to 6 months
One trial found greater quality of lif e in the
intervent ion group (measured with ICIQ-SF). Two
other trials found no evidence of a dif ference
between groups (measured with SF-Qualiveen
and York Incont inence Percept ion Scale)
- 201
(3 RCTs)
⊕⊕©©
LOW 12
Cost-ef fect iveness See comment See comment Not est imable (0 studies) - Not reported
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (unclear risk of bias in most domains)
2 Downgraded one level due to serious imprecision (single trial, small sample, wide conf idence interval)
3 Downgraded one level due to serious risk of bias (high risk of attrit ion bias, unclear risk in other domains)
4 Downgraded two levels due to very serious imprecision (single trial, small sample size, no events)
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Electrical stimulation plus behavioural therapy versus behavioural therapy alone
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Chile)
Intervention: Electrial st imulat ion plus behavioural therapy
Comparison: Behavioural therapy
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with behavioural
therapy alone
Risk with electrical
stimulation plus be-
havioural therapy
Part icipants cured or
improved
See comment See comment Not est imable (0 studies) - Not reported
Part icipants with im-
provement in urgency
urinary incont inence
See comment See comment Not est imable (0 studies) - Not reported
OAB-related quality of
lif e
Follow-up: 3 months
Intervent ion group reported signif icant ly better
quality of lif e measured with OAB-Q and Incont i-
nence Severity Index
- 82
(1 RCT)
⊕©©©
VERY LOW 12
Adverse ef fects See comment See comment Not est imable (0 studies) - Not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
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Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (high risk of attrit ion bias, low risk of select ion bias and unclear in other
domains)
2 Downgraded two levels due to very serious imprecision (single trial, small sample size, wide conf idence interval)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Electrical stimulation plus drug therapy versus drug therapy alone
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Turkey)
Intervention: Electrical st imulat ion plus drug therapy
Comparison: Drug therapy
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with drug therapy
alone
Risk with electrical
stimulation plus drug
therapy
Part icipants cured or
improved
See comment See comment Not est imable (0 studies) - Not reported
Part icipants with im-
provement in urgency
urinary incont inence
See comment See comment Not est imable (0 studies) - Not reported
OAB-related quality of
lif e
assessed with: IIQ-7
(lower scores indicate
greater quality of lif e)
Follow-up: range 12
weeks to 6 months
The mean OAB-related quality of lif e in the inter-
vent ion group was 1.50 lower (3.72 lower to 0.72
higher)
- 248
(2 RCTs)
⊕⊕©©
LOW 12
Adverse ef fects
Follow-up: 12 weeks
Study populat ion RR 0.45
(0.04 to 4.55)
38
(1 RCT)
⊕©©©
VERY LOW 13
111 per 1000 50 per 1000
(4 to 506)
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* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (unclear risk of bias in most domains)
2 Downgraded one level due to serious imprecision (few trials, conf idence intervals do not overlap)
3 Downgraded one level due to very serious imprecision (single trial, small sample size, wide conf idence interval)
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ES once a week versus ES twice a week
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (USA)
Intervention: ES once a week
Comparison: ES twice a week
Outcomes Impact of participants
(studies)
Quality of the evidence
(GRADE)
Part icipants cured or im-
proved
Follow-up: 6 months
100% (37/ 37) of part icipants
in both groups reported im-
provement in symptoms but
only 9/ 37 were sat isf ied
enough to request no further
treatment
37
(1 RCT)
⊕©©©
VERY LOW 12
Part icipants with improve-
ment in urgency urinary incon-
t inence
Not reported (0 studies) -
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group
and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of
the ef fect, but there is a possibility that it is substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate
of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent
f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (unclear risk of bias in most domains)
2 Downgraded two levels due to very serious imprecision (N=37 part icipants in trial but numbers not reported per group)
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ES once a week versus ES three times a week
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Italy)
Intervention: ES once a week
Comparison: ES 3 times a week
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with ES 3 times a
week
Risk with ES once a
week
Part icipants cured or
improved (follow-up
not reported)
Study populat ion RR 0.97
(0.60 to 1.57)
35
(1 RCT)
⊕©©©
VERY LOW 12
667 per 1000 647 per 1000
(400 to 1000)
Part icipants with im-
provement in urgency
urinary incont inence
(follow-up not reported)
Study populat ion RR 0.80
(0.29 to 2.21)
22
(1 RCT)
⊕©©©
VERY LOW 12
455 per 1000 364 per 1000
(132 to 1000)
OAB-related quality of
lif e (follow-up not re-
ported)
assessed with: I-QoL
(Higher scores indicate
greater quality of lif e)
I-QoL scores very sim ilar in the 2 groups (median
(range) N):
once a week: 77 (35-100), 17.
3 t imes per week: 78 (33-100), 18
- 35 (1 RCT) ⊕©©©
VERY LOW 12
Adverse ef fects (fol-
low-up not reported)
0 per 1000 0 per 1000 (0 to 0) not est imable 35 (1 studies) ⊕©©©
VERY LOW 12
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io4
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (unclear risk of bias in most domains)
2 Downgraded two levels due to very serious imprecision (single trial, small sample size, wide conf idence intervals around
est imate of ef fect)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Sensory threshold ES versus motor threshold ES
Patient or population: Adults with overact ive bladder (OAB)
Setting: Hospital (Brazil)
Intervention: Sensory threshold ES
Comparison: Motor threshold ES
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with motor thresh-
old ES
Risk with sensory
threshold ES
Part icipants cured or
improved
See comment See comment Not est imable (0 studies) - Not reported
Part icipants with im-
provement in urgency
urinary incont inence
See comment See comment Not est imable (0 studies) - Not reported
OAB-related quality of
lif e
assessed with: ICIQ-
OAB
Follow-up: 4 weeks
The mean OAB-related quality of lif e in the inter-
vent ion group was 0.07 lower (2.21 lower to 2.07
higher)
- 28
(1 RCT)
⊕©©©
VERY LOW 12
No evidence of a dif fer-
ence between groups
Adverse ef fects See comment See comment Not est imable (0 studies) - Not reported
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded one level due to serious risk of bias (low risk of performance, detect ion and attrit ion bias but unclear risk of
select ion bias)
2 Downgraded two levels due to very serious imprecision (single trial, small sample, wide conf idence interval)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
Summary of main results
To the best of our knowledge, this is the first systematic review
to synthesise all available data from randomised controlled trials
(RCTs) relating to the effectiveness of electrical stimulation (ES)
with non-implanted devices compared with any other treatment
for overactive bladder (OAB). The results of the review suggest
that ES shows promise in treating OAB.
Improvement of OAB symptoms
ES is likely to be more effective than placebo/sham treatment,
PFMT or drug therapy (Summary of findings 2; Summary of
findings 3; Summary of findings 7) in improving OAB symptoms.
Specifically considering urgency urinary incontinence (UUI), ES
may be more effective than placebo or sham treatment (Summary
of findings 2) but we are very uncertain that ES is better for UUI
than PFMT, (Summary of findings 3), nor can we be certain that
adding ES to PFMT leads to improvement in UUI (Summary
of findings 8). The conclusions regarding improvement in UUI
should be interpreted with caution due to the lack of clarity in the
trials’ reporting of rates of urgency incontinence at baseline.
Furthermore, it appears that while both intravaginal ES and per-
cutaneous tibial nerve stimulation are likely to lead to greater im-
provement in symptoms than sham/placebo, intravaginal ES is
likely to have a larger effect.
For OAB symptoms, low-quality evidence indicates that ES may
be more effective than no active treatment (Summary of findings
for the main comparison). This is supported by evidence from
symptom quantification, such as the number of people with noc-
turia or increased frequency. Additionally, low-quality evidence
suggests that ES may be more effective than biofeedback-assisted
PFMT (Summary of findings 4) but this is based on a single trial
and we did not identify any secondary outcome data to support
or refute this finding.
OAB-related quality of life
It is difficult to state with certainty that ES is likely to improve
OAB-related quality of life more than treatment with PFMT or
electro-acupuncture; notwithstanding the moderate quality of the
evidence identified, these findings are based on single small trials
and are therefore not conclusive (Summary of findings 3; Summary
of findings 6).
Low-quality evidence suggests that ESmay lead to improvedOAB-
related quality of life compared to no active treatment (Summary
of findings for themain comparison).We cannot be certain there is
any difference in OAB-related QoL between ES and drug therapy
Summary of findings 7), nor when ES is added to PFMT or drug
therapy, compared to PFMT or drug therapy alone (Summary of
findings 8; Summary of findings 10).
It is possible that ES improves OAB-related QoL more than
placebo/sham treatment, and that adding ES to behavioural ther-
apy is better than behavioural therapy alone in terms of OAB-
related QoL, but the very low quality of the evidence means that
we cannot draw these conclusions with any certainty (Summary
of findings 2; Summary of findings 9).
Adverse effects
Low-quality evidence suggests that there may be a lower risk of
adverse effects with ES than with oxybutynin or tolterodine (
Summary of findings 7).
Due to the very low-quality evidence available, we cannot be cer-
tain whether there are fewer adverse effects with ES compared
to placebo/sham treatment,magnetic stimulation, electro/laserop-
uncture or solifenacin succinate (Summary of findings 2; Summary
of findings 5; Summary of findings 6; Summary of findings 7).We
are also very uncertain whether adding ES to PFMT or to drug
therapy results in fewer adverse effects than PFMT or drug ther-
apy alone (Summary of findings 8; Summary of findings 10). Nor
can we tell if there is any difference in the risk of adverse effects
between different types of ES (Summary of findings 11; Summary
of findings 12; Summary of findings 13).
Effectiveness of ES over time
Based on the small number of trials reporting outcomes at the end
of treatment as well as after a longer follow-up period, it appears
that the effect of ES diminishes after the end of treatment. How-
ever, this was also the case for most other interventions and is likely
to be due to the nature of the condition. Where ES was found to
be more effective than a comparator intervention at the first mea-
surement point, this trend was generally found to be maintained
at the longer-term follow-up. Nonetheless, this evidence should
be considered in the context that the outcomes measured at mul-
tiple time points in this small set of trials tended to be objective
measures rather than the more reliable and meaningful subjective
report of symptoms.
Overall completeness and applicability of
evidence
The included studies do not address all of the objectives of the
review because many of them did not report data in a usable
way or did not measure the primary outcomes, that is, a sub-
jective report of symptoms. Five trials reported urodynamic out-
comes only (Berghmans 2002; Bower 1998; Vahtera 1997; Walsh
2001; Yamanishi 2000b), which was of limited use because sub-
jective, patient-reported cure or improvement should take prece-
dence over objective, clinician-observed outcomes; for instance, a
patient may still have OAB according to objective measurements
but if their subjective assessment is that of no bothersome symp-
toms, then usually no further treatment will be required. Future
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trials should ensure appropriate subjective outcomes are measured
and reported.
Of particular note is the absence of data on subjective cure or
improvement from the trials comparing ES plus drug therapy to
drug therapy alone. Furthermore, the paucity of data in many of
the included trials meant that we could not draw any conclusions
regarding adverse effects between ES and placebo/sham treatment
or other conservative treatments. Nor can we tell if adding ES to
another treatment increases the risk of adverse effects.
Another key outcome, QoL associated with OAB or incontinence,
was inadequately addressed by the included studies. While 22 of
the 64 trials incorporated a validated measure of QoL, it was dif-
ficult to discern a clear picture regarding clinically meaningful re-
sults. Two trials included definitions of clinical significance relat-
ing to theQoL instruments used (Oldham 2013; Svihra 2002); the
QoL findings of those trials were not clinically meaningful. The
remaining trials that measured QoL were unclear about the clini-
cal significance of their QoL instruments (Abdelbary 2015; Alves
2015; Bellette 2009; Chen 2015; Finazzi-Agrò 2010; Firra 2013;
Gaspard 2014; Gonzalez 2015; Orhan 2015; Peters 2010; Phillips
2012; Sancaktar 2010; Schmidt 2009; Schreiner 2010; Schreiner
2014; Seth 2014; Souto 2014; Vecchioli-Scaldazza 2013; Wang
2004;Wang 2009). It is therefore difficult to form any conclusions
regarding the potential for ES to improveQoL in relation toOAB.
Nevertheless, the findings presented here are based on evidence
from trial populations that were reasonably representative of OAB
in clinical practice, including people with both OAB-wet and
OAB-dry.
Economic commentary
To supplement the main systematic review of effects, we sought
to identify economic evaluations which have compared electrical
stimulation with non-implanted electrodes to other treatments.
Only one economic evaluation (Chen 2012) was identified. This
study was a cost-utility analysis, conducted using the framework of
a decisionmodel, comparingpercutaneous tibial nerve stimulation
(PTNS) with extended release tolterodine. The model was based
on direct medical costs, in 2010 USD, during a one year time
horizon and the analysis was conducted from a societal perspective.
The authors concluded that PTNS was not cost-effective com-
pared to tolterodine (incremental cost-effectiveness ratio (ICER)
of USD 70,754 per quality-adjusted life year, USD 20,754 above
the USD 50,000 acceptable threshold). Furthermore, sensitivity
analyses indicated that the ICER was above the acceptable thresh-
old in nine of eleven possible scenarios. The authors noted that
their findings were limited by the quality of the literature.
However, there was a degree of ambiguity in the study. Firstly, it
was unclear whether a Markov model or a simple decision tree
model was used. Secondly, a societal perspective would generally
be expected to incorporate more than direct medical costs so it
may be more accurate to consider this analysis to be have been
conducted from a healthcare payer perspective. Finally, it appears
that the authors have inaccurately interpreted the eleven scenarios
presented in the sensitivity analyses and therefore their conclusions
may be misleading.
We did not subject this economic evaluation to critical appraisal
and we do not attempt to draw any firm or general conclusions
regarding the relative costs or efficiency. The apparent scarcity of
relevant economic evaluations indicates that economic evidence
regarding is currently lacking.
Quality of the evidence
Despite the large number of identified trials (64), the amount
and quality of evidence is insufficient to reach a robust conclusion
regarding the effectiveness of ES compared to other active treat-
ments. The sample sizes for individual outcomeswere small, which
led to downgrading the quality of evidence in some instances be-
cause underpowered trials are likely to have a greater degree of
imprecision. Small sample sizes in individual trials can also lead to
under-powered meta-analyses, which then give inconclusive over-
all estimates of effect.
Assessing the risk of bias and methodological quality of the in-
cluded trials was limited by the extent to which adequate details
were provided in reports of trials. Future trials should adhere to
CONSORT guidelines to ensure clarity and completeness in the
reporting ofmethods (Schulz 2010). Risk of selection bias through
randomisation and allocation concealment was generally unclear
because of insufficient reporting. The risk of performance bias was
also relatively unclear because of a lack of information to judge
whether or not participants, healthcare providers and outcome as-
sessors were adequately blinded. In many trials, it would not have
been possible to blind participants; however, an element of risk
of bias remains where participants were not blinded, because self-
reported, subjective outcomes could have been affected by par-
ticipants’ perception of the intervention received, leading to un-
certainty regarding the extent to which the estimate of effect was
truly attributable to the intervention.
Potential biases in the review process
Every attempt was made to reduce the risk of bias in the review
process, with broad inclusion criteria and a comprehensive search
strategy to identify eligible trials. There were no language restric-
tions and we obtained translations of non-English trials wherever
possible. The risk of bias was further minimised by two review
authors undertaking independent screening of search results and
independent data extraction.
However, unclear reporting of trial methods and data, and subse-
quent problems obtaining clarifications from trial authors limited
the extent to which we could meaningfully compare all of the rel-
evant data from the identified trials.
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Agreements and disagreements with other
studies or reviews
To the best of our knowledge, this is the first systematic review of
RCTs to investigate the effectiveness of ES with non-implanted
devices compared to any other treatment for OAB. A systematic
review focusing on ES of the pelvic floor found evidence in favour
of ES for urinary incontinence, with or without OAB symptoms
(Jerez-Roig 2013). Similarly, a systematic review investigating ES
for any kind of urinary incontinence in women (Schreiner 2013)
found evidence suggesting that ES was more effective than other
treatments for UUI, but that the evidence for stress urinary incon-
tinence (SUI) or mixed urinary incontinence (MUI) was much
less clear. As UUI is one of the key symptoms of OAB, our find-
ings with regard to OAB can be taken together with the reviews by
Schreiner and colleagues and Jerez-Roig and colleagues to indicate
that ES is effective in treating OAB symptoms. Additionally, our
findings are in accord with Berghmans 2013, whose systematic
review of ES for any kind of urinary incontinence in men found
limited evidence that ES was more effective than sham treatment
and that ES enhanced the effectiveness of pelvic floor muscle train-
ing (PFMT) in the short term.
Schreiner and colleagues’ findings regarding different types of ES
were similar to ours in that the heterogeneity of ES interventions
in the identified trials was such that no conclusions could be drawn
on which types of ES may be more effective than others.
The findings of our review lend further weight to another sys-
tematic review (Rai 2012) comparing drug treatment with other
active treatments for OAB, which found limited evidence that ES
was more effective than drugs in improving OAB symptoms and
that there were fewer adverse effects associated with ES than with
drug treatment. Our review identified eight additional trials not
included by Rai 2012; consequently, the conclusions of our re-
view add strength to the evidence base for ES compared to drug
treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In conducting this review we have attempted to answer several
clinical questions.
• Is electrical stimulation (ES) with non-implanted
devices better than no active treatment, placebo or sham
treatment? Moderate-quality evidence suggests that ES is more
effective than no active treatment, placebo or sham treatment in
improving overactive bladder (OAB) symptoms, urgency urinary
incontinence (UUI) and OAB-related quality of life (QoL).
• Is one type of ES with non-implanted devices better
than another? No clear evidence was identified to suggest that
one type of ES was more effective than others. There was
substantial heterogeneity in the types of ES interventions in the
included studies. The variety of aspects of treatment such as
duration and frequency, duty cycle, current, route of
administration (e.g. vaginal, rectal) and approaches of electrodes
(e.g. transcutaneous, percutaneous) could produce different
effects through their different mechanisms, which means that
there are many variables to take into account when considering
the effectiveness of one type of ES compared to another and no
conclusions could be drawn based on the identified evidence.
• Is ES with non-implanted devices better than other
conservative treatments? Moderate-quality evidence suggests
that ES is more effective than pelvic floor muscle training
(PFMT) in improving OAB symptoms. It is very uncertain
whether ES is more effective than PFMT in improving UUI or
OAB-related QoL.
• Is ES with non-implanted devices better than drug
therapy?Moderate-quality evidence suggests that ES may be
more effective than drug therapy in improving OAB symptoms,
but for improving UUI and OAB-related QoL there was no
evidence to suggest a difference.
• Is ES with non-implanted devices added to other
treatments better than other treatments alone?We do not
know if adding ES to PFMT, to behavioural therapy or to drug
therapy leads to improvement in OAB symptoms or OAB-
related QoL. There is very limited evidence to suggest that
adding ES to PFMT may reduce UUI episodes.
• Is ES safe? There may be a lower risk of adverse effects with
ES than placebo, sham treatment, oxybutynin or tolterodine.
• Is ES cost-effective? We cannot tell from the identified
evidence. It is important to consider cost-effectiveness in any
intervention to assist policymakers, healthcare providers and
people with OAB in decision-making with regard to treatment.
Future trials should include a measure of costs from both the
provider and patient perspective, equated to a meaningful
patient-centred outcome.
Implications for research
This review highlights the urgent need to conduct well-designed
trials in this field. It is evident from our findings that the current
evidence base is inadequate to answer fully the question of the
effectiveness of ES with non-implanted electrodes for overactive
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bladder, therefore it is important that future trials should be ade-
quately powered and should measure the following.
• Subjective perception of symptomatic improvement
• Head-to-head comparisons of different types of ES
• Cost-effectiveness of ES compared to other active
treatments
• Clinically meaningful measurement of OAB-related QoL
• Adverse effects data
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aaronson 1995
Methods Study design: RCT
Period: October 1992-January 1994
Participants N: 47 randomised and analysed.
Age: 24-82 years
Sex: women
Inclusion criteria: genuine stress urinary incontinence (GSUI) or detrusor instability
(DI)
Exclusion criteria: not reported
Interventions For detrusor overactivity incontinence women only (DO)
A (n = x): probanthine
B (n = x): ES
2nd RCT in people with GSUI
C (n = x): PFMT
D (n = x): ES
Outcomes Cure - defined as cessation of incontinence. A: not reported B: not reported
Improvement defined as reduction in frequency of voids per 24 hours by ≥ 50%, or ≤
10 voids per 24 hours, or decrease number of pads per 24 hours by ≥ 50%
Cured or improved: A (n = x): unclear (50% ‘responded well’), B (n = x) 69%, C (n =
x) 44%, D (n = x) 66%
Notes No useable data
Study authors contacted for further data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Abdelbary 2015
Methods Study design: RCT
Setting: Egypt
Follow-up: 6 weeks’ treatment, 6 months’ follow-up
Participants N: 315 randomised, 300 analysed
Mean (SD) age: A, 49.7 (6.0); B, 47.7 (6.0); C, 48.0 (6.0)
Sex: women
Inclusion criteria: ≥ 40 years, no evidence of urinary tract infection, no SUI, no previ-
ous history of anti-incontinence or pelvic surgery or anti-incontinence drugs (within 3
months), and no history of bladder malignancy
Exclusion criteria: not reported
Interventions A: (n = 105) vaginal ES twice weekly for 12 sessions
B: (n = 105) local vaginal oestrogen 0.625 mg/g (Premarin), 2 g daily for 6 weeks
C: (n = ) ES plus local vaginal oestrogen
Outcomes Voids per day (mean, SD, N)
End of treatment: A 4.7 (0.8), 105. B 5.0 (0.9), 105. C 5 (0.8), 105
3 months: A 5.0 (1.0), 105. B 5.3 (0.9), 105. C 5 (0.8), 105
6 months: A 6.6 (1.5), 105. B 5.0 (0.8), 105. C 5 (0.8), 105
Voids per night (mean SD, N):
End of treatment: A 0.9 (0.7), 105. B 1.4 (0.8), 105. C 0.5 (0.5), 105
3 months: A 1.1 (0.9), 105. B 1.5 (0.8), 105. C 1 (0.9), 105
6 months: A 2.2 (0.9), 105. B 5.0 (0.8), 105. C .5 (0.8), 105
Incontinence episodes (mean SD, N)
End of treatment: A 0.1 (0.3), 105. B 0.4 (0.6), 105. C 0.07 (0.25), 105
3 months: A 0.1 (0.3), 105. B 0.5 (0.6), 105. C 0.09 (0.28), 105
6 months: A 0.4 (0.6), 105. B 0.4 (0.6), 105. C 0.09 (0.28), 105
Urgency episodes (mean SD, N)
End of treatment: A 2 (0.7), 105. B 4 (1.3), 105. C 1.4 (0.7), 105
3 months: A 2.7 (1.0), 105. B 4.5 (1.5), 105. C 1.6 (0.9), 105
6 months: A 4.7 (1.3), 105. B 4 (1.3), 105. C 2 (0.8), 105
QoL score (higher score = greater severity, instrument not reported) (mean SD, N)
End of treatment: A 2.8 (2), 105. B 5 (1.8), 105. C 2.9 (2.2), 105
3 months: A 4 (1.7), 105. B 6 (2), 105. C 3.7 (2.5), 105
6 months: A 7.6 (3), 105. B 6 (2), 105. C 4.8 (1.9), 105
Functional bladder capacity (ml) (mean SD, N)
End of treatment: A 343.8 (46), 105. B 310 (40.6), 105. C 361 (40), 105
Detrusor overactivity (mean SD, N)
End of treatment: A 27/105. B 32/105. C 12/105
Notes
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Abdelbary 2015 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated random numeric ta-
ble”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants, other
blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No differential withdrawal, no explana-
tion for withdrawals, no indication on how
missing data were dealt with in analysis
Alves 2015
Methods Study design: RCT
Setting: Brazil
Follow-up: 4 weeks’ treatment
Participants N: 28 randomised
Sex: women
Inclusion criteria: female, ≥ 60 years with likely urinary dysfunction, identified by a
score ≥ 8 points on OAB-V8 questionnaire
Exclusion criteria: urinary infection, identified by urine test, history of treatment for
OAB and hormone replacement therapy in the last six months, prior surgery to treat UI,
neurological diseases base, genital-urinary cancer history, complaints of pain in the lower
abdomen for more than six months, prior pelvic irradiation, genital prolapse above third
degree of Baden and Walker scale, use of cardiac pacemakers, metal implants in foot and
right ankle region, inability to respond to questionnaires properly and abstentions to
treatment
Interventions A: (n = 15) tibial nerve stimulation (TNS). 8 sessions (2 x 30-minute sessions per week)
F = 10 Hz, T = 200 µs. Sensory threshold, activating superficial cutaneous nerve fibres
with larger diameter
B: (n = 13) TNS 8 sessions (2 x 30-minute sessions per week). F = 10 Hz, T = 200 µs.
Motor threshold, non-painful contraction was induced and “the stimulation can simply
make pain relief in the same way that sensory stimulation level (blocking activation of
the peripheral or central inhibition.”
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Outcomes All scores are higher score = greater severity
ICIQ-OAB score (mean SD, N)
A 4.46 (2.66), 15. B 4.53 (3.07), 13
Bother of daytime frequency (mean SD, N)
A 3.20 (2.59), 15. B 3.38 (3.17), 13
Bother of nocturia (mean SD, N)
A 3.40 (3.26), 15. B 1.84 (2.51), 13
Bother of urgency (mean SD, N)
A 4.00 (2.59), 15. B 3.53 (3.59), 13
Bother of urgency incontinence (mean SD, N)
A 2.73 (3.65), 15. B 4.38 (4.29)
Micturitions per 24 h (mean SD N)
A 8.33 (2.52), 15. B 7.89 (2.64), 13
Nocturia episodes (mean SD, N)
A 1.26 (1.21), 15. B 1.05 (1.01), 13
Urgency episodes (mean SD, N)
A 0.79 (0.96), 15. B 0.58 (0.65), 13
Urgency incontinence episodes
A 0.33 (0.57), 15. B 0.84 (1.39), 13
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomisation of two groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “blind assessment and comparison between
groups”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “blind assessment and comparison between
groups”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals reported
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Amaro 2006
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Botucatu Medical School, Unesp - Univ Estadual Paulista, Brazil
Period: January 2001-February 2002.
Sample size: “Based on outcome measurements with no numerical variable…the statis-
tical test sample size had previously been established as at least 40 women.”
Follow-up: 7-week treatment period, follow-up appointments one month after end of
treatment
Participants N: 40 randomised
Mean age:
A: 49.0 (range 41-79)
B: 47.0 (range 40-78)
Sex: women
Inclusion criteria: symptoms of predominant urge incontinence
Exclusion criteria: vaginal prolapse greater than grade II (Baden), retention complaint or
obstruction diagnosis during USD, urinary infection, changes in cutaneous sensitivity,
metal implants, and neurological complaints
Interventions A: (n = 20): electrostimulation. 3 x 20-min sessions per week on alternate days over a
7-week period, performed using Dualpex Uro996. Frequency at 4 Hz, a 2-to 4-s work
rest cycle and a 0.1 us pulse width. The bipolar square wave could be delivered over a
range of 0-100 mA. Intensity was controlled according to participant discomfort level
feedback
B: (n = 20): sham. Same type of vaginal probe with wires disconnected so no electrical
energy was supplied
Outcomes Number of micturitions per 24 h (mean, SD*, N): A: 7.0 (1.78), 20; B: 7.5 (1.78), 20
P = 0.38
1 hour PAD test (g): A: 1.05; B: 1.13
Number of participants with UUI: A: 3/20 (15%), B: 6/20 (31.5%)
Number of participants ‘satisfied’: A: 16/20 (80%), B: 13/20 (65%)
Reduction in “analog wetness sensation”: A: 31.5%. B: 26.9%
Reduction in “analog discomfort sensation”: A: 39.7%; B: 24.5%
Pelvic floor muscle strength measured with portable perineometer (Dynamed) (cmH2O)
(mean, SD, N): A: 53.8 (18.6), 20; B: 46.8 (12.5), 20
Vaginal cone weight test (g) (mean, SD, N): A: 4.0 (1.3), 20; B: 2.0 (1.1), 20
Notes No SDs reported (except for 2 outcomes).
*SD calculated by FS using means and P value
No evidence of source of data in review
Information received from study authors
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “In the Randomization the participants in
each groups were raffled” (from correspon-
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dence with author)
Allocation concealment (selection bias) Unclear risk “the allocations were concealed because a
nurse, at each session, was responsible for
carrying out the random assignment of pa-
tients” (from correspondence with author)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded. ES sessions carried
out by physiotherapist and outcome as-
sessment carried out by different personnel
(from correspondence with author)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ES sessions carried out by physiotherapist
and outcome assessment carried out by
different personnel (from correspondence
with author)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported, % given with-
out denominators, unclear if all partici-
pants present for follow-up
Arruda 2008
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Department of Uroginecology, Federal University of São Paulo, Brazil
Period: August 2001-September 2005
Sample size: justified (a power calculation was performed based upon a predicted min-
imum difference of eight episodes of urinary leakage, with a significance level of 0.05,
yielding a power estimate of 90% for a sample size of 20 women per each group)
Follow-up: 12 weeks’ treatment, 1-year follow-up
Participants N: 77 randomised, 64 analysed
Mean age (SD): A 51.9 (13,4); B 51.5 (11.4); C 54.1 (11.6)
Sex: women
Inclusion criteria: OAB and DO
Exclusion criteria: persistent urinary tract infection, inability to comply with regular
follow-up visits, current pregnancy, postvoid residual volume greater than 100 mL,
contraindications to anticholinergic therapy, cardiac pacemaker, type III stress urinary
incontinence, uncontrolled metabolic conditions or indwelling catheterisation, using
medications including anticholinergic drugs, calcium antagonists, β agonists, dopamine
agonists, striated muscle relaxants, or oestrogens
Interventions A: (n = 26): oxybutynin immediate release 5 mg twice daily for 12 weeks
B: (n = 25): ES. Ambulatory stimulation applied vaginally by a physiotherapist, twice a
week, for 20 min at each session using 1 ms of intermittent biphasic waves, frequency
10 Hz. Current intensity ranged from 10-100 mA, according to participant tolerance to
the procedure
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Arruda 2008 (Continued)
C: (n = 26): exercises (PFMT), performed twice a week in orthostatic, sitting, and supine
positions. Each session had a total duration of 45 minutes. A total of 40 fast (2 and 5 s)
and 20 sustained (10 s) contractions with an equal period of relaxation between them
were administered by a physiotherapist in the outpatient setting
Outcomes Participants with urgency symptoms (subjective)
A 8/22. B 10/21. C 9/21
Participants not satisfied (subjective)
12 weeks: A 5/22. B 10/21. C 5/21
1 year: A 12/22. B 17/21. C 12/21
Participants not cured (objective evaluation: urodynamics)
A 14/22. B 9/21. C 10/21.
Number of leakage episodes per 24 hours (mean, SD, N)
A 7 (10.6), 22. B 7.9 (13.7), 21. C 7.8 (15.3), 21
Number of micturitions per 24 hours (mean, SD, N)
A 6.4 (1.6), 22. B 7.9 (2.63), 21. C 7.1 (2.1), 21
Number of nocturia episodes per night (mean, SD, N)
A 0.9 (0.8), 22. B 1.2 (1.3), 21. C 1.0 (1.1), 21
Number of pads used per 24 hours (mean, SD, N)
A 0.9 (1.5), 22. B 0.9 (1.7), 21. C 0.8 (1.3), 21
Post micturition residual volume, mL (mean, SD, N)
A 4.8 (9.4), 22. B 1.1 (2.5), 21. C 2.1 (3.5), 21
Maximum cystometric capacity, mL (mean, SD, N)
A 517.3 (191.7), 22. B 436.7 (178.7), 21. C 489.0 (141.3), 21
Volume at FDV (mean, SD, N)
A 157.3 (63.8), 22. B 123.8 (59.0), 21. C 137.6 (76.7), 21
*Involuntary detrusor contraction volume, mL (mean, SD, N)
A 188.6 (183.2), 22. B 173.3 (112.4), 21. C 114.3 (154.2), 21
Involuntary detrusor contraction maximal pressure, mmH2O (mean, SD, N)
A 19.6 (20.9), 22. B 22.4 (6.6), 21. C 17.2 (25.5), 21
Adverse effects
Dry mouth: A 16/22. B, C not reported
Difficulty on micturition: A 2/22. B, C not reported
Dizziness: A 1/22. B, C not reported
Blurred vision: A 1/22. B, C not reported
Constipation: A 1/22. B, C not reported
Notes *Value for group B reported in paper as 73.3; queried with author and correct value is
173.3
We contacted the main study author to clarify methodological aspects of the study and
request further information
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “blindly randomized to one of the three
treatment groups”
Additional information from study au-
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thor correspondence: “Patients were ran-
domised using a table of random numbers
generated by a statistical programon a com-
puter”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Additional information from author corre-
spondence: “patients and researchers knew
to which group the patients belonged”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Additional information from author corre-
spondence: “Data were analysed by a statis-
tician who did not know which group the
patients belonged to.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential withdrawal. Adequate ex-
planation for withdrawals
Barroso 2002
Methods Study design: RCT
Setting:Department ofGynecology andObstetricsHospital dasClínicas de PortoAlegre,
Rio Grande do Sul, Brazil
Period: March 2000-August 2001
Sample size: 36 participants for a power of 80% and a 2:1 ratio
Follow-up: 6 months
Participants N: 36
Sex: women
Mean (SD) age: A: 54 (9.5); B: 56 (12.2)
Inclusion criteria: SUI, UUI or MUI, understanding and signing a letter of informed
consent
Exclusion criteria: prolapse or first degree urogenital prolapse, intrinsic sphincter defi-
ciency, cardiac pacemaker, pregnancy or in the puerperal period, post-menopausal cli-
macteric’s symptoms and signs of urogenital atrophy, genitourinary surgery during the
previous 6months, previous ES of the pelvic floor, medication chronically known to pos-
sibly change voiding function, change in the dose or if they had begun to use a new med-
ication in the last 3 months, or during treatment with ES, reflex urinary incontinence,
paradoxical urinary incontinence, urinary incontinence of intravesical obstructive factor,
urinary incontinence caused by overflow, characterised by the presence of a large urinary
residual volume, urgency incontinence treated with medication during last 3 months,
or during treatment with ES; reflex urinary incontinence (clear presence of neurological
lesions); paradoxical urinary incontinence (presence of intravesical obstructive factor);
urinary incontinence caused by the presence of a large urinary residual volume; people
with urge incontinence who had treatment with medication during last 3 months
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Interventions A: transvaginal ES (n = 24). Battery-powered, portable device, 20 or 50 Hz, a pulse width
of 300 ms, with asymmetrical biphasic pulses, an adjustable current intensity (0-100
mA), a 1 s rise time, sustained for 5 s and resting for 5 s. A time-of-use counter allowed
a check on patient compliance with treatment, because it stored in the microcontroller
memory the total time of use, corresponding to the time during which current actually
circulated through the electrodes. Two 20-min sessions per day while recumbent, for 12
weeks
UUI or MUI: equipment programmed for 20 Hz
Stress urinary incontinence: equipment programmed for 50 Hz.
UUI or MUI: equipment programmed for 20 Hz
SUI: equipment programmed for 50 Hz
B: sham (n = 12). Identical equipment and regimen but without electrical stimulus
All participants requested to complete 3-day voiding diary at beginning of study and
again at 12 weeks’ follow-up
Outcomes Number of participants cured/improved at 12 weeks
A: 21 (88%) B: not reported
Number of voids per 24 hours (mean (SD) N)
A: 7.5 (2.0) 24; B: 10.5 (2.8) 12
Number of nocturia episodes (mean, SD, N)
A: 1.1 (0.5), 24; B: 2.3 (0.9), 12.
Number of incontinence episodes per 24 h (mean, SD): A: 1.3 (1.0) 24; B: 3.0 (0.9) 12
Number of uninhibited contractions per 24 h (mean, SD): A: 2 (8), 24; B: 4 (not
reported)
Maximum bladder capacity (mean, SD, N)
A: 425.0 mL (97.8), 24; B: 316.7 mL (71.8), 12
Notes Compliance: 60 h of equipment use was expected.
A: 46 hours
B: 40 hours
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The participants were randomized before
the study by drawing lots”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The participants were randomized before
the study by drawing lots, with no partic-
ipation by the examiner who, at the start
of the treatment of each patient, was al-
ready receiving the group determined by
randomization (study or control). Likewise
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the patients did not know intowhich group
they had been placed (active or placebo)
. The patients in the control group were
evaluated at different times from the study
group, to avoid any exchange of informa-
tion among them”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Urodynamic evaluations carried out by ex-
aminer unaware of the study. Participants
also unaware of intervention allocated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported
Bellette 2009
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Female Urology Clinic of the Hospital das Clínicas at Campinas (HC/UNI-
CAMP), Brazil
Follow-up: 4 weeks
Participants N: 37 randomised and analysed
Mean age: 47.73 (10.90)
Sex: women
Inclusion criteria: 18-85 years, symptoms of OAB for > 6 months, voiding frequency >
8 micturitions daily, episodes of nocturia and/or urgency
Exclusion criteria: pregnancy, neurological problems, accentuated dystopias (stages II
and III in the definitions of ICS), urinary tract infection and urinary stress incontinence
Interventions A: (n = 21): ES. Transcutaneous posterior tibial nerve stimulation. 8 sessions with Du-
alpex device 961, 30 min twice a week
B (n = 16) sham. Electrodes placed without electricity
Outcomes Participants with urgency
A 9/21. B 10/16.
Frequency of micturitions (mean, N)*
A 8.29, 21 B 10.55, 16
Decrease in frequency and urgency
A 62.5%. B 42.8% (P < 0.05)
OAB-Q severity score
A 31.72 (18.25), 21. B 51.21 (32.11), 16
OAB-Q total score
A 83.99 (16.99), 21. B 66.63 (25.06), 16
Nocturia episodes
A 1.14 (1), 21. B 2.06 (1.2), 16
Notes *Contacted study author to ask for SDs, no reply. Estimated SD used in meta-analysis
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization process was made by
the FCM’s statistics department”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The evaluationswere carried out by the in-
vestigator or the physiotherapist, and treat-
ment was performed by the same person
who evaluated the patient, thus creating a
bond with the physiotherapist.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “The evaluationswere carried out by the in-
vestigator or the physiotherapist, and treat-
ment was performed by the same person
who evaluated the patient, thus creating a
bond with the physiotherapist.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in
analysis. “All women were submitted to
eight sessions of therapy, all the question-
naires were completed and none of the
women failed to attend the sessions more
than 3 times. The reasons for missing ses-
sions were very variable, but did not alter
the results of the study.”
Berghmans 2002
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: hospital and private clinic (University HospitalMaastricht, Department of Urol-
ogy, the Netherlands)
Sample size: a level of significance of 95%, a power of 80%, an expected dropout rate of
10%, and an expected improvement of bladder overactivity status of treatment groups
in comparison with non-treatment group, expressed as a decrease of approximately 30%
in the Detrusor Activity Index (DAI), 20 participants in each of the 4 groups had to be
recruited. Therefore, the intended sample size was set on 80 people
Follow-up: unclear (9 weeks?)
Participants N: 80 randomised, 68 participated and analysed
(12 excluded as randomised ‘erroneously’)
Mean (SD) age:
A: 50.5 (11.8)
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B: 55.6 (14.8)
C: 61.9 (13.5)
D: 52.3 (15.4)
Sex: women
Inclusion criteria: Detrusor Activity Index 0.5 or greater; > 18 years, female, drug-free
interval of at least 4weeks before start of the study for the followingdrugs: anticholinergic,
beta sympathicomimetic, alpha-blocker and psychopharmacological agents
Exclusion criteria: mechanical intravesical obstruction, urinary calculus, repetitive symp-
tomatic UTI (> 3 x per year), colpitis, clinical evidence of disordered action of heart
(Lown III), pacemaker, pregnancy of lactating period, inability to comply with follow-
up, treatment with physical therapies within 3months before start of therapy, neurogenic
or congenital disorders resulting in urinary incontinence (e.g. spina bifida), psychological
disorders, irritation of the vagina (consult with the general practitioner and participant)
, poor adjustable diabetes mellitus: last HbA1C > 10, contra-indication for the use of an
intravaginal or anal electrode, not able to understand Dutch, not able to travel
Interventions A: controls (n = 14)
B: Lower Urinary Tract Exercises (LUTE) (n = 18). 1 session per week for 9 weeks.
Patient information and education; bladder training; specific PFMT aiming at detrusor
inhibition reflex (DIR); toilet behaviour aiming at the aspects of the micturition process
itself
C: FES (n = 17). FES was applied vaginally through plug-mounted electrodes. The
maximum level of the ES was 100 mA (Ieff = 6 mA), participant was instructed to use.
The maximal characteristics were (frequency modulation of 0.1 s trains of rectangular
biphasic 200 µs long pulses which varied stochastically between 4 and 10 Hz). Duration
of treatment unclear
D: FES + LUTE group (n = 19). Same LUTE programme plus an additional weekly
FES session (for 9 weeks)
Dropouts: A ?0, B 5, C 3, D 2
Outcomes Detrusor Activity Index (DAI): urodynamic variables of ambulatory cystometry com-
bined with data from micturition diary (i.e. condition-specific measure; 0-1 scale where
higher = worse) (mean, SD):
A 0.80 (0.26) 14, B 0.62 (0.33) 18, C 0.57 (0.33) 17, D 0.84 (0.27) 19
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was done in blocks of four
using opaque and sealed envelopes”
Allocation concealment (selection bias) Low risk “Randomization was done in blocks of four
using opaque and sealed envelopes”
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Berghmans 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Besides the participant and the physical
therapist all others, involved in randomi-
sation, registration and evaluation were
blinded for group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Besides the participant and the physical
therapist all others, involved in randomi-
sation, registration and evaluation were
blinded for group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout
A total number of 10 women dropped out
of the trial. 1woman stopped before start of
therapy, because she considered the burden
of investigation too high. During the treat-
ment period, 5 women stopped because of
illness (2 in group II and 2 in group III or
allegedly reasons of too much burden felt
(1 in group IV)
“Missing data in the set of post-treatment
DAI-scores were substituted by post-treat-
ment means of the empirical data accord-
ing to the intention-to-treat principle.”
Boaretto 2011
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Brazil
Period: August 2008-2010
Sample size: not reported
Follow-up: 4 weeks
Participants N: 73 randomised, unclear how many included in analysis
Mean (SD) age: 61.3 (not reported)
Sex: women
Inclusion criteria: women with OAB
Exclusion criteria: not reported
Interventions A: (n = 22) PFMT. 12 sessions. Group exercises performed in sitting, standing and supine
positions with 20 contractions of 2 s, 10 contractions of 5 s and 5 contractions every 10
s
B: (n = 22) ES, pulse width 200 ms. Transcutaneous posterior tibial nerve stimulation
(TPTNS). Frequency 10 Hz. 12 x 30-min sessions
C: (n = 16) functional ES with vaginal electrode, pulse width 500 microseconds. Fre-
quency 10 Hz.12 30-minute sessions
D: (n = 13) oxybutynin. 5 mg immediate release twice daily for 12 weeks
79Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boaretto 2011 (Continued)
Outcomes Satisfaction
A 91% (20/22). B 77% (17/22). C 69% (11/16). D 61.5% (8/13)
(not satisfied: A 2/22. B 5/22. C 5/16. D 5/13.)
Notes Data presented for urinary frequency, nocturia, urgency and urgency incontinence but
not usable
Unable to find contact details for study authors
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized into four treatment groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals reported. Outcome data
presented without denominators or SDs
Booth 2013
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: UK
Period: not reported
Sample size: not reported
Follow-up: 6 weeks
Participants N: 30 randomised, 28 analysed
Sex: men and women
Mean age: 84.2 (10.0)
Inclusion criteria: men and women > 65 in residential care home settings or sheltered
accommodation with bothersome LUTS, urinary incontinence, faecal incontinence, or
constipation; capacity to provide ongoing informed consent to participate
Exclusion criteria: pacemaker in situ, leg ulcers or broken skin on lower limb, periph-
eral vascular disease, reduced/absent sensation at the electrode sites, moderate or severe
cognitive impairment or learning difficulties, UTI on assessment, or clinical diagnosis
of only SUI
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Interventions A: (n = 15) PTNS. 2 x 30-min sessions per week for 6 weeks. Frequency 10 Hz and pulse
width 200 ms in continuous modeThe intensity level of the stimulation current range
(0-50 mA)
B: (n = 13) Sham. Same procedure with stimulation current reduced to 2 mA
Outcomes Number of participants with no improvement in incomplete bladder emptying
A 7/15, B 12/13
Number of participants with no improvement in voiding frequency
A 4/15, B 7/13
Number of participants with no improvement in urgency
A 4/15, B 9/13
Number of participants with no improvement in nocturia
A 8/15, B 10/13
Number of participants with no improvement in weak urinary stream
A 6/15, B 12/13
Number of participants with no improvement in intermittency
A 10/15, B 11/13
Number of participants with no improvement in urinary straining
A 9/15, B 12/13
Number of participants with no improvement in frequency of UI episodes
A 8/15. B 11/13.
Number of participants with no improvement in amount of urine leaked
A 7/15. B 11/13.
Number of participants with no improvement in interference with everyday life
A 6/15. B 7/13.
Number of participants with no improvement in constipation
A 14/15, B 6/13
Number of participants with no improvement in bowel urgency
A 11/15, B 12/13
Number of participants with no improvement in faecal leakage
A 8/15, B 10/13
Reduction in AUASI score (median, IQR, N):
A -7 (-8 to -3), 15. B 1 (-1 to 4), 13. (P < 0.001, Mann-Whitney U 16.5000, Z -3.742)
Reduction in ICIQ-SF score (median, IQR, N):
A 2 (0 to -6), 15. B 0 (-3 to 3), 13. (P = 0.132)
Number of participants with no improvement in ICIQ-SF score
A 5/15. B 7/13
Notes Two participants had predominantly faecal incontinence.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “online randomization service”
Allocation concealment (selection bias) Unclear risk Not reported
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded. “Staff were blind to
the group allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Fidelity to the protocol was high and 28 of
the 30 participants completed the 12 ses-
sion course, with two discontinued at ses-
sion five because they developed infections”
Bower 1998
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Australia
Period: January 1996-February 1997
Sample size: 40% volume increase and 35% decrease in maximum detrusor pressure 16
participants would be required per group for an 80% chance of detecting significant
change
Follow-up: immediately following single ES session
Participants DO group: 48 randomised
Urgency group: 31 randomised
Mean (SD) age: overall 55.4 (16.8). DO group: 56.5 (16.8). Urgency group: 56.3 (16.
9)
Sex: women
Inclusion criteria: DO or urgency
Exclusion criteria: UTI, pregnancy, cardiac pacemaker, impaired cognition, neurogenic
bladder dysfunction or cystocele beyond the introitus
Interventions DO group
A1 (n = 16) TENS - suprapubic placementFrequency 150 Hz, 200 ms pulse width
B1 (n = 16) TENS - sacral placementFrequency 10 Hz, 200 ms pulse width
C1 (n = 15) sham ES
Urgency group
A2 (n = ?) TENS - suprapubic placementFrequency 150 Hz, 200 microsecond pulse
width
B2 (n = ?) TENS - sacral placement Frequency 10 Hz, 200 mspulse width
C3 (n = ?) sham ES
Outcomes Vol. at FDV (mean, SD, N)
A1 208.5 (132), 16. B1 154 (61), 16. C1 186 (77), 15
A2 180 (51). B2 111 (37). C2 138 (51) (n not reported)
Max. cystometric capacity (mean, SD, N)
A1 352 (144), 16. B1 305 (146), 16. C 313.5 (81), 15
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A2 291 (51). B2 241 (53). C2 285 (45) (n not reported)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized to 3 groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both the supervising urogynaecologist
and the patient were blind to group alloca-
tion”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data for urgency group not presented with
numbers of participants, unclear howmany
in urgency group were randomised to each
intervention
Brubaker 1997
Methods Study design: RCT
Multicentre or single-centre: 4 centres
Setting: Rush-Presbyterian-St.Luke’s Medical Center, Chicago; Methodist Hospital, In-
dianopolis; Greater Baltimore Medical Center; and the Oregon Health Science Univer-
sity, Portland, USA
Period: not reported
Sample size: not reported
Follow-up: 8 weeks
Participants N: 148 enrolled, 121 randomised and analysed
Mean (SD) age for all participants (not stratified by GSUI/DO): A 56 (11.9); B 57.7
(12.4)
Sex: women
Inclusion criteria: women with symptoms or urodynamic evidence of genuine stress
incontinence or detrusor instability
Exclusion criteria: urinary incontinence other than genuine stress incontinence, detrusor
instability, ormixed incontinence. Age <25 years, leakage episodes≤ 3/weeks, inadequate
cognitive ability (investigator judgment), infected urine, anatomic defect that precluded
use of device, postvoid residual > 100 mL, implanted electric device, genitourinary
surgery < 6 months previously, medication alteration≤ 3 months previously, anticipated
geographic relocation during study
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Interventions For DO and mixed women only (n = 61):
A (n = 33) transvaginal electric stimulation. Device: InCare Microgyn II. 20 Hz fre-
quency, 2-second/4-second work-rest cycle, pulse width 0.1-us. Bipolar square wave
could be delivered over a range of 0-100 mA. 20 min daily
B (n = 28) sham. Identical device with disconnected wire so no electricity supplied. 20
min daily
Outcomes Definition of cure: absence of abnormality as measured objectively by urodynamics
Number of participants with DO:
A 14/32, B 23/28
UI frequency 2.2
No improvement 2.3
Compliance 2.4
Notes We contacted the main author of the study to request further information about further
3 publications of the same study. The study authors replied with information
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers,
and used for stratified randomisation
Allocation concealment (selection bias) Unclear risk The study nurse at each site was responsi-
ble for carrying out the random assignment
of participants in accordance with the ran-
domisation scheme
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The study nurse at each sitewas aware of the
difference in probes, however the physician
investigators were masked as to the type of
vaginal probe provided to each participant
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data sent to centralised data manager
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “A total of 148 women were enrolled, 18%
of whom withdrew from the study, leaving
of a total 121 participants who completed
the study. There was no statistically sig-
nificant difference between the treatment
groups with respect to withdrawal rates:
21% for the sham group and 14% for the
stimulation group.”
No explanation reported for withdrawals
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Chen 2015
Methods Study design: RCT
Setting: China
Follow-up: 4 weeks’ treatment
Participants N: 100 randomised
Inclusion criteria: neurogenic DO secondary to spinal cord injury
Exclusion criteria: urinary tract infection, tumour of the urinary system, urinary calculus,
vesicoureteral reflux confirmed by video urodynamics, bladder compliance > 10 mL/
cmH2O
Interventions A (n=50) PTNSusing adhesive skin surface electrodes.Continuous, bi-polar squarewave
formwith pulse duration of 200µs and stimulation frequency of 20Hz. “The stimulator
was controlled to determine the minimal current needed to induce a toe twitch. The
intensity was then increased to the highest level tolerated by the participant who cannot
induce lower limb muscle spasm in complete SCI patients and uncomfortable feeling
on stimulating sites in incomplete SCI patients”
B (n = 50) solifenacin succinate 5 mg per day
Outcomes Leakage volume per day (ml) (mean SD, N)
A 541.4 (47.5), 50. B 449.1 (89.2), 48
I-QoL (mean, SD, N)
A 25.2 (1.0), 50. B 24.2 (1.0), 48
Adverse effects: A 0/50 B 5/50 (all dry mouth)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “the patients were randomized into two
groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants, other
blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Nodifferential withdrawal, adequate expla-
nation for withdrawals
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Eftekhar 2014
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Iran
Follow-up: 12 weeks’ treatment
Participants N: randomised and analysed
Sex: women
Inclusion criteria: women with neurologic OAB confirmed by urodynamic diagnosis
Exclusion criteria: not reported
Interventions A: PTNS. 34-gauge needle placed 5 cm near internal malleolus. Sessions lasted 30 min
B: 4 mg tolterodine daily for 3 months
Outcomes Sexual function
Subjective assessment of pelvic disorders
Notes No useable data. Contacted study author 21-04-2016
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated numbers”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “nor patients nor the physician were
blinded to the patient’s group”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “nor patients nor the physician were
blinded to the patient’s group”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Before study began, 2 in PTNS group and
8 in the control group withdrew. No expla-
nation reported
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Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Rome, Italy
Period: not reported
Sample size: not reported
Follow up: not reported
Participants N: 35 randomised and analysed
Mean (SD) age: not reported
Sex: 28 women, 7 men
Inclusion criteria: OAB not responding to antimuscarinic therapy
Exclusion criteria: not reported
Interventions Says all cases treated in the same way as detailed in Stoller 1999.
A (n = 17, 14 F, 3 M) weekly PTNS
B (n = 18, 14 F, 4 M ) 3 times per week PTNS - every 2 days
Outcomes Success = > 50% reduction in micturitions/24 hours
OR
If incontinent, > 50% reduction in UI episodes/24 hours
A 11/17 (4/11 incontinent participants). B 12/18 (5/11 incontinent participants)
Subjective improvement after 6-8 sessions
A 17/17. B 18/18
Adverse effects
A 0/17. B 0/18
Adverse effects: “None of the patients discontinued the treatment and all considered it
tolerable and painless”
Incontinence episodes per 24 hours (median, range, N)
A 1 (0-3), 11. B 1 (0-3), 11
Micturitions per 24 hours (median, range, N)
A 8 (5-15), 17. B 8 (6-18), 18
SF-36 (median, range, N)
A 62 (24-81), 17. B 62 (25-80), 18
I-QoL (median, range, N)
A 77 (35-100), 17. B 78 (33-100), 18
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”
Allocation concealment (selection bias) Unclear risk Not reported
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants, other
blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants randomised seem to be in-
cluded in analysis
Finazzi-Agrò 2010
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Tor Vergata University Hospital in Rome, Italy
Period: February 2007-February 2009
Sample size: with a sample size of 15 in each group this study had a power of 82.3% to
yield a statistically significant result assuming that the difference in proportions was 0.45
(specifically 0.05 vs 0.50). This effect was selected because the magnitude was reasonable
according to previously published findings. To account for a dropout rate of 10% the
number of participants to be recruited was set at 17 for each group, 34 total
Follow-up: 4 weeks
Participants N: 35 randomised, 32 analysed
Mean age (no SD reported): A 44.9; B 45.5
Sex: women
Inclusion criteria: female, urgency incontinence and urodynamically diagnosed detru-
sor overactivity incontinence, unresponsive to behavioural and rehabilitation therapy or
antimuscarinics, able to give written, informed consent, 18 years of age or older, men-
tally competent and able to understand all study requirements, able to understand the
procedures, advantages and possible side effects, willing and able to complete a 3-day
voiding diary and I-QoL questionnaire, bladder capacity 100 mL or greater, no signs of
neurologic abnormalities at objective examination; no history of neurologic pathology,
no pharmacological treatment or pharmacological treatment unchanged for 30 days be-
fore beginning the study
Exclusion criteria: pregnancy or intention to become pregnant during the study, active
UTI or recurrent UTI (more than 4 per year), presence of urinary fistula, bladder or
kidney stones, interstitial cystitis, cystoscopic abnormalities that could be malignant,
diabetes mellitus, cardiac pacemaker or implanted defibrillator
Interventions A (n = 18) PTNS. 12 sessions, 30 min, 3 times a week for 4 weeks. 34-gauge needle
inserted percutaneously approx 5 cm cephalad to the medial malleolus of right or left
ankle; surface electrode placed on medial aspect of ipsilateral calcaneous. Stimulation
current (0-10 mA) with a fixed frequency of 20 Hz and a pulse width of 200 ms was
increased until flexion of the big toe or fanning of all toes became noticeable. The current
was set at the highest level that was tolerable to the participant
B (n = 17) sham. Same schedule as PTNS group with stimulator briefly activated for
88Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Finazzi-Agrò 2010 (Continued)
approximately 30 seconds so the participant felt a minor electrical sensation in the skin
Outcomes Number of participants with < 50% reduction in urgency incontinence episodes:
A 5/17. B 18/18
Number of incontinence episodes per 24 hours (mean, range, N):
A 1.8 (1.2-2.2), 17. B 3.8 (3.0-4.5), 15
Number of micturitions per 24 hours (mean, range, N):
A 9.5 (8.4-10.7), 17. B 13.9 (11.3-16.5), 15
Voided volume mL (mean, range, N):
A 150.5 (126.8-174.3) 17. B 150.4 (125.8-175.1), 15
I-QoL score (mean, range, N):
A 69.9 (65.8-73.3), 17. B 70.6 (62.2-79.1), 15
Notes Contacted study author asking for SDs 27-11-14
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated randomization list.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk To verify participant blindness with respect
to the assigned treatment after 3 sessions
participants were asked which procedure
they believed they received
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The results of the 2 groups were collected
by 2 physicians, and analysed by a third
physician and a statistician, both of whom
were blinded regarding the procedure used
in any single participant
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the PTNS group 1 participant and in the
placebo group 2 did not complete the study
for personal reasons not related to the used
technique. There remained 17 participants
in the PTNS group and 15 in the placebo
group. There was a loss of less than 20% so
considered at low risk of bias
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Firra 2013
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: USA
Period: not reported
Sample size: “to achieve a power of 0.80 with an estimated conventional large effect size
(f = 0.40), we sought a sample size of 66 women (33 with urge UI and 33 with stress
UI) with 11 participants per treatment by diagnosis group.”
Follow-up: 8 weeks
Participants N: 63 randomised, 48 analysed
Mean (SD) age:
UUI overall 61.0 (12.4), A 57.3 (12.5) B 66.5 (12.4) C 63.0 (14.5)
SUI overall 55.1 (14.4), D 52.7 (15.0) E 63.6 (13.3) F 48.2 (16.2)
Sex: women
Inclusion criteria: SUI or UUI diagnosed by urodynamics or Medical, Epidemiological
and Social Aspects of Aging (MESA) questionnaire, parous or nulliparous women 21
years or older, manual dexterity to dial the Liberty Electrical Stimulation Unit, fluent
English,≥ 3 incontinent episodes in 3 days.Women onHRT tomaintain same oestrogen
intake throughout study, women not taking hormones were asked not start an oestrogen
regimen during study
Exclusion criteria: zero score on Oxford pelvic floor muscle strength scale, denervation
injury to the sphincters, anti-incontinence surgery, vaginal extent to extent that middle
finger could not be inserted into vagina, BMI > 50, stage III/IV prolapse, pregnancy,
neurologic conditions, any potentially confounding prescriptions drugs
Interventions UUI
A (n = 7) intravaginal ES plus PFMT. 14 sessions of 60 min PFMT exercises, then 30
min (12.5 Hz) at highest tolerable intensity Tampon-shaped Liberty ES device
B (n = 8) PFMT alone. 60 minutes twice a week for 8 weeks
C (n = 7) no active treatment
SUI
D (n = 14) as per group A
E (n = 15) as per group B
F (n = 12) as per group C
Outcomes York Incontinence Perception Scale (YIPS) score (higher score is better) (mean, SD, N):
UUI: A 41.2 (10.2), 6. B 47.0 (5.5), 6. C 28.8 (2.9), 6
SUI: D 46.4 (7.2), 9. E SUI 44.8 (6.3), 12. F 29.9 (2.2), 9
% change in YIPS score (mean, N):
UUI: A 38.7%, 6. B 78.7%, 6. C -2.4%, 6
SUI: D 57.8%, 9. E SUI 37.0%, 12. F 2.0%, 9
Pelvic floor muscle strength, cm H2O (mean, SD, N):
UUI: A 27.0 (16.0), 6. B 47.2 (22.7), 6. C 34.3 (25.5), 6
SUI: D 36.7 (14.1), 9. E 32.5 (18.5), 12. F 26.1 (18.6), 9
% change in pelvic floor muscle strength, cm H2O:
UUI: A 8.9%, 6. B 155.1%, 6. C 1.2%, 6
SUI: D 119.8%, 9. E 49.8%, 12. F 5.2%, 9
Incontinence episodes in 3 days (mean, SD, N):
UUI: A 3.0 (4.4), 6. B 2.3 (2.9), 6. C 7.8 (5.9), 6
90Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Firra 2013 (Continued)
SUI: D 1.4 (1.6), 9. E 4.1 (4.2), 12. F 8.0 (5.6), 9
*incontinence episodes per day (mean, SD, N):
A 1.0 (1.47), 6. B 0.8 (0.97), 6. C 2.6 (1.97), 6
D 0.5 (0.53), 9. E 1.4 (1.4), 12. F 2.7 (1.87), 9
% change in incontinence episodes in 3 days (mean, N):
UUI: A -78.1%, 6. B -70.5%, 6. C -4.0%, 6
SUI: D SUI -83.7%, 9. E SUI -66.9%, 12. F SUI 50.9%, 9
Frequency of micturitions in 3 days (mean, SD, N):
UUI: A 25.7 (9.4), 6. B 23.5 (5.9), 6. C 24.2 (10.4), 6
SUI: D 24.1 (10.4), 9. E 22.8 (8.3), 12. F 24.6 (8.9), 9
*frequency of micturitions per day (mean, SD, N):
A 8.6 (3.13), 6. B 7.8 (1.97), 6. C 8.1 (3.47), 6
D 8.0 (3.47), 9. E 7.6 (2.77), 12. F 8.2 (2.97), 9
% change in frequency of micturitions in 3 days (mean, N):
A -19.2%, 6. B -16.7%, 6. C 27.4%, 6
D -6.6%, 9. E -8.8%, 12. F -14.9%, 9
Notes Different numbers of participants reported in thesis and journal article
*Mean (SD) per day calculated from 3-day data: mean and SD divided by 3
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “2 containers were prepared representing
diagnosis groups (urge or stress inconti-
nence). Each container held 33 slips of pa-
per with 11 reading “e-stim,” 11 reading
“therapeutic exercise” and 11 reading “con-
trol.” The office assistant offered the cor-
rect diagnostic container to the participant
on the second visit.”
Allocation concealment (selection bias) Low risk ”2 containers were prepared representing
diagnosis groups (urge or stress inconti-
nence). Each container held 33 slips of pa-
per with 11 reading “e-stim,” 11 reading
“therapeutic exercise” and 11 reading “con-
trol.” The office assistant offered the cor-
rect diagnostic container to the participant
on the second visit.”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The primary researcher performed the
outcome measures and administered the
exercise programs. She was blinded to the
participants’ diagnosis as determinedby the
MESA but was not blinded to group allo-
cation.”
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk “The primary researcher performed the
outcome measures and administered the
exercise programs. She was blinded to the
participants’ diagnosis as determinedby the
MESA but was not blinded to group allo-
cation.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some differential attrition: “of those who
dropped out after randomizationmost (11/
16) were in the exercise and stimulation
group...there was no indication that dis-
comfort was a factor.”
Franzén 2010
Methods Study design: RCT
Multicentre or single-centre: 3 centres in Sweden
Period: September 2001 and December 2005
Sample size: the power analysis was calculated on the basis of the primary outcome mea-
sure, reduction of micturitions per 24 h. The minimal patient-perceivable improvement
has been found to be a mean reduction of micturitions per 24 h equivalent to 20%.
A reduction smaller than 20% would thereby not be of any significant clinical impor-
tance. There is a large uncertainty regarding the efficacy that can be expected for both
ES treatment and drug treatment being 30% to 50%. Under the assumption that ES
treatment would give a 70% reduction of symptoms and drug treatment (tolterodine)
a 50% reduction and thereby give a difference between treatments of 20%, a Chi2 test
with a 2-sided significance level of 5% yielded a power of 80% for a sample size of 103
participants in each group. If the assumption was even bigger difference in efficacy, 70%
for ES treatment vs. 40% for tolterodine, the sample size with an additional 10% to
compensate for dropouts would be 55 participants in each group
Follow-up: 24 months
Participants N: 72 randomised and 61 analysed at 6 months, 52 analysed at 12 months, 46 at 24
months
Sex: Women
Mean (SD) age: A 55 (11); B 61 (12)
Inclusion criteria: urgency incontinence symptoms for≥ 3 months, increased frequency
of micturition (≥ 8 micturitions per 24 hours), mean volume of urine voided per mic-
turition ≤ 200 mL, total urine volume per 24 hours of < 3000 mL during a 48-hour
bladder diary
Exclusion criteria: Persistent UTI, post-void volume greater than 150 mL, history of
neurological disease or dementia, pregnancy, contraindications to anticholinergic ther-
apy, and a cardiac pacemaker. Participants were also excluded if they had used tolterodine
or any other anticholinergic drugs in order to treat urgency/urge incontinence during
the last 2 months or had received ES treatment within the last 3 years
Interventions A (n = 33). ES vaginally and/or transanally with the MS-310 Device, MIC Rehab
AB. Over 5-7 weeks, 10 stimulation treatments 1-2 times per week for 20 min with a
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frequency of 5-10 Hz. The maximum ES was done with maximum tolerable intensity,
which was adjusted up to the level of tolerable discomfort
B (n =31) tolterodine SR 4 mg orally once daily for 6 months, with dose reduction
allowed to tolterodine SR 2 mg daily if intolerable side effects occurred
Outcomes Number of participants with moderate or severe urgency symptoms:
A 10/33, B 12/31
Number of participants with no improvement in urgency symptoms:
A 9/33, B 9/31
Change in frequency of micturition (mean, 95%CI (SD)*, N):
6 months:
A -2.8 (-3.6 to -2.2 (1.96)), 30. B −3.2 (−4.1 to −2.4 (2.41)), 31
12 months:
A−3.1 (95% CI,−4.0 to−2.1 (2.65)), n = 30. B−3.1 (95% CI,−4.3 to−1.9 (3.41)
) n = 31
24 months:
A −3.4 (−4.6 to −2.2 (3.35), n = 30. B −3.7 (−4.8 to −2.6 (3.12)), n = 31
Change in mean urine volume (mL) (mean, 95%CI (SD)*, N):
A 54 (28-80 (72.66)), 30. B 55 (36-74 (53.97)), 31
Side effects:
A 0/33
B** 9/30 dry mouth, 1/30 muscular pain
KHQ: see Table 3. Various outcomes reported
Notes *SD calculated by FS, using 95% CI
**based on information received from study author
6-month data used in analysis because treatment was given for 6 months. Most other
included studies provided data for end of treatment period
N per treatment group at 12 and 24 months not given, assumed same as 6 months
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization sequence was developed
centrally, using a computer random num-
ber generator.”
Allocation concealment (selection bias) Low risk “Assignment was enclosed in sequentially
numbered opaque sealed envelopes by a
person not involved in the study. Patients
were included into the study and allocated
to treatment group by the clinical staff re-
sponsible for the study at each participat-
ing center, by opening the lowest numbered
envelope”
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Blinding of study personnel and partici-
pants to treatment assignment for the du-
ration of the study was not possible due to
the nature of the interventions.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. Adequate expla-
nation for withdrawals
Gaspard 2014
Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: Belgium
Period: November 2010 - November 2012
Sample size: 15 per group required for 80% power to detect between-group difference
Follow-up: 9 weeks’ treatment, 6 months’ follow-up
Participants N: 31 randomised and analysed
Mean (SD) age: A 43.5 (14.0). B 40.5 (9.5)
Sex: women and men
Inclusion criteria: EDSS score < 7 and, urgency symptoms, nocturia, urgency inconti-
nence, urinary retention and/or weak stream, post-voiding symptoms such as incomplete
bladder emptying sensation
Exclusion criteria: acute MS episodes during the study, UTI, pelvic-perineal treatment
in the past 6 months, pregnancy
Interventions A (n = 16) PFME with biofeedback. One 30-min session per week for 8 weeks
B (n = 15) ES + PFME. As per group A plus transcutaneous posterior tibial nerve
stimulation. Frequency 10 Hz, 220 µs pulse width. One 30-min session per week for
9 weeks. Rectangular biphasic pulse. An external electrode was located 5 cm above the
medial malleolus and 1 cm behind the tibia. The other electrode was positioned on the
dorsum of the foot. 20 s on, 4 s off
Outcomes Number of participants not satisfied:
A 1/16. B 4/15
SF-Qualiveen total score (higher score = greater severity) (median, IQR, N):
9 weeks: A 1.000 (0.656, 1.719), 16. B 1.375 (0.625, 2.188), 15
6 months: A 1.313 (0.687, 1.625), 16. B 1.500 (0.344, 2.094), 15
*mean, SD, N
9 weeks: A 1.07 (0.65), 16. B 1.51 (0.83), 15.
6 months: A 1.21 (0.74), 16. B 1.39 (0.91), 15
Bladder hyperactivity score (median, IQR, N):
9 weeks: 5.00 (1.50, 8.00), 16. B 6.00 (2.5, 9.25), 15
6 months: 7.00 (3.50, 9.50), 16. B 5.00 (4.25, 7.75), 15
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*mean, SD, N
9 weeks: A 5.4 (3.67), 16. B 6.75 (3.91), 15
6 months: A 6.42 (3.9), 16. B 6.5 (3.45), 15
Daily urgency episodes (median, IQR, N):
9 weeks: A 1.2 (0.3, 5.0), 16. B 0.7 (0.2, 4.3), 15
6 months: A 2.0 (0.3, 2.7), 15. B 1.4 (0.0, 2.0), 15
*mean, SD, N
9 weeks: A 2.69 (3.02), 16. B 2.63 (3.08), 15
6 months: A 2.25 (2.53), 16. B 1.67 (1.64), 15
Adverse effects: A 0/16. B 0/15
Notes Subcategories of Qualiveen scores available in paper
Emailed study authors asking for means (SDs) 2 April 2015. Replied with data marked
*
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were randomised”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not possible.
Other blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Data analysis was blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential withdrawal. Adequate ex-
planations for withdrawal not reported. In-
tention-to-treat analysis carried out
Gonzalez 2015
Methods Study design: randomised cross-over trial
Setting: Chile
Follow-up: switch modalities at 3 months, follow-up at 6 months
Participants N: 82 randomised
Sex: not reported
Inclusion criteria: OAB symptoms
Exclusion criteria: unable to comply with follow-up or had a history of neurological
disease
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Interventions A (n = 40 randomised and 31 analysed): transcutaneous posterior tibial nerve stimulation
and behavioural therapy. Twice a week for 6 weeks
B (n = 42 randomised and 37 analysed): behavioural therapy. One-to-one interview and
assessment with a continence physiotherapist and written information
After 3 months both groups switched treatment modalities for another 3 months
Outcomes After 3 months’ treatment:
Visual analogue scale (VAS) (higher score = greater severity) (mean SD, N):
A 5.81 (2.89), 31. B 7.50 (2.50), 37
Incontinence severity index (ISI) (higher score = greater severity) (mean, SD, N):
A 5.15 (3.23), 31. B 7.38 (4.00), 37.
Patient’s Global improvement (PGI-I):
A 85.7%. B 60.9%
OAB-Q (higher score = greater severity) (mean SD, N):
A 100.81 (41.50), 31. B 127.71 (40.64), 37
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated sequence”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals: A 9/40, B 5/42. No explana-
tions for withdrawal
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Methods Study design: RCT
Multicentre or single-centre: multicentre
Setting: USA
Period: June 2011-December 2013
Sample size: the sample size calculation was determined using the 2-sided Chi2test with
a significance level of 5% and 80% power based upon the following assumptions: (1)
proportion of responders at end of 12 weeks of treatment would be 50% in the active
(test) group and 25% in the inactive (control) group; (2) a responder was defined as
a subject who experienced decrease of ≥ 50% in mean UUI episodes (leaks) between
baseline and week 12 of the study; (3) 20% dropout rate
Follow-up: 12 weeks
Participants N: 163 randomised
Mean age (SD): A 60.8 (14.3); B 62.4 (13.8)
Sex: 138 women, 25 men
Inclusion criteria: men and women, at least 18 years of age. Failure on primary OAB
treatment, such as behaviour modification or fluid/diet management, AND at least 1
anti-cholinergic drug (unless participant was contra-indicated for anti-cholinergic use).
Symptoms of OAB for at least 6 months
Exclusion criteria: Dysfunctional voiding symptoms unrelated to OAB, such as clinically
significant bladder outlet obstruction, and urinary retention (pvr > 100 cc). Morbidly
obese, defined as having BMI > 40 kg/m2. Stress predominant MUI. Neurological dis-
ease affecting urinary bladder function, including but not limited to Parkinson’s disease,
multiple sclerosis, stroke, spinal cord injury and uncontrolled epilepsy. Pelvic surgery
(such as sub-urethral sling, pelvic floor repair) within the past 6 months. Intravesical
or urethral sphincter Botulinum Toxin Type A injections within the past 12 months.
Any neuromodulation therapy for OAB within the past 3 months. Failure to respond
to previous neuromodulation therapy for OAB. Leading edge of any vaginal prolapse
beyond hymenel ring. Prior peri-urethral or transurethral bulking agent injections for
bladder problems within the past 12 months. Any skin conditions affecting treatment
or assessment of the treatment sites. History of lower back surgery or injury that could
impact placement of the patch, or where underlying scar tissue or nerve damage may im-
pact treatment. Presence of an implanted electro-medical device (e.g. pacemaker, defib-
rillator, InterStim®, etc.), or any metallic implant in the lower back. Pregnant, nursing,
suspected to be pregnant (by urine pregnancy method), or plans to become pregnant
during the course of the study. Known latex allergies, or allergies or hypersensitivity to
patch materials that will be in contact with the body (e.g. hydrogel, acrylic-based adhe-
sive, polyurethane). Uncontrolled diabetes and/or diabetes with peripheral neuropathy.
Current UTI or history of recurrent UTIs (> 3 UTIs in the past year). History of lower
tract genitourinary malignancies within the last 6 months or any previous pelvic radia-
tion. Any clinically significant systemic disease or condition that in the opinion of the
Investigator would make the patient unsuitable for the study
Interventions A (n = 80) 1 VERV electrode patch worn per week for 12 weeks
B (n = 83) 1 sham electrode patch worn per week for 12 weeks
Outcomes Change in urgency (urinary) incontinence episodes per day (median (IQR), N):
A -3.7 (-4.7 to -1.0), 68. B -1.7 (-3.3 to -1.0), 75. P = 0.2191)
Change in urinary frequency per day (median (IQR), N):
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A -1.0 (-2.7 to 0.3), 80. B -1.3 (-3.0 to -0.3), 83. P = 0.2893
Change in volume per void (mL) (median (IQR), N):
A 1.0 (-26.6 to 23.5), 80. B 8.8 (-24.3 to 33.3), 83. P = 0.3387
Change in urgency episodes (median (IQR), N):
A -1.7 (-3.3 to 0.3), 80. B -1.7 (-3.3 to 0.3). P = 0.6557
Change in OAB-symptom composite score (median (IQR), N):
A -5.8 (-14.7 to 1.3), 80. B -8.0 (-15.3 to 0.3), 83. P = 0.4354
Change in OAB-Q score (median (IQR), N):
A 8.8 (1.6 to 20.0), 56. B 9.2 (-0.8 to 27.2), 66. P = 0.9918
Percentage of participants with improvement in severity according to Patient Perception
of Bladder Condition scale:
A 53.7% of 80 (43/80). B 44.2% of 83 (37/83)
Percentage of participants with overall improvement according to Treatment Benefit
Scale:
A 55.4% of 56 (31/56). B 42.4% of 66 (28/66)
Percentage of participants with Improvement as measured by Overactive Bladder Satis-
faction With Treatment Questionnaire:
A 65.3% of 32 (21/32). B 57.6% of 34 (20/34)
Percentage of participants improved as measured by clinicians using Clinical Global
Impressions:
A 23.2% of 80 (19/80). B 24.2% of 83 (20/83)
Participants with adverse effects:
A 30/80. B 29/82
Notes Emailed study author asking for means (SDs) 6 January 2015
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Allocation: randomized”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Masking: Double Blind (Subject, Investi-
gator)”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Masking: Double Blind (Subject, Investi-
gator)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. Adequate expla-
nation for withdrawals
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Kosilov 2013
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Russia
Period: 2008-2010
Details of sample size calculation: not reported
Follow-up: 1-month’s treatment, 12 months’ follow-up
Participants N: 229 randomised, 208 analysed at 12 months
Mean (SD) age: 66.3 (range 65-77)
Sex: women
Inclusion criteria: elderly womenwith urodynamic impairments and clinically confirmed
OAB
Exclusion criteria: not reported
Interventions All groups: trospium 60 mg + solifenacin 40 mg for 6 weeks then one of the following,
beginning 2.5 months after end of drug treatment:
A (n = 59) drugs: trospium 60 mg + solifenacin 40 mg for a month
B (n = 51) detrusor ES: an active electrode (50-70 cm2) above the pubis, and a passive
electrode (150 cm2) in lumbosacral area, diadynamic current, frequency 20 Hz, mod-
ulation depth 50%-75%, intensity 20-40 mA, exposure 15 min, a course consisting of
15 procedures every other day
C (n = 63) conservative treatment: laseropuncture by helium-neon laser (632.8 nm) at
acupuncture points RP 6, RP 9, VC 2 within 1-1.5 min for each point every day, light
guide output power, 2 mW, 25 procedures
D (n = 56) placebo
Outcomes Daily urinary incontinence episodes (mean, SD, N)
6 months: A 1.1 (0.7), 59. B 2.2 (0.9), 51. C 3.8 (0.8), 63. D 2.7 (1.1), 56
12 months: A 1.5 (0.9), 59. B 3.7 (1.3), 51. C 5.5 (1.4), 63. D 4.8 (2.4), 56
Volume at FDV, mL (mean, SD, N):
6 months: A 289.3 (37.6), 59. B 297.0 (45.3), 51. C 254.5 (49.1), 63. D 279.7 (54.8),
56
12 months: A 257.5 (28.9), 59. B 210.9 (28.7), 51. C 199.3 (49.4), 63. D 192.9 (28.
9), 56
Volume at maximal desire to urinate, mL (mean, SD, N):
6 months: A 313.7 (47.1), 59. B 334.8 (38.3), 51. C 286.0 (36.6), 63. D 311.5 (51.7),
56
12 months: A 279.9 (33.8), 59. B 251.9 (42.9), 51. C 178.9 (29.0), 63. D 206.3 (SD
missing), 56
Maximum bladder pressure, cmH2O (mean, SD, N):
6 months: A 32.8 (6.0), 59. B 35.4 (9.3), 51. C 38.9 (7.8), 63. D 31.0 (7.9), 56
12 months: A 28.8 (4.7), 59. B 30.9 (4.9), 51. C 29.8 (6.3), 63. D 23.9 (5.4), 56
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk “we randomized 229 women”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 14 participants withdrew due to side ef-
fects, 2 discontinued due to the lack of
an immediate positive effect; and 2 with-
drew for reasons unrelated to the treatment
course
Numbers of withdrawals not reported per
treatment group.
Lima 2011
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: not reported
Period: not reported
Sample size: not reported
Follow-up: not reported
Participants N: 45
Sex: women
Mean age: not reported
Inclusion criteria: women with OAB symptoms
Exclusion criteria: not reported
Interventions A (n = 16) PFMT
B (n = 14) Intravaginal ES. Twelve 30-min sessions
C (n = 15) Transcutaneous posterior tibial nerve stimulation. Twelve 30-minsessions
Outcomes Symptoms of urgency incontinence, defined as “absence, a little, more or less and much”
Notes No useable data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Lin 2004
Methods Study design: RCT
Setting: China
Follow-up: 4 weeks’ maximum treatment
Participants N: 60 randomised
Sex: not reported
Interventions A (n = 35) vaginal/anorectal ES, 8-70 mA, 20 min, 20-30 sessions
B (n = 25) 2 mg tolterodine daily, 2-4 weeks
Outcomes Cure rate:
A 13/35. B 10/25
Improved:
A 13/35. B 9/25
Satisfied or fairly satisfied:
A 19/35. B 20/25
Side effects:
Dry mouth: A 1/35. B 20/25
Uroschesis: A 0/35. B 2/25
Constipation: A 1/35. B 6/25
Blurred vision: A 0/35. B 1/25
Notes Only partial translation available
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly divided”
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants, other
blinding unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential withdrawal
Lo 2003
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Department of a Regional Hospital in Perth, Western Australia
Period: not reported
Sample size: 50 participants in each group would be sufficient to give 0.8 power at the
0.05 alpha level for two-sided alternative. Calculation of sample size was performed
using the PASS statistical software (NCSS, Kaysville, Utah, USA). Parameters used in
the calculations were derived from Jundt et al and Lamhut
Follow-up: 4 weeks
Participants N: 24 randomised and analysed
Sex: women
Mean age (SD):
A (n =12) 52.1 (17.5)
B (n = 12) 55.1 (15.1)
Inclusion criteria: women, aged 20 years or older, with stress or UUI
Exclusion criteria: altered mental state, urinary incontinence caused by problems other
than stress or urge, transient incontinence, or severe disability requiring full assistance
with all acts of daily living
Interventions A (n = 12) PFMT. 12 sessions (3 per week for 4 weeks): 10 sets of 5 contractions with
30-s rest between each set. Then repeated after an hour
B (n = 12) ITT plus PFMT. 12 sessions (3 per week for 4 weeks) of 50 pelvic floor
contractions followed by ITT with Nemectrodyne 5 stimulator then another 50 con-
tractions. 2 anterior flat electrodes placed over obturator foramen 1.5cm to 2 cm lateral
to symphysis, 2 posterior electrodes placed medial to ischial tuberosities either side of
anus. ITT was at highest tolerable frequency between 0-100 Hz for 15 min (session 1),
then 30 min for sessions 2-12
Outcomes Pelvic floor muscle strength measured with perineometer (mean, SD, N):
A 9.55 (3.50), 12. B 8.08 (4.83), 12
Pad test (g) (mean, SD, N):
A 1.25 (1.76), 12. B 9.00 (29.3), 12
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Frequency (number of micturitions per day) (mean, SD, N):
A 6.29 (2.2), 12. B 7.24 (2.62), 12
Nocturia (number of nocturia episodes per night) (mean, SD, N):
A 0.45 (0.86), 12. B 0.99 (1.04), 12
Change in pelvic floor muscle strength (mean, SD, N):
A 2.03 (2.10), 12. B 2.04 (2.47), 12. (P = 0.253)
Change in pad test (g) (mean, SD, N):
A -4.33 (8.37), 12. B -85.1 (150), 12. (P = 0.101)
Change in frequency (mean, SD, N):
A -0.07 (1.76), 12. B -1.81 (1.62), 12. (P = 0.006)
Change in nocturia (mean, SD, N):
A -0.49 (0.89), 12. B 0.86 (1.14), 12. (P = 0.199)
No improvement in stop/start test, defined as change from unable to stop to being able
to slow, or change from able to slow to able to stop:
A 9/12. B 6/12 (P = 0.2)
No improvement in urgency (not defined):
A 8/12. B 4/12
Notes We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
No useable data. Not stratified by stress/urgency incontinence
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were randomly allocated as
soon as they gave written consent, using the
sealed envelope method”
Allocation concealment (selection bias) Unclear risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were not blinded due to the
nature of the interventions but unclear if
this would have effect on outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Only the assessor but not the patients
could be blinded.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
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Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: USA
Period: not reported
Sample size: not reported
Follow-up: 5 weeks’ treatment then another 5 weeks’ treatment if improvement observed
after first 5 weeks, then follow-up six months after end of 10 weeks’ treatment
Participants N: 42 recruited, 37 randomised and analysed
Mean (SD) age: 61 (17)
Sex: women
Inclusion criteria: DO
Exclusion criteria: not reported
Interventions A (n = 18) ES once a week for 5 weeks
B (n = 19) ES twice a week for 5 weeks
Medicon MS-210 with vaginal and anal probes
Outcomes Incontinence episodes after 5 weeks (mean, N): 12 (37)
Participants not improved after 5 weeks (N): 0
Participants satisfied enough to request no further treatment:
25% (9)
Adverse effects:
Discomfort: 16% (6/37)
Leg tremor: 8% (3/37)
UTI: 8% (3/37)
Notes Data not presented by treatment - not useable
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized into two treatment groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of participants not possible.
Other blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 5/42 participants withdrew before treat-
ment; no explanation reported. All partici-
pants treated included in analysis. Nowith-
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drawals due to adverse effects
Manriquez 2013
Methods Study design: RCT
Setting: Chile
Follow-up: 12 weeks’ treatment
Participants N: 56 randomised
Sex: women
Age: not reported
Inclusion criteria: OAB according to ICI 2002 definition
Exclusion criteria: not reported
Interventions A (n = 28?) transcutaneal tibial nerve stimulation, twice a week with at least 48 h intervals
for 12 weeks
B (n = 28?) long release oxybutynin 10 mg
Outcomes Frequency (mean? range, N):
A 4 (2-7), 28. B 8 (1-13), 28
Urgency (mean? range, N):
A 4 (1-6), 28. B 7 (4-15), 28
Urgency incontinence (mean? range, N):
A 2 (0-3), 28. B 6 (1-11), 28
Daily pads (mean? range, N):
A 0 (0-3), 28. B 4 (3-6), 28
Notes Numbers randomised to each group not reported, assume equal numbers
Table does not state if means or medians are reported.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “the randomization was made by permuted
blocks”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
105Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Manriquez 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Marques 2008
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Brazil
Period: not reported
Sample size: not reported
Follow-up: 4 weeks
Participants N: 43 randomised
Mean (SD) age: not reported
Sex: women
Inclusion criteria: OAB
Exclusion criteria: not reported
Interventions A (n = ?) ES 30 min, twice per week for 4 weeks TENS, biphasic with 200 ms pulse
duration, 10 Hz frequency, variation of intensity and frequency through one channel
and two electrodes
B (n = ?) unclear if sham or no active treatment: “same protocol but without electrical
stimulation.”
Outcomes Daytime frequency: difference between groups P = 0.0001 (in favour of intervention)
Nocturia: difference between groups P = 0.0186 (in favour of intervention)
Improvement in SUI: difference between groups P = 0.0273 (in favour of intervention)
Urgency symptoms: difference between groups P = not significant
Participants with no involuntary detrusor contraction: A 4/?. B 5/?
Notes No useable data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized’ ‘divided into two different
groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear howmany participants included in
analysis
Monga 2011
Methods Study design: RCT
Multicentre or single-centre: multi-centre
Setting: UK
Period: not reported
Sample size: not reported
Follow-up: 4 weeks
Participants N: 74 randomised, 64 analysed
Mean (SD) age: not reported
Sex: men and women
Inclusion criteria: ≥ 18 years, OAB symptoms ≥ 6 months, failure of OAB therapies
such as behaviour modification and failure of ≥ anti-cholinergic drug for OAB
Exclusion criteria: not reported
Interventions Patient-managed neuromodulation system (PMNS): transdermal amplitude-modulated
signal through a patch applied to the skin, controlled by wireless handheld remote
control. Patch worn for 4 weeks, placed by investigator initially
A (n = 30) Investigator placement group. Participants returned every 7 days for patch
removal and placement of a new patch on contra-lateral side
B (n = 34) Subject placement group. Participants returned on day 7 for investigator
observation of patch self-placement and replaced patch at home for the remaining 2
weeks
Outcomes UUUI episodes (mean, SD, N):
2.2 (2.5), 64.
% change from baseline in UUI episodes (mean, SD, N):
-2.7% (3.1), 64.
Change from baseline in UUI episodes (mean, SD, N):
-47.8 (60.6), 64.
Voiding frequency (mean, SD, N):
9.4 (2.7), 64.
% change from baseline in voiding frequency (mean, SD, N):
-1.9% (2.5), 64.
Change from baseline in voiding frequency (mean, SD, N):
-15.0 (19.1)
Volume per void (mean, SD, N):
187.6 (75.0), 64.
% change from baseline in volume per void (mean, SD, N):
8.2% (46.7), 64.
Change from baseline in volume per void (mean, SD, N):
7.5 (26.4), 64.
Urgency episodes (mean, SD, N):
7.8 (3.3), 64.
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% change from baseline in urgency episodes (mean, SD, N):
-2.2 (2.8), 64.
Change from baseline in urgency episodes (mean, SD, N):
-21.2 (28.6), 64.
Notes Not useable - results not presented per treatment group
Contacted study author requesting data per group 17 February 2015. Author responded
“The device has been withdrawn. Probably doesn’t need to be in the review.”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “subjects were randomized”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No explanation reported for withdrawals.
Data not presented per treatment group
Monteiro 2014
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Brazil
Period: February-June 2008
Sample size: “Pocock formula, with 47% of neurogenic OAB prevalence and decrease of
30% after treatment”
Follow-up: 45 days’ treatment, 12 months’ follow-up
Participants N: 24 randomised and analysed
Mean (SD) age: A 65.1 (3.6). B 56.1 (10.9)
Sex: men
Inclusion criteria: ≥ 18 years with neurogenic OAB, with stroke occurring between 6
months and 3 years before recruitment
Exclusion criteria: implanted cardiac pacemaker, UTI, bladder cancer, pre-existing uri-
nary incontinence before stroke, or surgery in the urogenital region
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Interventions A (n = 12) ES of posterior tibialis nerve. Negative electrode was placed on the medial
malleolus, and the positive electrode was placed 10 cm above the negative electrode,
also on the medial side. The rhythmic flexion of the second toe during the stimulation
determined the correct position of the negative electrode. The intensity level was set
below the threshold that causes motor contraction because the participant should be
comfortable and no pain should occur during the procedure. ES of the posterior tibialis
nerve was performed for 30 minutes twice weekly over 12 sessions (45 days), with a
frequency of 10 Hz and a pulse width of 200 µs in continuous mode
B (n = 12) no active treatment for OAB. 12 stretching sessions of the lower limbs
Outcomes Participants with no improvement in OAB symptoms:
12 months: A 0/12. B 9/12
Participants with urinary urgency:
45 days: A 7/12. B 10/12
12 months: A 6/12. B 9/12
Participants with UUI:
45 days: A 8/12. B 9/12
12 months: A 7/12. B 8/12
Participants with nocturnal enuresis:
45 days: A 0/12. B 2/12
12 months: A 0/12. B 2/12
Participants with nocturia:
45 days: A 5/12. B 9/12
12 months: A 1/12 B 6/12
Participants with increased daytime frequency:
45 days: A 3/12. B 11/12
12 months: A 0/12. B 9/12
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk All participants were numbered sequen-
tially from 1-24 and divided into 2 groups
of 12 assigned to the treatment group
Allocation concealment (selection bias) Unclear risk All participants were numbered sequen-
tially from 1-24 and divided into 2 groups
of 12 assigned to the treatment group
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported. Impossible to blind partici-
pants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in
analysis. One dropout. “One patient in the
placebo group died after treatment, but was
analyzed as if improved.”
Oldham 2013
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: UK
Period: not reported
Sample size: the study was powered to detect a 3-point (common standard deviation of
6) between-group difference on the ICIQ-UI (scale of 0-21) with 80% power at a 5%
level of significance
Follow-up: 12 weeks
Participants N: 124 randomised, 97 analysed
Mean (SD) age: A 47.9 (8.9). B 48.2 (8.6)
Sex: women
Inclusion criteria: women, 18-65 years with self-reported SUI, UUI, or MUI
Exclusion criteria: Pregnancy or a baby in the last 3 months. Recent abdominal surgery
and previous or current active therapy for pelvic malignancy. Implanted pacemaker.
Manual dexterity insufficient to place the device. Previous treatment for incontinence
(including supervised PFME. Presence of a neurological condition such as multiple
sclerosis or Parkinson’s disease
Interventions A (n = 64) ES. Pelviva device inserted like a tampon into the vagina. The stimulation
programme was delivered using a duty cycle of 10-sstimulation followed by 10-s rest
that runs for a period of 30 min, pre-programmed to automatically gradually ramp-up
the intensity of stimulation over a 24-s period to reach a therapeutic level and switch
off automatically after 30 min. During the 10 seconds ’on time’ the device delivered 10
repeats of a short high intensity burst of 50 Hz stimulation immediately preceded by a
doublet (125 Hz), superimposed on continuous low frequency 2 Hz stimulation
Plus standardised advice about how and when to undertake PFME. These included 10
slow and controlled squeezing and lifting contractions and 10 quick contractions each
repeated 3-4 times a day
B (n = 60) unsupervised conservative treatment (no active treatment). Standardised
advice about how and when to undertake PFME. These included 10 slow and controlled
squeezing and lifting contractions and 10 quick contractions each repeated 3-4 times a
day
Outcomes Participants with no improvement in symptoms (i.e. same or worse ICIQ score):
A 9/49. B 14/46
*A UUI 5/50. B 6/47.
*A MUI 8/50. B 19/47.
*A UUI+MUI 13/50. B 25/47
Participants with SUI, UUI or MUI
A 94% (i.e. 46/49) B 100% (i.e. 46/46)
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International Consultation on Incontinence Questionnaire - Urinary Incontinence
(ICIQ-UI) score (higher score is increased severity) (median, range, N):
A 6 (0-17), 49. B 9 (3-18), 46
Leak frequency (0-5 scale, higher score is more leaks) (median, range, N):
A 1 (0-4), 49. B 2 (1-4), 46
Leak interference (0-10 scale, higher score is more interference) (median, range, N):
A 3 (0-10), 49. B 4 (0-10), 46
Leak amount (0-6 scale, higher score is greater amount) (median, range, N):
A 2 (0-6), 49. B 2 (2-4), 46
Adverse effects: A 0/49. B 0/46
Notes *Outcome data not separated by SUI/UUI/MUI - contacted study author 3 February
2015, replied with supplementary data
Femeda, the company responsible for developing and producing the Pelviva device was
the trial sponsor. The sponsor was responsible for developing the Pelviva device, was the
funder of the study, and was engaged in the development of the trial design. The sponsor
has provided full access to the data and is fully informed of this publication process. The
primary author (J.O.) takes full responsibility for the integrity of the data and accuracy
of the data analysis
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “subjects were assigned by a simple com-
puter generated AB randomization list to
either the exercise or Pelviva group.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Participants could not be blinded to the
treatment group and were aware of the
study hypothesis. Every care was taken to
ensure the assessor remained blind to treat-
ment allocation and participants were ad-
vised not to discuss their treatment with
them.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “the assessor remained blind to treatment
allocation”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No differential dropout. No explanations
for withdrawals
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Methods Study design: RCT
Multicentre or single-centre: single
Setting: Spain
Period: not reported
Details of sample size calculation: no previous data available for power calculation
Follow up: 12 weeks
Participants N: 24 randomised, 22 analysed
Mean (SD) age: 60 (14.4)
Sex: women
Inclusion criteria: urgency incontinence, either men or women, 45-75 years, moderate-
severe on ICIQ-SF and CACV, previous conservative treatment, at least 1 year of incon-
tinence, willing to participate
Exclusion criteria: neurological damage to tibial nerve, diseases of central nervous sys-
tem, previous incontinence surgery, pacemaker, not well-controlled cardiac disease, preg-
nancy, important venous disease in the lower limbs, skin problems in lower limbs that
would impede acupuncture, treatment with oral anticoagulants, acute infectious pro-
cesses, psychiatric or cognitive impairments
Interventions AWQ-104L Digital. 20 Hz, 320 µs. Square wave, current 0-10 mA. 30 mm x 1.5”
needle
A (n = 12) electrostimulation with SP 6 Sanyinjiao
B (n = 12) percutaneous tibial nerve stimulation
Outcomes Micturitions per day (mean (SD) N)
A 7.73 (1.67), 11. B 8 (1.73), 11
Nocturia episodes (mean (SD), N)
A 2.09 (1.92), 11. B 1.09 (1.51), 11
Urgency episodes per 24 h (mean (SD) N)
A 5.09 (3.42), 11. B 3.09 (2.21), 11
Incontinence episodes per 24 h (mean (SD), N)
A 4.55 (4.03), 11. B 1.64 (1.91), 11
B-SAQ score score (mean, SD, N)
Symptoms: A 7.82 (1.83), 11. B 5.09 (2.17), 11
Complaints/problems: A 7.27 (2.24), 11. B 5.18 (2.56), 11
ICIQ-SF score (mean (SD), N)
A 7.27 (2.24), 11. B 5.18 (2.56), 11
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation table
Allocation concealment (selection bias) Low risk Allocation carried out centrally by member
of research team not involved in the inter-
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vention
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants can’t be blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded - had no in-
volvement in carrying out intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential attrition
Orhan 2015
Methods Study design: RCT
Period: January 2010 and April 2011
Setting: not reported
Sample size: not reported
Follow-up: 12 weeks’ treatment
Participants N: 30 randomised
Sex: not reported
Age: not reported
Inclusion criteria: people OAB in whom all conventional therapies had failed
Exclusion criteria: not reported
Interventions A: percutaneous posterior tibial nerve stimulation
B: anticholinergic agent
C: PTNS plus anticholinergic agent
Outcomes A (n = not reported) percutaneous posterior tibial nerve stimulation
B (n = not reported) anticholinergic agent
C (n = not reported) PTNS plus anticholinergic agent
Notes Urinary Distress Inventory (UDI-6)
Incontinence Impact Questionnaire (IIQ-7)
Over Active Bladder symptom scores (OABSS)
“there was a statistically significantly higher improvement in PTNS and PTNS + ACA
groups when compared to group 2” (B: anticholinergic agent alone)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly divided into 3 groups.”
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Peters 2009
Methods Study design: RCT
Multicentre or single-centre: 11 centres in the USA
Setting: not reported
Period: June 2006-September 2008
Sample size: the sample size used to support this analysis was based on the assumptions of
significance level of 5%, power of 80%, and expected mean reduction in voids of 1.8 for
tolterodine and 3.6 for PTNS based on previously published efficacy data. Secondary end
points were analysed using 2-sided t tests with 95% CI. An independent biostatistician
performed all analyses using SAS® Version 9.2. All voiding diary data were sent to the
biostatistician for compilation and analysis
Follow-up: 12 weeks
Participants N: 100 randomised, 85 analysed
Mean (SD) age: A 57.5 (15.2); B 58.2 (11.3)
Sex: 94 women, 6 men
Inclusion criteria: adults with OAB symptoms, with or without a history of previous
anticholinergic drug use, with at least 8 voids per 24 h documented by history and
physical and voiding diary
Exclusion criteria: OAB pharmacotherapy within the previous month, primary com-
plaint of SUI, demonstrated sensitivity to tolterodine or its ingredients, pacemakers or
implantable defibrillators, excessive bleeding, urinary or gastric retention, nerve damage
or neuropathy, uncontrolled narrow angle glaucoma, positive urinalysis for infection or
pregnancy, or current pregnancy or planning to become pregnant during the trial
Interventions A (n = 50) PTNS. 1 session per week for 12 weeks (no details reported on frequency,
make/model of stimulator etc)
B (n = 50) tolterodine. Extended-release 4 mg daily for 90 days (decreased to 2 mg if
intolerability was experienced - 2 participants reduced to 2 mg)
Outcomes Number of participants not cured or improved (subject assessment):
A 9/44. B 19/42
Number of participants not cured or improved (investigator assessment):
A 9/44. B 17/42
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Number of voids per 24 hours (mean, SD, N):
A 9.8 (3.0), 41. B 9.9 (3.8), 43
Number of nocturia episodes (mean, SD, N):
A 1.7 (1.1), 41. B 1.9 (1.6), 43
Number of urgency incontinence episodes per 24 hours (mean, SD, N):
A 1.2 (1.6), 41. B 1.8 (2.5), 43
Number of moderate to severe urgency episodes per 24 hours (mean, SD, N):
A 3.9 (2.8), 41. B 4.5 (3.6), 43
Volume voided per 24 hours (cc) (mean, SD, N):
A 185.5 (81.1), 41. B 158.7 (99.8), 43
Change in number voids per 24 hours (mean, SD, N):
A -2.4 (4.0), 41. B -2.5 (3.9), 43
Change in number of nocturia episodes per 24 hours (mean, SD, N):
A -0.7 (1.0), 41. B -0.6 (1.7), 43
Change in number of urgency incontinence episodes per 24 hours (mean, SD, N):
A -1.0 (2.2), 41. B -1.7 (3.8), 43
Change in number of moderate to severe urgency episodes per 24 hours (mean, SD, N):
A -2.2 (4.3), 41. B -2.9 (4.8), 43
Change in volume voided per 24 hours (cc) (mean, SD, N):
A 32.8 (61.3), 41. B 17.6 (58.4), 43
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random blocks design stratified by inves-
tigational site
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawn prior to 12 week follow-up:
withdrew consent n = 5; lost to follow-up
n = 1; withdrew consent n = 3; treatment
unsuccessful n = 3; others n = 1
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Methods Study design: RCT
Multicentre or single-centre: multicentre
Setting: USA
Period: September 2008-January 2009
Sample size: “A sample size estimate of approximately 214 participants, 107 per study
arm, calculated using a 2-sided Fisher’s exact binomial test based on an estimated 60%
responder rate in the PTNS group and a 40% responder rate in the sham group with a
5% significance level and 80% power.”
Follow-up: 13 weeks
Participants N: 220 randomised (174 women, 46 men), 208 analysed
Mean age (no SD): A 62.5; B 60.2
Sex: men and women
Inclusion criteria: > 18 years of age, score of > 4 on the OAB-Q short form for urgency,
average urinary frequency of > 10 voids per day, self-reported bladder symptoms > 3
months, self-reported failed conservative care, discontinued all antimuscarinics for > 2
weeks, capable of giving informed consent, ambulatory and able to use toilet indepen-
dently without difficulty, capable and willing to follow all study-related procedures
Exclusion criteria: pregnant or planning to become pregnant during study duration,
neurogenic bladder, Botox® use in bladder or pelvic floor muscles within past year,
pacemakers or implantable defibrillators, current UTI, current vaginal infection, Use
of Interstim®, use of Bion®, Current use of TENS in pelvic region, back or legs,
previous PTNS treatment, use of investigational drug/device therapywithin past 4weeks,
participation in any clinical investigation involving or impacting gynaecologic, urinary
or renal function within past 4 weeks
Interventions A (n = 110) PTNS. One 30-minute session per week for 12 weeks. 34-gauge needle
electrode inserted at a 60º angle approximately 5 cm cephalad to the medial malleolus,
slightly posterior to the tibia. PTNS surface electrode placed on the ipsilateral calcaneus
and 2 inactive sham surface electrodes, 1 under the little toe and 1 on the top of the
foot. Current level of 0.5-9 mA at 20 Hz was selected based on each participant’s foot
and plantar motor and sensory responses
B (n = 110) sham PTNS. One 30-minute session per week for 12 weeks. Streitberger
placebo needle was used to simulate the location and sensation of PTNS needle electrode
insertion. An inactive PTNS surface electrode was placed on the ipsilateral calcaneus.
Two active TENS surface electrodes were placed, 1 under the little toe and 1 on the top
of the foot
Outcomes “responder was defined as reporting bladder symptoms as moderately or markedly im-
proved on a 7-level GRA at week 13”
Moderate or marked improvement on global response assessment:
A 60/110. B 23/110
No improvement in OAB symptoms:
A 50/110. B 87/110
No improvement in urinary urgency:
A 59/103. B 81/105
No improvement in urinary frequency:
A 54/103. B 82/105
No improvement in urgency incontinence:
A 64/103. B 81/104
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Frequency of voiding per 24 hours (mean, SD, N):
A 9.8 (2.8), 103. B 11.0 (3.1), 105
Frequency of nocturia (mean, SD, N):
A 2.1 (1.4), 103. B 2.6 (1.6), 105
Mean voided vol (cc) (mean, SD, N):
A 183.0 (75.6), 103. B 172.6 (90.6), 102
Adverse effects:
A 6/110. B 0/110
Change in OAB-Q symptom score (mean, SD, N) (lower score is better):
A -36.7 (21.5), 101. B -29.2 (20.0), 102
Change in SF-36 score (mean, SD, N) (higher score is better):
A 34.2 (21.3), 103. B 20.6 (20.6), 105
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All subjects were randomized 1:1 at the
first intervention visit to PTNS or sham
using a random block design stratified by
investigational site.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Subjects and study coordinators were
blinded to the intervention”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. ITT analysis car-
ried out for primary outcome
Phillips 2012
Methods Study design: RCT
Setting: USA
Follow-up: 4 weeks
Participants N: 74 randomised
Sex: men and women
Age: not reported
Inclusion criteria: symptoms OAB with UUI for at least 6 months, other therapies
previously failed, including ≥ anticholinergic drug
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Exclusion criteria: not reported
Interventions A (n = 34 patient-managed neuromodulation system (PMNS) patch - subject placement
B (n = 30) patient-managed neuromodulation system (PMNS) patch - investigator
placement
Outcomes % reduction in UUI episodes
OAB-Q score
Adverse effects
Notes No useable data. Numbers per group not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized between two treatment
groups”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Preyer 2007
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: not reported
Period: June 2004 and July 2006
Sample size: not reported
Follow-up: 12 weeks
Participants N: 31 randomised (n analysed unclear)
Sex: women
Mean (SD) age: 59.4 (10.9)
Inclusion criteria: adults with urgency incontinence and urge symptoms
Exclusion criteria: contraindications against anticholinergics, pregnancy, tolterodine be-
fore
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Interventions A (n = 16) PTNS, one 30-min session per week for 12 weeks
B (n =15) tolterodine 2 mg daily for 12 weeks.
Outcomes Change in number of micturitions per 24 h (mean, 95%CI (SD)*, N):
A -0.1 (-3.3 to 3.6 (7.04)), 16. B -0.7 (-2.3 to 3.7 (5.93)), 15. (P = 0.77)
Change in number of incontinence episodes per 24 hours (mean, 95%CI (SD)*, N):
A -1.3 (0.6 to 3.2 (2.65)), 16. B -2.6 (0.1 to 5.3 (5.14)), 15
Change in number of urgency episodes per 24 hours (mean, 95%CI (SD)*, N):
A -9.3 (7.0 to 11.7 (4.80)), 16. B -9.5 (6.3 to 12.7 (6.32)), 15
Side effects: A 1/16. B 6/15
Change in QoL (instrument used not reported) (mean, 95%CI (SD)*, N):
A 4.4 (1.7 to 7.1 (5.51)), 16. 4.6 (2.1 to 7.0 (4.84)), 15.
Notes *SD calculated by FS
Dropouts: A 3. B 2. Unclear if these participants included in analysis
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants (10.3%) in the PTNS group
and; 2 (6.9%) in the drug group (toltero-
dine)
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Methods Study design: RCT
Multicentre or single-centre: multicentre
Setting: 3 centres in Austria and Germany
Period: not reported
Details of sample size calculation: “A provisional power calculation based on an exag-
gerated difference of 20% was performed for this pilot study. A reduction from a mean
micturition per 24 h after a 3months treatment with tolterodine of 13-10.4 under PTNS
(assuming a common standard deviation of 2.7) could have been detected with 80%
power and a two-sided significance level of 5% with 18 patients per group”
Follow up: 3 months’ treatment
Participants N: 36 randomised and 32 analysed
Mean (SD) age:not reported
Sex: women
Inclusion criteria: female; minimum age of 18 years; complaints of OAB dry or wet
consistentwith the IUGA/ICS criteria; noprior treatmentwith PTNSor anticholinergics
Exclusion criteria: pregnancy or intention to become pregnant during the study period;
active or recurrent UTIs (more than 4 per year); residual urine of more than 100 ml; his-
tory of urinary fistula, bladder or kidney stones, interstitial cystitis; history of cystoscopic
abnormalities or possible malignancy, diabetes mellitus, cardiac pacemaker or implanted
defibrillator; history of anatomic or post traumatic malformations of the lower limbs;
immobility; contraindications for anticholinergics or PTNS; disability to understand the
study requirements and procedures, advantages and possible side effects
Interventions A (n = 18 randomized and 16 analysed) PTNS. One 30 min session per week for 3
months. “PTNS was performed as described by Stoller et al. (Stoller 1999) and Vandon-
inck et al. (Vandoninck 2003) (Urgent PC1 device by UroplastyTM”
B (n = 18 randomised and 16 analysed) tolterodine 2 mg twice daily
Outcomes Micturitions per 24 h (mean, SD, N):
A 10.4 (4.1), 16. B 9.1 (3.6), 16
QoL measured by VAS (higher score = greater severity) (median, range, N):
A 1.9 (0-8), 16. B 2.7 (0-8.5), 16
Incontinence episodes in 24 h (median, range, N):
A 0 (0-6), 16. B 1 (0-5), 16
Adverse effects: A 3/18 (pain at puncture site). B 9/18 (dry mouth and dizziness)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was centralised by tele-
phone and the random allocation sequence
was generated by computer assistance using
a method of adaptive randomisation”
“Stratification for randomisation was done
for micturitions per 24 h (0-8, 9-12, 13-
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24, 25), incontinence episodes in 24 h (0-
2, 3-10, 11-18, 19-24, 25), age (18-44, 45-
55, 56-65, 66 years), and smoking.”
Allocation concealment (selection bias) Low risk “the random allocation sequence was gen-
erated by computer assistance using a
method of adaptive randomisation”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The patients and assessors were not
blinded”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “The patients and assessors were not
blinded”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential withdrawal. Adequate rea-
sons for withdrawals (not related to inter-
ventions)
Sancaktar 2010
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Turkey
Period: not reported
Sample size: not reported
Follow-up: 12 weeks
Participants N: 40 randomised
Sex: women
Mean age (range): overall 46.4 (33 to 61); mean (SD): A 45.4 (8.7). B 47.4 (10.1)
Inclusion criteria: severe OAB symptoms defined as median 6 urgency incontinence
episodes per 48 hours
Exclusion criteria: stress incontinence, genital prolapse higher than Stage II on POP-Q
system, ocular, cardiological, neurological or metabolic disease, history of pelvic surgery
ultrasonographic evidence of postvoidal retention more than 100 mL and bladder ca-
pacity less than 200 mL, menopausal symptoms indicating significant decrease in QoL,
presence of UTI, prior treatment for OAB
Interventions A (n = 20) tolterodine 4 mg daily for 12 weeks
B (n = 20) Stoller Afferent Neuro-stimulation (SANS) plus tolterodine 4 mg daily for 12
weeks. One 30-min session per week for 12 weeks. 34-G acupuncture needle inserted at
30º angle into 2-3 cm superior-medial aspect of tibial medial malleolus along posterior
tibial nerve trace. 20 Hz frequency, 0.2 ms duration, amplitude of stimulus adjusted
according to participant toleration
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Outcomes Frequency per 24 hours (mean, SD, N):
A 6.4 (0.6), 18. B 4.5 (0 [sic]), 20. (P < 0.05)
Urgency episodes per 24 hours (mean, SD, N):
A 7.6 (0.9), 18. B 5.7 (0.6), 20. (P < 0.05)
Incontinence episodes per week (mean, SD, N):
A 12.3 (0.8), 18. B 6.4 (0.5), 20. (P < 0.001)
IIQ-7 score (mean, SD, N) (higher score is worse incontinence):
A 11.2 (2.7), 18. B 9.0 (0.8), 20.
Adverse events:
Severe dry mouth: A 3/18. B 2/20
Severe constipation: A 2/18. B 2/20
Headache: A 1/18. B. 0/20
Local irritation on puncture site: A N/A. B 1
> 1 adverse event: A 2/18. B 1/20
Notes We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was obtained using a list
of random numbers.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 withdrawals from tolterodine alone
group; no reason reported
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Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Hosptial das Clínicas de Porto Alegre (HCPA), Brazil
Period: January 2006-May 2007
Sample size: to detect a difference of one standard deviation in the study variables after
12 weeks of treatment, the sample size was established as 11 participants per group. This
sample size assumes a significance level of 5% power of 90% and a correlation between
measurements at the 2 different points of 0.5
Follow-up: 12 weeks’ treatment, 6 months’ follow-up
Participants N: 32 randomised
Sex: Women
Age mean (SD): A 54.7 (6.94); B 49.18 (6.06); C 52.09 (13.78)
Inclusion criteria: women were older than 30 years of age; SUI or MUI; had not received
any clinical or surgical treatment during the previous 6 months; were free of significant
genital prolapse (below stage 2 on the pelvic organ prolapse quantification system);
and had no urethral sphincter involvement (leak point pressure less than 60 cmH 0)
. The criteria for prolapse classification were defined in accordance with International
Continence Society (ICS) guidelines
Exclusion criteria: not reported
Interventions All participants received identical specially designed equipment, providing real-time in-
formation on the contraction waveform and information or guidance. Vaginal probe
transducer for monitoring pelvic muscle contraction pressure during exercises. Pro-
grammable for either PFMT plus biofeedback, PFMT plus ES or PFMT without feed-
back
All participants same exercise programme: supine position with rapid contractions (2
seconds contraction, 4 seconds rest) then slow contractions (4 seconds contraction, 4
seconds of rest), repeated 3 times with rest interval
A (n = 10) PFMT plus biofeedback for 12 weeks. Device displays information on con-
traction intensity
B (n = 11) PFMT plus ES for 12 weeks. Frequency 50 Hz and pulse duration of 300 µs
C (n = 11) PFMT alone for 12 weeks. Participants received no information from device
on contraction intensity
Outcomes Subjective self-evaluation at 12 weeks:
Cure or significant improvement: 71.9% (23/32)
Partial improvement: 18.8% (6/32)
Poor response: 9.4% (3/32)
Perineometric intensity (pelvic floor muscle strength) (IC cm H2O) (mean, SD, N):
12 weeks: A 57.93 (26.15), 10. B 49.7 (25.87), 11. C 47.67 (25.26), 11
6 months: A 51.12 (28.69), 10. B 41.85 (26.1), 11. C 48.88 (19.25), 11
Number of daytime micturitions (median, IQR, N):
12 weeks: A 7 (4-8.25), 10. B 5 (5-6), 11. C 7 (5-10), 11
6 months: A 7.5 (6-9.25), 10. B 4.5 (4-6), 11. C 1.5 (0-3), 11
Number of nocturia episodes (median, IQR, N):
12 weeks: A 1 (1-2), 10. B 0 (0-1), 11. C 2 (1-2), 11
6 months: A 1.5 (0-3), 10. B 1 (0.75-2.25), 11. C, 1 (0.75-2.25), 11
Number of SUI episodes (median, IQR, N):
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12 weeks: A 1 (0-2), 10. B 0 (0-1), 11. C 2 (0-3), 11
6 months: A 1 (0.75-2.25), 10. B 0.5 (0-1.25), 11. C 0 (0-5.25), 11
Number of UUI episodes (median, IQR, N):
12 weeks: A 0 (0-1.25), 10. B 0 (0-0), 11. C 1 (0-2), 11
6 months: A 0.5 (0-1), 10. B 0 (0-0), 11. C 2 (1-3), 11
KHQ scores (mean, SD, N):
12 weeks: A 44.25 (9.11), 10. B 33.12 (19.54), 11. C 48.7 (22.21), 11
6 months: A 41.12 (15.44), 10. B 28.25 (11), 11. C 49.3 (24.96), 11
Notes No useable data because SUI and MUI participants not separated. Cure/significant
improvement not stratified by treatment group
Emailed study author 19/12/2014
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly allocated”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported. Blinding of participants not
possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The examiner who performed perineom-
etry was blinded to the patients [sic] group.
”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in the
analysis. No dropouts reported
Schreiner 2010
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Urogynecology Section of the Gynecology Department in São Lucas Hospital
of Pontificia Universidade Católica do Rio Grande do Sul, Brazil
Period: February 2008-October 2008
Sample size: not reported
Follow-up: 12 weeks’ treatment, 2 years’ follow-up
Participants N: 52 randomised, 51 analysed
Mean (SD) age: overall: 68.3 (5.3); A 67.6 (5.2); B 68.9 (5.4)
Sex: women
Inclusion criteria: UUI and age of 60 years of more
Exclusion criteria: the presence of urinary infection during the recruitment process,
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prior surgery for urinary incontinence, history of genito-urinary cancer, prior pelvic
irradiation, pure SUI, genital prolapse above the second degree of Baden Walker, and
inability to perform the Kegel exercises
Interventions All participants: PFMT (Kegel exercises); 15 contractions 3 times per day for 12 weeks
A (n = 25) transcutaneous tibial nerve stimulation. One 30-minute session per week for
12 weeks. Pulse duration 200 ms, frequency 10 Hz
B (n = 26) PFMT only
Outcomes Daytime frequency (mean, SD, N):
A 5.9 (1.4), 25. B 6.8 (1.9), 26
Change in daytime frequency (mean, SD, N):
A -1.4 (2), 25. B -0.2 (0.9), 26
Number of nocturia episodes (mean, SD, N):
A 1.3 (1.5), 25. B 2.4 (1.3), 26
Change in nocturia (mean, SD, N):
A -1.6 (1.1), 25. B -0.4 (1.1), 26
Number of SUI episodes (mean, SD, N):
A 2.4 (3.4), 25. B 4.0 (6.0), 26
Change in SUI episodes (mean, SD, N):
A -1.1 (4.9), 25. B -1.9 (3.1), 26
Number of UUI episodes (mean, SD, N):
A 1.8 (2.7), 25. B 4.6 (3.7), 26
Change in UUI episodes (mean, SD, N):
A -6.3 (5.3), 25. B -1.3 (1.6), 26
Number of participants with > 50% reduction in UUI episodes:
A 76.0% (19/25). B 26.9% (7/26) (P = 0.001)
Subjective global satisfaction:
12 weeks: A 68.0% (17/25). B 34.6% (9/26) (P = 0.017)
2 years: A 64.7%. B not reported
Number of participants with UUI:
A 44.0% (11/25). B 80.8% (20/26)
ICIQ-SF score (mean, SD, N):
A 7.9 (4.5), 25. B 10.6 (4.4), 26
Adverse effects:
A 0. B 0
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”The patients were randomly divided
(through simple random number genera-
tor) into two groups.“
Allocation concealment (selection bias) Unclear risk Not reported
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk ”One patient from group 1 (with electri-
cal stimulation of the tibial nerve) left the
study due to health problems unrelated to
the therapy
Schreiner 2014
Methods Study design: RCT
Setting: Brazil
Follow-up: 3 months’ treatment, 12 months’ follow-up
Participants N: 106 randomised
Sex: women
Inclusion criteria: elderly women (> 60 years) with UUI
Exclusion criteria: not reported
Interventions A (n = 50) conservative treatment. 12 weeks of bladder retraining and PFME
B (n = 51) transcutaneous tibial nerve ES
Outcomes ICIQ-SF: “there was a greater improvement in the group treated with ES in all parame-
ters.”
Recurrence of incontinence within 12 months:
A not reported. B 16/34
Satisfaction at end of treatment: A 32.0% (16/50). B 66.7% (34/51)
Notes 71% had associated stress incontinence
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “the study design was a randomized clinical
trial, parallel group”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants, other
blinding not reported
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 12-month data reported only for propor-
tion of ES participants satisfied at end of
treatment, no 12-month data for bladder
training group
Seth 2014
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: UK
Period: not reported
Sample size: not reported
Follow-up: 12 weeks
Participants N: 48 randomised and 35 analysed
Mean (SD) age: not reported
Sex: not reported
Inclusion criteria: either multiple sclerosis or idiopathic OAB
Exclusion criteria: not reported
Interventions A (n = 24*) 30 min stimulation once per day for 12 weeks with Geko device
B (n = 24*) 30 min stimulation once per week for 12 weeks with Geko device
Outcomes Improvement in ICIQOAB score: -10.2 (-13.5 to -6.9, P = 0.001)
Improvement in ICIQLUTS-QOL score: -40.8 (-57.4 to -24.3, P = 0.000)
*Responders: 18/34
Notes N randomised per group not reported. Outcome data not presented per group
Contacted study author for more information 5 February 2014 - replied with data
marked *
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk 48 randomised, 35 completed study (dif-
ferential attrition: 20 with MS, 15 with id-
iopathic OAB). Unclear how many with-
drew from each group. Unclear if all
randomised participants were included in
analysis
Shepherd 1984
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: UK
Period: not reported
Sample size: not reported
Follow-up: 12 weeks
Participants N: 107 randomised, 94 analysed
SUI 42
UUI 26
MUI 39
Mean (SD) age: not reported
Sex: women
Inclusion criteria: SUI, UUI or MUI
Exclusion criteria: not reported
Interventions A (n = 53) ES under general anaesthesia. Single session. Scott electrode in vagina, large
indifferent electrode under buttocks. Current up to 40 v, 10-50 Hz for 20 min
B (n = 54) sham treatment. Single session. Vaginal electrode but no current
Outcomes Participants with no improvement in frequency of incontinence:
A 16/45. B 18/49
Participants not dry:
A 37/45. B 43/49
Participants with no improvement in pad changes:
A 27/45. B 31/49
Participants with no improvement in objectively measured pelvic floor control:
A 23/45. B 23/49
Participants with no improvement in incontinence:
A 18/45. B 16/49
Notes Not useable because data not presented by SUI/UUI/MUI groups
Risk of bias Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Allocated at random into trial and control
groups.”
Allocation concealment (selection bias) Low risk “a sealed envelope was opened stating
which group the patient was in”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants blinded. Other blinding not
reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Patients’ subjective statements
were recorded by a single observer who was
unaware of the treatment allocation”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Nodifferential dropout.No explanation re-
ported for withdrawals
Shepherd 1985
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: UK
Period: not reported
Sample size: not reported
Follow-up: 6 months
Participants N: 40 randomised, 15 analysed
Mean (SD) age: not reported
Sex: women
Inclusion criteria: genuine stress incontinence or DO
Exclusion criteria: not reported
Interventions A (n = 6 SUI, 4 DO) ES. Intra-vaginal cushion attached to stimulator worn around the
waist. Cushion worn for 8 h per 24, night or day according to participant preference.
Stimulation: 50 Hz (SUI participants), 10 Hz (DO participants)
B (n = 3 SUI, 2 DO) sham ES. Identical device to Group A but not activated
Outcomes Subjective and objective improvement in symptoms
Notes No useable data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All participants given identical devices but
unaware which were activated. “The code
was held by themanufacturer and only bro-
ken when the trial was completed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Withdrawal per group not reported. Sub-
stantial withdrawal overall: 15/40 com-
pleted trial
Slovak 2015
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: UK
Period: June 2013 and December 2014
Sample size: not reported
Follow up: 4 weeks’ treatment, then 4 weeks’ follow-up
Participants N: 22 randomised, 19 analysed
Mean (SD) age: 59 (7.9)
Sex: 9 men, 10 women
Inclusion criteria: people with idiopathic OAB symptoms who had not responded or
could not tolerate (due to side effects) conventional drug therapy,
Exclusion criteria: not reported
Interventions A (n = 7 analysed) ES with unilateral PTNS with conventional TENS* machine using a
pair of adhesive surface electrodes and a stimulus intensity just below that which would
cause a motor contraction of toes/shoulder muscles. Electrodes placed above and below
the medial malleolus on the right ankle
B (n=6 analysed) ESwith bilateral PTNS. Electrodes placed in same position as unilateral
stimulation group but on both ankles
C (n = 6 analysed) sham stimulation, electrodes placed on the anterior aspect of the left
shoulder
Outcomes Decrease in micturitions per 24 h (mean, 95%CI, N):
A 1.7 (-9 to 3.7), 7. B 2.8 (-6.7 to 1.1), 6. C 0.7 (-2.1 to 6.3)
Decrease in urgency episodes (mean, 95%CI, N):
A 1.3 (-5.0 to 2.2), 7. B 3.2 (-8.5 to 2.1), 6. C 0.7 (-5.0 to 3.7)
Number of responders (defined as > 30% reduction in daily micturitions and/or urgency
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episodes, and self-reported subjective improvement:
A 3/7. B 2/6. C 1/6
Notes *no explanation given for TENS abbreviation
“Initial effects were reported after the first week of the therapy in all responders. In the
majority of responders the effects ceased at the follow-up visit, four weeks after therapy
had finished.”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated”
Allocation concealment (selection bias) Low risk “opaque sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded. “The participants
were unaware that one of the stimulation
groups was considered as a placebo group.”
“The researcher who provided the training
to participants was not blinded…data were
recorded only by the participants”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “the research team did not interact with
participant’s outcome questionnaires and
bladder diary, and data were recorded only
by the participants”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Per-protocol analysis. No reasons given for
participant withdrawal
Smith 1996
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Department of Urology, Lahey Clinic, Burlington, Massachusetts, USA
Period: October 1992- January 1994
Sample size: not reported
Follow-up: 16 weeks
Participants N: 57 randomised in total. 38 with DI randomised and analysed
Mean age (range):
A 65 (45-82)
B 60 (44-73)
Sex: Women
Inclusion criteria: genuine SUI or DI
Exclusion criteria: type 3 SUI, pregnancy, history of prolonged urinary retention, vaginal
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vault prolapse, diminished sensory perception or cardiac pacemaker
Interventions A (n = 20) propantheline bromide 7.5 mg to 45 mg 2-3 times daily (“or until side effects
prevented its continuance”) for at least 4 months
B (n = 18) ES. 5-s impulse time, duty cycle 1-2, increasing monthly treatment time from
15, 30, 45 and 60 min. Amplitude started at 5 mA and did not exceed 25 mA. Twice
daily for 4 months
Outcomes Number of participants cured (defined as cessation of incontinence and no longer re-
quiring pads):
A 3/20. B 4/18
Number of participants with objective improvement (defined as reduction of ≥ 50% in
episodes and pads, and ≤ 10 voiding episodes per 24 hours):
A 7/20. B 9/18
Number of participants with no improvement:
A 10/20. B 5/18
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “patients were randomized to 1 of 2 treat-
ment arms”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blindparticipants. Blinding
of others not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
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Methods Study design: cross-over RCT
Multicentre or single-centre: single-centre
Setting: University of New South Wales, New South Wales, Australia
Period: not reported
Sample size: the study was designed to obtain a type 1 error of 5% and a power of 85%
which gave a sample size of 35
Follow-up: 6 weeks
Participants N: 43 randomised and analysed
Mean (SD) age: 50 (15)
Sex: 13 men, 30 women
Inclusion criteria: history of frequency, urgency and urge incontinence with no previous
treatment for at least 6 months
Exclusion criteria: not reported
Interventions A (n = 43) oxybutynin 2.5 mg twice daily, titrated to 5 mg 3 times daily by day 7
B (n = 43) TENS 20 Hz, pulse width 0.2 ms on a continuous mode up to 6 hours daily
for 6 weeks
All participants had washout period of 2 weeks then 6 weeks of the other treatment
Outcomes Number of daily voids (mean, SD, N):
A 9 (5), 43. B 9 (4), 43
Number of participants with no subjective improvement:
A 30/40. B 29/38
Total bladder capacity (mL) (mean, SD, N):
A 303.3 (142.5), 43. B 222.1 (99.2), 43
Volume at first desire to void (mL) (mean, SD, N):
A 191.8 (130.1), 43. B 117.4 (84.7), 43
Residual volume (mL) (mean, SD, N):
A 81.3 (81.3), 43. B 38.9 (55.03), 43
Volume at instability (mL) (mean, SD, N):
A 180.9 (92.8), 43. B 96.3 (55.9), 43
Number of participants with > 25% improvement in bladder capacity:
A 6/43. B 2/43
Number of participants with > 25% improvement in daily voids:
A 21/43. B 24/43
Number of participants with side effects (N unclear):
Dry mouth: A 87.2% (37/43). B 6.2% (3/43)
Blurred vision: A 52.6% (23/43). B 6.2% (3/43)
Dry skin: A 29.7% (13/43). B 6.2% (3/43)
Skin irritation: A 25.6% (11/43). B 28.1% (12/43)
Cost per participant:
A oxybutynin £15.00 for 6 weeks
B ES, including consumables, £60 for 6 weeks
Notes N assumed to be 43 unless otherwise stated
Data not useable. Cross-over design requires paired difference and SD for each outcome
but paper reports insufficient data for analysis
Contacted study author asking for further data 26 January 2015
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized to initial treat-
ment with either transcutaneous electrical
nerve stimulation or oxybutynin. After a
washout period of 2 weeks, patients were
started on the second arm of treatment”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blindparticipants. Blinding
of others not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear if data available for all participants.
Also risk of carry-over effect is unclear
Sotelo 2011
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: USA
Period: not reported
Sample size: not reported
Follow-up: 8 days
Participants N: 50 randomised and analysed
Mean (SD) age: 57
Sex: not reported
Inclusion criteria: OAB
Exclusion criteria: not reported
Interventions A (n = 15) ES, no tub bathing or exercise. Horizontal placement of electrode patch near
sacral nerve
B (n = 15) ES, no tub bathing or exercise. 30º angle placement of electrode patch near
sacral nerve
C (n = 5) ES, with daily tub bathing or swimming. Horizontal placement of electrode
patch near sacral nerve
D (n = 5) ES, with daily tub bathing or swimming. 30º angle placement of electrode
patch near sacral nerve
E (n = 5) ES, with daily 30-min exercise regimen. Horizontal placement of electrode
patch near sacral nerve
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F (n = 5) ES, with daily 30-min exercise regimen. 30-degree angle placement of electrode
patch near sacral nerve
Outcomes Adverse effects: 1 participant (not reported by group)
Patch awareness, discomfort, bother, 1-10 VAS (mean, SD), N):
A + B: 1.4 (1.1), 30. C + D: 1.2 (0.9), 10. E + F: 1.3 (1.0), 10
Notes No useable data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomized to one of two sacral placement
angles”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data not reported per group
Souto 2014
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Brazil
Period: August 2008-May 2010
Details of sample size calculation: “a prior power calculation…even after dropout, 80%
sample power was kept (post hoc analysis)”
Follow-up: 12 weeks’ treatment, 6 months’ follow-up
Participants N: 75 randomised, 58 analysed
Mean (range) age: A 56.9 (33-77). B 57.7 (34-79). C 60.1 (33-77)
Sex: women
Inclusion criteria: clinical complaints of OAB: urinary frequency, nocturia, and/or ur-
gency incontinence with negative urinalysis and urine culture
Exclusion criteria: previous treatment, residual urine, cognitive and psychiatric deficits,
pregnancy, glaucoma, SUI, any pelvic organ prolapse quantification system (POPQ) C
grade II, neurogenic OAB, those using anticholinergic drugs, calcium antagonists, b-
antagonists, and dopamine antagonists
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Interventions A (n = 25) ES of posterior tibial nerve using Neurodyn Portable. 10 Hz frequency, pulse
width of 250 µs. Two 30-minute sessions per week for 12 weeks
B (n = 25) slow release oxybutynin 10 mg, once daily for 12 weeks
C (n = 25) multimodal treatment, A + B
Outcomes Frequency (mean*, N):
12 weeks: A 8, 18. B 7.9, 19. C 7.6, 21. (P = 0.75)
24 weeks: A 7.9, 18. B 9.2, 19. C 7.8, 21 (P = 0.51)
Participants with urinary incontinence:
12 weeks: A 11% (2/18). B 31% (6/19). C 19% (4/21)
24 weeks: A 14% (3/18). B 34% (6/19). C 18% (4/21)
Participants with nocturia:
12 weeks: A 11% (2/18). B 5% (1/19). C 14% (3/21). (P = 0.24)
24 weeks: A 13% (2/18). B 15% (3/19). C 14% (3/21). (P = 0.51)
International Consultation on Incontinence Questionnaire (ICIQ-SF) score (mean*,
range, N):
12 weeks: A 7.2 (0-18), 18. B 9.8 (0-18), 19. C 7.9 (0-14), 21
24 weeks: A 8.3 (0-20), 18. B 13.3 (8-20), 19. C 7.4 (0-14), 21
ICIQ-OAB (mean*, range, N):
12 weeks: A 5.9 (1-11), 18. B 4.6 (0-10), 19. C 2.9 (0-5), 21
24 weeks: A 6.1 (1.-12), 18. B 9.2 (4-13), 19. C 3.0 (0-5), 21
Bother: 0-10 analogue scale (mean, range, N):
12 weeks: A 3.9 (0-8), 18. B 3.4 (0-9), 19. C 1.7 (0-4), 21
24 weeks: A 4.2 (0-8), 18. B 7.0 (2-10), 19. C 1.6 (0-4), 21
Notes *SD not reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “patients were divided randomly
into three groups using online randomiza-
tion”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible to blind participants. Person-
nel not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Patients who failed to comply with the 12
weeks of treatment (Week 12) and/or did
not attend the reassessment after treatment
(Week 24) at 6 months follow-up were ex-
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cluded from analysis.”
No differential withdrawal. No reasons
given for withdrawals
Spruijt 2003
Methods Study design: RCT
Multicentre or single-centre: single-centre.
Setting: Vrije University Medical Center Amsterdam, the Netherlands
Period: January 1996 and May 1998
Sample size: 75 participants for this study (alpha = 5%, beta 10%, estimated difference
= 10%)
Follow-up: 8 weeks
Participants N: 72 enrolled, 37 randomised, 35 analysed
Sex: women
Median age (range): A 72 (65-92); B 74 (66-86)
Inclusion criteria: women ≥ 65 with symptoms of SUI, UUI or MUI for ≥ 3 months,
urinary leakage of 10 cc or more per 24 h
Exclusion criteria: persistent UTI (positive urine culture after antibiotic treatment), re-
current UTI (within 4 weeks after treatment), bladder pathology or dysfunction because
of fistula, tumour, pelvic irradiation, neurological or other chronic conditions (diabetes
mellitus, Parkinson’s disease), any incontinence treatment during the past 6 months,
genital prolapse to, or beyond, the introitus, having a pacemaker, and insufficient mental
condition/cognition
Interventions A (n = 25) ES. Three 30-min sessions, with 5min rest between each 15 min of treatment,
per week for 8 weeks. Frequency 50 Hz for predominant SUI and 20 Hz for predomi-
nant UUI. 2-s contraction time and duty cycle of 1-2 s, stimulation intensity gradually
increasing up to the level of tolerable discomfort (0-100 mA)
B (n = 12) PFMT. Verbal instructions on performing Kegel exercises at home for 8 weeks
Outcomes Urinary leakage per day (mg) (mean, range, N):
A 65 (0-489), 24. B 26 (4-157), 11
Number of participants with no objective improvement:
A 17/24. B 7/11
Pelvic muscle strength (mean, range, N):
A 15.375 (1.75-40.00), 24. B 10.00 (3.25-23.00)
Number of participants with DI defined as spontaneous detrusor contraction(s) of 15
cm H2O or more on (ambulant) urodynamic registration (ICS standard):
A 14/24. B 5/11
Number of participants with no subjective improvement (measured with PRAFAB score)
:
A 13/24. B 6/11
Notes No useable data - not presented by SUI/UUI/MUI participants
Study authors contacted for data 09-02-2015
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked randomisation according to
Pocock’s method
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was one participant in each group
lost to follow-up.
Svihra 2002
Methods Study design: quasi-RCT
Multicentre or single-centre: not reported
Setting: Slovakia
Period: 2001
Sample size: not reported
Follow-up: 5 weeks
Participants N: 28
Sex: women
Mean age (range): 54 (45-63)
Inclusion criteria: OAB without bladder outlet obstruction confirmed by urodynamic
examination
Exclusion criteria: not reported
Interventions A (n = 9) SANS ES (Stoller Afferent Neuro Stimulation). One 30-min session per week
for 5 weeks. Frequency 1 Hz, square impulse duration 0.1 ms, intensity 25 mA
B (n = 10) oxybutynin 3 mg 3 times per day
C (n = 9) no active treatment
Outcomes IPSS (mean, SD, N)
A 6 (4), 9. B not reported. C not reported
Incontinence Quality of Life Questionnaire (I-QoL) score (mean, SD, N):
A 68 (20), 9. B not reported. C not reported
Behavioural Urge Score (BUS) (mean, SD, N):
A 0.43 (0.16), 9. B not reported. C not reported
Change in IPSS (mean, N):
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A 60%, 9. B 80%, 10. C 20%, 9
Change in I-QoL (mean, N):
A 100%, 9. B 90%, 10. C 25%, 9
Change in BUS (mean, N):
A 30%, 9. B 30%, 10. C 5%, 9
Number of participants with no significant improvement in IPSS, IQoL, BUS:
A 4/9. B not reported. C 9/9
Number of participants with adverse effects:
A 0/9. B 2/10 (dry mouth). C not reported
Notes Only adverse events data were useable
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Nine randomly chosen females formed the
group with SANS stimulation, ten females
formed the oxybutynin group and nine fe-
males the group without treatment.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Vahtera 1997
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Finland
Period: not reported
Details of sample size calculation: not reported
Follow-up: 2 weeks’ treatment then 6 months’ follow-up
Participants N: 80 randomised, unclear how many analysed
Mean (SD) age: A women 42.2 (8.9). A men 45.3 (6.3). B women 45.7 (10.7). B men
41.8 (11.8)
139Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Vahtera 1997 (Continued)
Sex: 50 women, 30 men
Inclusion criteria: stable phase of MS, baseline Expanded Disability Score≤ 6.5, LUTS,
postvoid residual volume < 100 mL
Exclusion criteria: pregnancy, cardiac pacemaker or any metallic implant near the treated
area, history of pelvic malignancy, dementia or any nervous system disorder other than
MS
Interventions A (n = 40) ES. 6 sessions over two weeks. Intravaginal electrodes for women, intra-anal
for men. 10 minutes of each frequency: 5-10 Hz, 10-50 Hz, 50 Hz (7 s pulse, 25 s pause)
, with 3 min rest in between. Currents at maximal tolerated intensity. After 6 ES sessions
biofeedback used to teach PFME, participants advised to continue PFME 3-5 times per
week for ≤ 6 months
B (n = 40 no active treatment
Outcomes Urgency, urine leakage, volume of urine loss, voiding need during daytime, slow urine
flow, sensation of incomplete bladder emptying, need of assistance in emptying bladder
Notes No useable data: no outcomes reported by treatment group
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Men and women were separately random-
ized into a treatment group”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No outcomes reported for control group
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Methods Study design: cross-over RCT
Multicentre or single-centre: not reported
Setting: Italy
Period: June 2010-October 2011
Sample size: not reported
Follow-up: approximately 6months (40 days’ drug treatment, 6 weeks ES, with 3-month
washout period in between)
Participants N: 40 randomised, 30 analysed
Sex: women
Mean age (range): 62 (35-81)
Inclusion criteria: women with OAB syndrome
Exclusion criteria: stress incontinence,UTI, neurological disease, bladder lithiasis, genital
prolapse higher than stage II on POP-Q system, uncontrolled narrow angle glaucoma,
pelvic tumours, postvoid residual urine ≥ 100 mL, or previously treated with pelvic
surgery, radiation therapy or antimuscarinic agents
Interventions A (n = 20) solifenacin succinate, 5 mg daily for 40 days. 3-month washout period then
percutaneous tibial nerve stimulation, 30-min session twice a week for 6 weeks
B (n = 20) reverse of group A
Outcomes Number of voids per 24 hours (mean, SD, N):
Post-SS: A 10 (2.1), 14. B 10.4 (1.8), 16
Post-ES: A 8.5 (2.3), 14. B 9.4 (1.9), 16
Number of nocturia episodes:
Post-SS: A 1.9 (1.4), 14. B 2.1 (1.4), 16
Post-ES: A 1.6 (1.3), 14. B 1.7 (0.9), 16
Number of urgency incontinence episodes:
Post-SS: A 2.6 (1.6), 14. B 2.7 (1.6), 16
Post-ES: A 1.7 (1.3), 14. B 1.7 (1.5), 16
Voided volume (cc?) (mean, SD, N):
Post-SS: A 147.4 (27.5), 14. B 145.5 (29.6), 16
Post-ES: A 157.5 (25.5), 14. B 156.1 (18.4), 16
QoL measured with Overactive Bladder Questionnaire Short Form (6 item OAB-Q SF
score (mean, (SD), N)) (lower score is better):
Post-SS: A 3.2 (1.1), 14. B 3.5 (1.2), 16
Post-ES: A 2.7 (1.0), 14. B 3.0 (1.0), 16
QoLmeasured with Overactive Bladder Questionnaire Short Form (13 itemOAB-Q SF
score (mean, (SD), N)) (lower score is better):
Post-SS: A 3.1 (1.1), 14. B 3.4 (1.2), 16
Post-ES: A 2.9 (0.9), 14. B 2.9 (1.1), 16
Urgency measured with Patient Perception of Intensity of Urgency Scale (PPIUS score
(mean, (SD), N)) (lower score is better):
Post-SS: A 2.7 (1.2), 14. B 2.7 (1.3), 16
Post-ES: A 2.1 (0.9), 14. B 2.2 (1.1), 16
Improvement measured with Patient Global Impression of Improvement questionnaire
(PGI-I score [mean, SD, N]) (lower score is more improvement)
Post-SS: A 2.9 (1.1), 14. B 3.1 (1), 16
Post-ES: A 2.1 (0.7), 14. B 2.3 (0.7), 16
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Notes We included data from first period of randomisation only
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Follow-up was performed by a physician
who was not involved in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk A: 2 participants withdrew due to side ef-
fects, 2 withdrew after SS due to improved
symptoms, 2 refused to undergo further
therapy
B: 3 withdrew due to improved symptoms,
1 refused to undergo further therapy
Vohra 2002
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Bedford, UK
Period: not reported
Sample size: not reported
Follow-up: 12 weeks
Participants N: 22 randomised, 21 analysed
Sex: not reported
Mean age (range): 52.6 (28-78)
Inclusion criteria: symptoms of at least six months duration, clinical diagnosis of urgency,
frequency syndrome and urodynamic findings of DO
Exclusion criteria: not reported
Interventions A (n = 11) Stoller Afferent Nerve Stimulation (SANS) one 30-minsession per week for
12 weeks. Stimulation of posterior tibial nerve with percutaneous needle, current up to
10 mA
B (n = 10) sham treatment without nerve stimulation
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Outcomes Number of participants with no improvement:
A 2/11. B 10/10
Notes ---
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Patients were computer randomised to ei-
ther the treatment arm or as controls”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one participant discontinued the
treatment.
Walsh 2001
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: not reported
Period: not reported
Sample size: not reported
Follow-up: not reported
Participants N: 146 randomised and analysed
Mean age (range): 47 (17-79)
Sex: 35 men /111 women
Inclusion criteria: urgency incontinence; idiopathic DI, SU, or DH secondary to either
spinal injury, myelomeningocele, or multiple sclerosis
Exclusion criteria: not reported
Interventions A (n = 74) transcutaneous neurostimulation. One session: electrode pads of a transcu-
taneous neurostimulator (Coba 208 neurostimulator unit, Tenscare Ltd., Surrey, UK)
were affixed bilaterally to the skin overlying the S3 dermatomes (situated at the junction
of buttock and upper thigh) in all participants. Standard urodynamic filling cystometry
was performed via a dual-lumen 7-Ch fluid filled catheter system at a 50 mL/minute fill
rate
B (n = 72) sham treatment. Standard urodynamic filling cystometry was performed via a
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dual-lumen 7-Ch fluid filled catheter system at a 50 mL/minute fill rate. Electrode pads
in place but without applying current
Outcomes Infused bladder volume (mL) at FDV (mean, SD, N):
A 167.2 (11.3), 74. B 114.2 (10.7), 72
Detrusor pressure at FDV (mean, SD, N):
A 8.4 (1.3), 74. B 9.4 (1.5), 72
Infused bladder volume (mL) at SDV (mean, SD, N):
A 247.4 (12.8), 74. B 193.7 (18.4), 72
Detrusor pressure at SDV (mean, SD, N):
A 10.9 (3.1), 74. B 10.6 (1.8), 72
Infused bladder volume (mL) at sensation of urgency (Urge) (mean, SD, N):
A 331.5 (15.9), 74. B 255.4 (11.4), 72
Detrusor pressure at Urge (mean, SD, N):
A 18.6 (3.2), 74. B 22.6 (5.3), 72
Maximum infused cystometric capacity (mL) (CMax) (mean, SD, N):
A 404.2 (26.7), 74. B 315.9 (22.9), 72
Detrusor pressure at CMax (mean, SD, N):
A 20.5 (3.2), 74. B 25.9 (3.5), 72
Notes We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomized into age- and
gender-matched control and study groups.
”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study and
were included in the analysis
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Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Taiwan
Period: July 2001-December 2002
Sample size: on the basis of the outcome measures (including QOL assessment, bladder
diary, participant perception of improvement and satisfaction with treatment, and the
improvement rate of ES, PFMT, and BAPFMT, which was 49%, 82.39%, and 80.7%,
respectively), the authors conducted a test with a significance level of 0.05 and power
of 0.9 and anticipated that groups of equal size were required. The total sample size
required was at least 109.5
Follow-up: 12 weeks
Participants N: 120 randomised, 103 analysed
Mean age: A 50.09; B 52.32; C 55.74
Sex: women
Inclusion criteria: OAB symptoms for≥ 6months, 16-75 years old, frequency of voiding
≥ 8 times per day, ≥ 1 urgency incontinence episode per day
Exclusion criteria: pregnancy, deafness, neurologic disorders, diabetes mellitus, pace-
maker or intrauterine device use, genital prolapse greater than Stage II of the Interna-
tional Continence Society grading system, residual urine greater than 100 mL, and UTI
Interventions A (n = 40) PFMT. At least 3 times daily, performed according to PERFECT scheme
(power/endurance/repetition//fast contraction),
B (n = 38) BAPFMT. Intravaginal electromyogram probe (Periform, NeenHealth-Care)
twice per week, participants contracted or relaxed pelvic floor muscles according to visual
EMG signals. Also encouraged to perform PFMT at home according to PERFECT
scheme
C (n = 42) ES. Two 20-min sessions per week with intravaginal electrode (Periform,
Neen HealthCare); biphasic, symmetric, pulsed current with frequency of 10 Hz, pulse
width 400 µs, duty cycle of 10 s on, 5 s off, and intensity varying with patient tolerance
(minimum 20-63 mA, maximum 40-72 mA)
Outcomes Number of participants with urgency incontinence (no improvement):
A 21/34. B 17/34. C 17/35
Number of participants with no improvement in OAB:
A 21/34. B 17/34. C 17/35
KHQ total score (mean, SD, N) (lower score is better):
A 50.27 (171.42), 34. B 185.86 (176.57), 34. C 180.08 (176.03), 35
Data for all 9 KHQ domains available: see Table II
Notes Gives data for incontinence episodes per day but then states “We decided not to use this
parameter as an outcome measure because of the large number of incomplete records,
which could have resulted in a statistical bias.”
We contacted the main author of the study to clarify methodological aspects of the study
and request further information. Awaiting reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “The allocation of the three study groups
was undertaken by sequentially opening a
sealed envelope, prepared by the Biostatis-
tics Center for Chang Gung Medical Col-
lege in blocks of 6”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants could not be blinded.
“The physiotherapist conducted the regi-
mens while unaware of the progress and
outcomes of the interventions.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The principal investigator was not in-
volved in any of the interventions and was
unaware of the group allocation.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential dropout. Adequate expla-
nation for dropouts
Wang 2006
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Taiwan
Period: July 2004-November 2005
Sample size: on the basis of the reduction rate of urge incontinence after ES, oxybutynin,
and placebo (51%, 7; 76%, 5; and 19%, 8 respectively), we conducted a test with a
significance level of 0.05 and power of 0.95 and anticipated that groups of equal size
were required. We concluded that at least 72 women were required
Follow-up: 12 weeks
Participants N: 74 randomised, 68 analysed
Sex: women
Mean age (SD): not reported
Inclusion criteria: OAB ≥ 6 months, age 16-80, in particular urinary urgency 4 times
or more per day
Exclusion criteria: pregnancy, neurologic disorders, diabetes mellitus, demand cardiac
pacemaker or intrauterine device use, genital prolapse greater than Stage II of the Inter-
national Continence Society grading system, a postvoid residual urine volume greater
than 100 mL, overt SUI, a history of anti-incontinence surgery, and UTI
Interventions A (n = 25) ES. Two 20-min sessions per week. Biphasic, symmetric, pulsed current with
a frequency of 10 Hz, pulse width of 400 ms, duty cycle of 10 son and 5 s off, and
intensity varying with participant tolerance (minimum 20-63 mA and maximum 40-72
mA)
B (n =26) oxybutynin 2.5 mg, 3 times per day for 12 weeks
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C (n = 23) placebo tablets identical to oxybutynin, 3 times per day for 12 weeks
Outcomes No improvement in urgency:
A 10/24. B 14/23. C 19/21
Daily voided volume (mL) (median, range, N):
A 2270 (1210-3106), 24. B 2100 (1619-3200), 23. C 2305 (1351-3221) 21
Pad count (median, range, N):
A 0 (0-2), 24. B 0 (0-2.5), 23. C 1 (0-3), 21
Urgency episodes per 24 h (median, range, N):
A 1.0 (0.0-12.3), 24. B 6 (0.5-13), 23. C 7.4 (3.9-13.4), 21
Frequency per 24 h (median, range, N):
7.8 (1.8-13.0), 24. B 7.4 (2-14), 23. C 10 (6.6-16.3), 21
Nocturia episodes per night (median, range, N):
A 0 (0-3.0), 24. B 0 (0-2.0), 23. C 1 (0-3.6), 21
Urgency incontinence episodes per 24 h (median, range, N):
A 0.5 (0-2), 24. B 0 (0-2), 23. C 1 (0-2), 21
Change in daily voided volume (mL) (median, range, N):
A 70 (-216 to 1190), 24. B 10.5 (-1031 to 962), 23. C -14.5 (-590 to 413), 21
Change in pad count (median, range, N):
A -0.9 (-2.1 to 2), 24. B 0 (-1 to 2), 23. C 0 (-4 to 3), 21
Change in urgency episodes per 24 h (median, range, N):
A -3 (-14 to 0.5), 24. B -3 (-12 to -0.1), 23. C -1.3 (-10.5 to 2)
Change in frequency per 24 h (median, range, N):
A -3.0 (-14 to 0.5), 24. B -2.15 (-12.8 to 2.3), 23. C -0.75 (-6.5 to 2.3)
Change in nocturia episodes per night (median, range, N):
A -0.8 (-6.5 to 0.4), 24. B 0 (-2 to 1), 23. C 0 (-1.5 to 2)
Change in urgency incontinence episodes per 24 h (median, range, N):
A 0 (-2 to 2), 24 B 0 (-1 to 1), 23. C 0 (-2 to 1), 21
Notes Contacted study author December 2014 to clarify if this is different study from Wang
2009. Awaiting reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Low risk “The allocation of the three study groups
was undertaken by sequentially opening a
sealed envelope, prepared by the Biostatis-
tics Center for Chang Gung Medical Col-
lege in blocks of six for each patient”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “For the pharmacotherapy groups, the pa-
tients and all investigators were unaware of
the regimen they received from the central
pharmacy of our hospital.”
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Not possible to blind ES group
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The principal investigator was not in-
volved in any of the interventions and was
unaware of the group allocation.”
“For the pharmacotherapy groups, the pa-
tients and all investigators were unaware of
the regimen they received from the central
pharmacy of our hospital.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “One woman in the ES group withdrew
because of fear of the electricity. Three
women in the oxybutynin group withdrew,
all because of intolerable dry mouth. Two
women in the placebo group withdrew be-
cause they felt no response.”
Wang 2009
Methods Study design: RCT
Multicentre or single-centre: single-centre
Setting: Taiwan
Period: July 2006-November 2007
Sample size: calculations for the treatment and placebo groups were based on the as-
sumption that participants in the treatment groups had a 0.76 probability and others in
the placebo group had a 0.36 probability of achieving a better outcome (increased UFI)
. To achieve 0.80 power with 0.05 significance level, it required at least 24 participants
in each group
Follow-up: 12 weeks
Participants N: 73 randomised, 73 analysed
Sex: women
Mean age (SD): overall 53.14 (9.98); A 51.46 (9.92); B 54.92 (9.83); C 53.17 (10.30)
Inclusion criteria: OAB for ≥ 6 months (symptom of urgency ≥ 3 times daily)
Exclusion criteria: pregnancy, neurologic disorders, diabetes mellitus, demand cardiac
pacemaker or intrauterine device use, genital prolapse greater than the ICS grading system
stage II, overt SUI, a history of anti-incontinence surgery, UTI and participants receiving
any OAB treatment during the 14-day washout/run-in period preceding randomisation
Interventions A (n = 26) ES. Two 20-min sessions per week for 12 weeks with intravaginal electrode
(Periform,NeenHealthCare). Biphasic, symmetric, pulsed current with varying intensity
B (n = 24) Oxybutynin. Three 2.5 mg per day for 12 weeks
C (n = 23) placebo. 1 tablet identical to oxybutynin, 3 times per day for 12 weeks
Outcomes No improvement in urgency:
A 9/26. B 12/24. C 20/23
Number of micturitions per 24 hours (median, range, N):
A 7.05 (2.7, 12), 26. B 5.35 (1, 13.1), 24. C 8.8 (4.1, 13), 23
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Number of incontinence episodes (median, range, N):
A 0.85 (0, 2.8), 26. B 0.3 (0, 2.1), 24. C 0.8 (0, 4.3), 23
Number of urgency episodes (median, range, N):
A 2.4 (0, 6.9), 26. B 3.05 (1, 8.1), 24. C 7.2 (3.5, 10.2), 23
Number of nocturia episodes per night (median, range, N):
A 1.65 (0, 4.3), 26. 1.45 (0, 5.4), 24. C 3 (0.1, 4.1), 23
Change in number of micturitions per 24 hours (median, range, N):
A 3.6 (−2.1, 7.2), 26. B 5.3 (−3.5, 10.9), 24. C 1.6 (−5.2, 7.7), 23
Change in number of incontinence episodes (median, range, N):
A 0 (−2.8, 3.3), 26. B 0.4 (−0.3, 3.2), 24. C 0.2 (−2.5, 2.2), 23
Change in number of nocturia episodes per night (median, range, N):
A 2.8 (−2.7, 7.8), 26. B. 2.35 (−3.1, 6.2), 24. C −0.3 (−6.2, 4.7), 23
Change in number of nocturia episodes per night (median, range, N):
A 0 (−3.2, 3.5), 26. B 0.45 (−5.4, 3), 24. C 0 (−4.1, 2.7), 23
KHQtotal score (median, range, N):
A 142.25 (-11.5, 432.4), 26. B 104.75 (-49.9, 383.8), 24. C 36.7 (-137.2, 525), 23
All nine KHQ domains available: see Table 5
Notes Contacted author to clarify if this study is study is separate from Wang 2006. Awaiting
reply
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Predetermined computer-generated ran-
domization code’ was used. Participants
were ‘assigned randomly in sequential or-
der.”
Allocation concealment (selection bias) Unclear risk Not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The principal investigator was not in-
volved in any of the interventions and was
unaware of the group allocation.”
“For the pharmacotherapy groups, [groups
B and C] the subjects and all investigators
were unaware of the regimen they received
from the central pharmacy of our hospital.
”
Group C received “a placebo looking ex-
actly the same as Oxybutynin.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Three patients in the ES and four each in
the oxybutynin and placebo groups with-
drew after randomisation, leaving 23 in the
ES, 20 in the oxybutynin, and 19 in the
placebo group who completed the study
Reasons for withdrawal not reported.
ITT analysis carried out “based on the data
obtained from initially randomized 73 sub-
jects.”
Wise 1992
Methods Study design: comparative (unclear if randomised)
Multicentre or single-centre: single-centre
Setting: UK
Period: not reported
Details of sample size calculation: not reported
Follow-up. not reported
Participants N: 40 recruited
Mean (SD) age: not reported
Sex: women
Inclusion criteria: urodynamically proven idiopathic DO
Exclusion criteria: not reported
Interventions A (n = ?) ES. Daily session at home for 6 weeks with intravaginal maximal electrical
stimulator
B (n = ?) terodiline 25 mg daily for 6 weeks
Outcomes Reduction in symptoms: urgency, frequency, urgency incontinence, stress incontinence
Notes No data reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Wise 1993
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: UK
Period: not reported
Sample size: not reported
Follow-up: 6 weeks
Participants N: 60 randomised
Sex: women
Mean age: not reported
Inclusion criteria: urodynamically proved DI
Exclusion criteria: not reported
Interventions A (n = 32) oxybutynin hydrochloride 5 mg
B (n = 28) ES. 20-min sessions. Participants taught to insert vaginal electrodes and
gradually increase stimulus to just below level of discomfort. Frequency 20 Hz, current
0-90 mA
Outcomes Adverse effects:
A 7/32. B 0/28
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Sixty women were recruited and ran-
domised”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
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Incomplete outcome data (attrition bias)
All outcomes
High risk Differential dropout: “Nine patients in the
oxybutynin group failed to complete the
full treatment period. In seven cases this
was due to unacceptable drug side effects.
All patients in the MES group completed
six weeks therapy and all found themethod
of treatment acceptable.”
Yamanishi 2000a
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Japan
Period: not reported
Sample size: not reported
Follow-up: After 4-week treatment, participants who were cured or improved were fol-
lowed up monthly on the basis of the records in the frequency/volume chart to evaluate
post-stimulation effects. If the participant relapsed, the stimulation was repeated peri-
odically in the same way using the same device until continence was regained
Participants N: 68 randomised, 58 analysed
Sex: 29 men and 39 women
Mean age (range): 70 (35-87)
Inclusion criteria: urinary incontinence due to DO
Exclusion criteria: not reported
Interventions A (n = 37) ES. Two15-min sessions per day for 4weeksAlternating pulses of 10-Hz square
waves of 1-ms pulse duration and a maximum output current of 60 mA, stimulation up
to maximum tolerable level
B (n = 31) sham device identical to active device but with no stimulus output
Outcomes Number of daytime voids (mean, N (SD not reported)):
A 8, 32. B 7.5, 26
Number of nighttime voids (mean, N (SD not reported)):
A 2, 32. B 2.3, 26
Number of leaks (mean, N (SD not reported)):
A 1.2, 32. B 2.4, 26
Bladder capacity at first desire to void (mL) (mean, SD, N):
A 174.2 (83.1), 32. B 130.0 (69.9), 26
Maximum cystometric capacity (mL) (mean, SD, N):
A 285.0 (143.4), 32. B 182.9 (99.0), 26
Detrusor pressure at maximum sensation (cm H2O) (mean, SD, N):
A 34.6 (12.5), 32. B 50.9 (29.8). 26
Number of pad changes per 24 hours (mean, SD, N):
A 0.8 (1.2), 37. B 1.1 (2.0), 31
Urgency score (0-3 scale: from 0 = none to 3 = very much) (mean, SD, N):
A 1.7 (0.7), 37. B 2.0 (0.8), 31
Quality of life score (0-3 scale: from 0 = delighted to 3 = mostly dissatisfied) (mean, SD,
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Yamanishi 2000a (Continued)
N):
A 1.6 (0.7), 37. B 2.2 (0.9), 31
Number with DO: A 24/32, B 24/26
Number of participants with no improvement in DO:
A 4/32 (FS1) . B 17/26 (FS2)
Subjective impressions (very good or good, fair or not good): number of participants
with fair or not good (i.e. not satisfied):
A 13/32. B 17/26
Not cured (cure defined as ”no incontinence on the frequency/volume chart and no
detrusor overactivity according to cystometry“) i.e. number of participants with UUI:
A 25/32. B 25/26
Not improved (improvement defined as ”if the frequency of the incontinence decreased
bymore than 50% compared with the baseline level or the cystometric capacity increased
by more than 50 mL“) i.e. number of participants with no improvement in UUI:
A 6/26. B 19/28. (FS3)
Adverse effects:
A 2/37. B 2/31
Notes No SDs
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”Patients were randomly assigned to either
the active or the sham device.“
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ”The sham device was identical to the ac-
tive device in appearance but with no stim-
ulus output.“ ’Neither doctors, nurses, nor
patients knew which device was active or
sham.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No differential attrition. “Four patients
(three in the active group and one in the
sham group) did not return after the first
visit, and four patients (two at both groups)
discontinued because of disagreeable feel-
ings or vaginal pain”
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Yamanishi 2000b
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: Japan
Period: not reported
Details of sample size calculation: not reported
Follow-up: single session
Participants N: 32 randomised and analysed
Mean (SD) age: A 66.8 (11.4). B 57.1 (20.1). Overall 62.3 (16.6)
Sex: 15 men, 17 women
Inclusion criteria: DO
Exclusion criteria: not reported
Interventions A (n = 17) functional ES. Alternating pulses of 10-Hz square waves 1 ms duration,
maximum output current 60 mA. Stimulation up to maximum tolerable level. Device
designed for home use. Surface electrodes for men (dorsal part of penis), vaginal plug
for women
B (n = 15) functional magnetic stimulation. Magnetic coil on armchair seat; perineum
positioned to feel highest contraction of vaginal/anal sphincter. Intensity gradually in-
creased up to tolerable limit, continuous eddy current 10 Hz, maximum output at the
100% setting of at least 270 J
Outcomes Participants with DO:
A 17/17. B 12/15
Bladder capacity at first desire to void, mL (mean, SD, N):
A 220.4 (110.9), 17. B 225.1 (123.7), 15
Maximum cystometric capacity, mL (mean, SD, N):
A 266.9 (151.0), 17. B 290.5 (146.3), 15
Detrusor pressure at maximum capacity, cmH20 (mean, SD, N):
A 15.4 (10.5), 17. B 13.9 (15.4), 15
Amplitude of detrusor overactive contraction, cmH20 (mean, SD, N):
A 51.3 (36.9), 17. B 51.5 (48.2), 15
Bladder compliance at maximum sensation, mL/ cmH20 (mean, SD, N):
A 24.3 (18.3), 17. B 32.7 (25.6), 15
Adverse effects: A 0/17. B 0/15
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”
Allocation concealment (selection bias) Unclear risk “using envelopes containing a card indicat-
ing FES or FMS”
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Yamanishi 2000b (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants included in
analysis. No withdrawals reported
AUASI: Americal Urological Association Symptom Index
BAPFMT: biofeedback-assisted pelvic floor muscle training
BMI: body mass index
B-SAQ: Bladder Self-assessment questionnaire
CI: confidence interval
DH: detrusor hyperreflexia
DI: detrusor instability
DO: detrusor overactivity
ES: electrical stimulation
FDV: volume at first desire
FES: functional electrical stimulation
GSUI: stress urinary incontinence
HRT: hormone replacement therapy
ICIQ: International Consultation on Incontinence questionnaire (SF: short form)
ICS: International Continence Society
ITT: interferential therapy
ITT analysis: intention-to-treat analysis
IQR: interquartile range
KHQ: King’s Health Questionnaire
LUTS: lower urinary tract symptoms
MS: multiple sclerosis
MUI: mixed urinary incontinence
OAB: overactive bladder
PFME: pelvic floor muscle exercises
PFMT: Pelvic floor muscle training
QoL: quality of life
RCT: randomised controlled trial
SANS: Stoller Afferent Neuro-stimulation
SD: standard deviation
SDV: strong desire to void
SU: sensory urge
SUI: stress urinary incontinence
TENS: transcutaneous electrical nerve stimulation
UI: urinary incontinence
UTI: urinary tract infection
UUI: urgency urinary incontinence
VAS: visual analogue score
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelghany 2001 Not RCT
Abel 1996 Not RCT
Al-Mulhim 2002 Not RCT
Almeida 2004 Not RCT
Angioli 2013 Not RCT
Baynham 2003 Not non-implanted device
Bazarim 2011 Not OAB
Bidmead 2002 Not OAB
Blok 2003 Not non-implanted device
Bocker 2002 Not OAB
Bolukbas 2005 Not RCT
Borawski 2007 Not non-implanted device
Bourcier 1994 Not OAB
Boy 2007 Not RCT
But 2003 Not electrical stimulation
Caputo 1993 Not RCT
Caraballo 2001 Not RCT
Casolati 2011 Not RCT
Chandi 2002 Not RCT
Congregado 2004 Not RCT
Das 2002 Not non-implanted device
De Laet 2005 Not RCT
Delneri 2000 Not OAB
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(Continued)
Doganay 2010 Not RCT
Dunkley 2002 Not electrical stimulation
Edwards 1973 Not electrical stimulation
Edwards 2000 Not OAB
Elgamasy 1996 Not RCT
Esa 1991 Not RCT
Everaert 1999 Not OAB
Fall 1977 Not RCT
Fehrling 2007 Not RCT
Finazzi-Agró 2011 Not RCT
Franco 2011 Not RCT
Fujishiro 2002 Not electrical stimulation
Geirsson 1997 Not RCT
Glybochko 2010 Ineligible intervention
Govier 2001 Not RCT
Gungor 2011 Not RCT
Hasan 1994 Not non-implanted device
Hoffmann 2005 Not OAB
Holtedahl 1998 RCT of PFMT + ES + oestrogen versus ‘wait’ group. Women have SUI or undefined UI, but no
definite diagnosis of OAB
Indrekvam 2001 Not RCT
Jacomo 2013 Not RCT
Jahr 2005 Not RCT
Karademir 2005 Ineligible comparison
Kaya 2011 Ineligible intervention
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(Continued)
Kirschner-Hermanns 2003 Not RCT
Kralj 2001 Not RCT
Kölle 1995 Not RCT
Latini 2006 Not RCT
Lu 2012 Not RCT
Lucio 2013 Not OAB
MacDiarmid 2010a Not RCT
MacDiarmid 2010b Not RCT
Madersbacher 2004 Not RCT
Marcelissen 2011 Not RCT
Marchal 2011 Not RCT
Mauroy 2001 Not RCT
McClurg 2004 Not OAB
McClurg 2006 Not OAB
McClurg 2008 Not OAB
McGuire 2009 Not non-implanted device
McIntosh 1993 Not RCT
Memtsa 2009 Not RCT
Mok 2007 Not electrical stimulation
Moore 2003 Not electrical stimulation
NCT00534521 2007 Not OAB
NCT00547378 2007 Not non-implanted device
NCT00695058 2008 Withdrawn prior to enrolment
NCT00928499 2009 Not non-implantable device
NCT01023269 2009 Not non-implanted device
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(Continued)
NCT01043848 2009 Not OAB
NCT01972061 2013 Not RCT
NCT02029027 2012 Not OAB
NCT02107820 2014 Ineligible comparator
NCT02176642 2014 Ineligible comparator
NCT02185235 2014 Not OAB
NCT02190851 2014 Not OAB
NCT02239796 2014 Not OAB
Neimark 2010 Not RCT
Nuhoglu 2006 Not RCT
Oh-Oka 2007 Not RCT
Okada 1998 Not RCT
Onal 2012 Not RCT
Ozdedeli 2010 Ineligible comparator
Parsons 2004 Not OAB
Pennisi 1994 Not RCT
Perissinotto 2013 Not OAB
Peters 2012 Not RCT
Petersen 1994 Not RCT
Polo 2012 Not RCT
Portigliotti 1996 Not RCT
Preisinger 1990 Not OAB
Rasero 2005 Not RCT
Reilly 2008 Not non-implanted device
Ricci 2004 Not non-implanted device
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(Continued)
Sale 1994 Not electrical stimulation
Seif 2003 Not RCT
Seo 2004 Not OAB
Shafik 2004 Unclear if RCT/OAB
Shah 2012 Not RCT
Siegel 1997 Not RCT
Stein 1995 Not RCT
Surwit 2010 Not RCT
Suzuki 2007 Not electrical stimulation
Van Del Pal 2006 Not RCT
Van Meel 2012 Not RCT
Van-Balken 2001 Not RCT
Van-Balken 2006 Not RCT
Vandoninck 2004 Not RCT
Vecchioli-Scaldazza 1997 Not RCT
Veloso 2011 Not RCT
Voorham 2006 Not RCT
Voorham-Van Der Zalm 2007 Ineligible intervention and comparator is urodynamic evaluation only
Wallis 2006 Not electrical stimulation
Walsh 2000 Ineligible intervention
Webb 1992 Not non-implanted device
Wooldridge 2009 Not RCT
Yamanishi 2006 Not electrical stimulation
Yamanishi 2012 Not electrical stimulation
Yamanishi 2013 Not electrical stimulation
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Yasar 2009 Not RCT
Yaski 2013 Not RCT
Yasuda 1994 Not OAB
Yokoyama 2004 Not RCT
Yoong 2010 Not RCT
Yoong 2013 Not RCT
ES: electrical stimulation
OAB: overactive bladder
PFMT: pelvic floor muscle training
RCT: randomised controlled trial
SUI: stress urinary incontinence
Characteristics of studies awaiting assessment [ordered by study ID]
Zhao 2000
Methods
Participants
Interventions
Outcomes
Notes Awaiting translation
Characteristics of ongoing studies [ordered by study ID]
NCT01464372
Trial name or title Electromagnetic Stimulation for the treatment of urge urinary incontinence and overactive bladder (ELEC
STIM)
Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: USA
Follow-up: unclear
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Participants N: 130
Sex: women
Inclusion criteria: age 18 +, UUI, urinary frequency
Exclusion criteria: primary complaint of stress incontinence, neurogenic bladder, overflow incontinence,
functional incontinence
Interventions A: Electrical field stimulation device
B: Sham nerve stimulation device
Outcomes Reduction of incontinence episodes
Serious adverse events or unanticipated adverse device effects
Starting date October 2011
Contact information info@emkinetics.com
Notes Study terminated. Contacted manufacturer 20 February 2015
NCT01783392
Trial name or title Peripheral Electrical Stimulation for the Treatment of Overactive Bladder (PESTOB)
Methods Study design: RCT
Multicentre or single-centre:
Setting:
Follow-up: 4 weeks
Participants N: 36
Sex: men and women
Inclusion criteria: at least 18 years of age, documented symptoms of idiopathic OAB for at least 3 months,
failure of primary OAB treatment, such as behaviour modification or fluid/diet management, participants
can remain on stable medication, willing and capable of understanding and complying with all requirements
of the protocol
Exclusion criteria: urinary retention or post voiding residual greater than 100 mL, clinically significant
bladder outlet obstruction, stress predominant MUI, neurological disease affecting urinary bladder function,
including but not limited to Parkinson’s disease, multiple sclerosis, stroke, spinal cord injury, pelvic surgery
(such as sub-urethral sling, pelvic floor repair) within the past 6 months, de novo OAB following pelvic
surgery, sub-urethral sling, intravesical or urethral sphincter. Botulinum Toxin Type A injections within the
past 6 months, PTNS therapy for overactive bladder within the past 6 months, any form of ES to the pelvis
or lower limbs within 4 weeks, vaginal prolapse greater than Stage II in the anterior compartment of the
vagina using ICS Pelvic Organ Prolapse Quantification (POPQ) criteria, prior periurethral or transurethral
bulking agent injections for bladder problems within the past 12 months, history of pelvic radiation therapy,
any skin conditions affecting treatment sites, lacking dexterity to properly utilise the components of the
stimulator system, presence of an implanted electro-medical device (e.g. pacemaker, defibrillator, InterStim®,
etc), pregnant, nursing, suspected to be pregnant (by urine pregnancy method), or plans to become pregnant
during the course of the study, recurrent UTI (> 3 UTI’s in the past year), history of, or current, lower tract
genitourinary malignancies, any clinically significant systemic disease or condition that in the opinion of the
Investigator would make the patient unsuitable for the study, any other clinical trial within 6 months
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Interventions A: Unilateral PTNS. 40 min every day for a duration of 4 weeks. The participant places the cathode electrode
above, and the anode electrode behind the medial malleolus, over the posterior tibial nerve and sets the
stimulation intensity to a comfortable level
B: Bilateral PTNS. 40 min every day for a duration of 4 weeks. The participant places the cathode electrode
above, and the anode electrode behind the medial malleolus, over the posterior tibial nerve on both legs and
sets the stimulation intensity to a comfortable level
C: Shoulder stimulation. 40 min every day for a duration of 4 weeks. The participant places the cathode and
the anode electrodes on the lateral side of the left shoulder
Outcomes Change in frequency of voiding
Change in Patient Perception of Bladder Condition (PPBC)
Changes in symptom severity score and health-related quality of life score (HRQL) based on OAB-Q
Changes in the mental/physical scores of RAND36
Change in urinary symptoms score and bother symptom score based on the ICIQ-OAB questionnaire
Starting date March 2013
Contact information Martin Slovak m.slovak@sheffield.ac.uk
Notes Contacted February 2015. Manuscript due for submission shortly
NCT01912885
Trial name or title Comparison of posterior tibial nerve electrical stimulation protocols for overactive bladder syndrome
Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: Brazil
Participants N: 145
Sex: women
Inclusion criteria: age 18 +, cognitive level adequate for understanding orientations during treatment; clinical
diagnosis of OAB syndrome for at least six months prior to the study
Exclusion criteria: pregnant women or women who wish to get pregnant; neurological disease; urinary infec-
tion; nephrolithiasis; SUI; MUI; women in pharmacological treatment for OAB; women undergoing hor-
mone replacement therapy in the last 6 months; peripheral neuropathy; cystocoele stage two or higher
Interventions A: Placebo: electrodes will be fixed to one leg and sessions will be held once a week
B: ES on 1 leg once a week
C: ES on 1 leg twice a week
D: ES on 2 legs once a week
E: ES on 2 legs once a week
F: ES on 2 legs twice a week
Outcomes Change in urinary frequency in 12 sessions
Number of micturitions per day
Change in nocturia in 12 sessions
Number of micturitions per night, interrupting sleep
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Change in urinary urgency in 12 sessions
Number of urgent micturitions per day
Change in urinary urge-incontinence in 12 sessions
Number of leaks per day
Starting date March 2012
Contact information Nanci Valeis nanci.valeis@hc.fm.usp.br
PI Munick L Pierre
Notes Currently recruiting participants
NCT01940367
Trial name or title Electrical nerve stimulation for overactive bladder a comparison of treatments
Methods Study design: RCT
Multicentre or single-centre: unclear
Setting: USA
Participants N: 114
Sex: women
Inclusion criteria: Female age >18 years, predominant complaint urge urinary incontinence (3 ormore episodes
per week) OR overactive bladder (8 or more voids per day, and/or 2 or more voids per night), failed trial
of conservative therapy (bladder training, fluid modification, diet modification, caffeine restriction, pelvic
floor training), failed trial of anticholinergic either due to inability to take the medication, adverse reaction to
medication, or no improvement onmedication, willing andmentally competent to participate in study, willing
to complete study questionnaires, no contraindications to undergoing percutaneous tibial nerve stimulation
or TENS therapy
Exclusion criteria: Age < 18 years, presence of urinary fistula, recurrent or current urinary tract infection (5 or
more infections in the last 12months), bladder stones, bladder cancer or suspected bladder cancer, haematuria,
pregnancy or planning to become pregnant during the study (urine pregnancy test will be administered
to those who are premenopausal and who have not had a hysterectomy), central or peripheral neurologic
disorders such asmultiple sclerosis, Parkinson’s disease, spina bifida, or other spinal cord lesion, metal implants
such as pacemaker, implantable defibrillator, or metal implants where percutaneous tibial nerve stimulation
or TENS device needs to be placed (sacrum or ankle/leg), uncontrolled diabetes, diabetes with peripheral
nerve involvement, anticoagulants, current use of anticholinergics or use within the last 4 weeks, current use
of botulinum toxin bladder injections or bladder botulinum toxin injection within the last year, current use
of InterStim® therapy or currently implanted InterStim® device or leads, bladder outlet obstruction, urinary
retention or gastric retention, painful bladder syndrome/interstitial cystitis
Interventions A: PTNS once weekly for 30 min for 12 weeks. If at 12 weeks participants are considered to have a positive
response to therapy, they will continue maintenance therapy in a tapered fashion: participants will come in
every 2 weeks for the next 8 weeks for 30-mintreatments (4 visits total), then every 3-4 weeks for 30-min
treatments for the remaining 32 weeks of the year (8-10 visits)
B: TENS. Home TENS device (EMPI TENS Select) and for self-treatment daily for 2 h per day (1 h in the
morning and 1 h in the evening) for 12 weeks. If considered to have a positive response with TENS treatment
at 12 weeks, participants will continue by weaning use over a 3-month time period, beginning with 3 x per
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week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 h per day
Outcomes Success at 1 year, defined as a 50% or more reduction in the total number of incontinence episodes, or a 25%
or more reduction in number of daily or nightly voids AND that the participant continues to use the therapy
at 1 year. Therefore primary response is: 50% reduction in incontinence, OR 25% reduction in nightly voids
AND continued use of therapy at 1 year
Participant compliance defined as 75% adherence to the recommended use for each device
Changes in the OAB-Q
Changes in urodynamic studies
Starting date October 2013
Contact information PI Mary E McVearry
Shannon Lamb, Physician, Walter Reed National Military Medical Cente
Notes Due to complete December 2016
NCT02110680
Trial name or title
Methods RCT
Setting: Israel
Follow-up: 12 weeks
Participants Estimated enrolment: 40
Inclusion criteria
• men and women
• age above 18
• OAB symptoms more than 6 months before run into the study
• OAB symptoms refractory to medical oral and cognitive treatments
• Adverse events or unwillingness to continue with above mentioned treatments
• people with OAB symptoms with no evidence of neuropathic nature
• people who signed informed consent fully understanding the treatment and study design
Exclusion criteria: children, people who were unable to or did not sign an informed consent or do not
understand the study design and the treatment, implanted electric devices (e.g. cardiac stimulators etc.), post
voiding residual more than 100 mL, neuropathic OAB or pelvic ongoing malignancy or prior pelvic radiation,
treated in the last 6 months with SNM, posterior tibial nerve stimulation or intravesical Botox injections,
de novo OAB after recent implantation of tension-free vaginal tape (TVT) procedure, SUI predominant
complaints in people with MUI, significant pelvic organ prolapse in women or an evidence of significant
bladder outlet obstruction in male patients, history of recurrent UTIs during the last 2 years, any medical
condition that involves skin on the lower extremity, bilateral leg amputation, any medical condition that in
the investigator’s opinion could have an adverse impact on the participant during the study, participation in
a clinical study at the last 6 months
Interventions TENS at posterior tibial nerve area
Sham comparator: TENS at shoulder area
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Outcomes Day and night-time frequency of micturitions
OAB-Q
Participant perception of bladder condition (PPBC)
Participant perception of global improvement (PPGI)
Quality of life 5 dimensions (EQ5D)
Starting date April 2014
May 2015 - study withdrawn prior to enrolment
Contact information Michael Vainrib, M.D. mvainrib@gmail.com
Notes Estimated Study Completion Date:
NCT02311634
Trial name or title
Methods RCT
Setting: China
Follow-up: 4 weeks’ treatment, 1 year follow-up
Participants N = 80
Inclusion criteria
• Female, 25-85 years
• UUI history
• Positive pad test result
• Urodynamic study: a decrease in bladder capacity at the first desire for urination; a decrease in
maximum bladder capacity; low compliance bladder
Exclusion criteria
• UUI that can be relieved by drugs
• Neurogenic or non-neurogenic UUI
• Other types of incontinence such as SUI and overflow incontinence
Interventions Electrical pudendal nerve stimulation at a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 min
3 times a week for a total of 4 weeks
Transvaginal ES at a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of
15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min 3 times a week for a total of 4 weeks
Outcomes Severity of UUI symptoms
24-hour urine leakage amount
Starting date December 2014
Contact information Xiaoming Feng, Ph.D fengtcm@126.com
Notes Estimated Study Completion Date: Jan 2016
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NCT02377765
Trial name or title
Methods RCT
Setting: UK
Follow-up: 6 months
Participants N = 24
Inclusion criteria
• Women
• Over 18 years of age
• Clinically diagnosed with idiopathic OAB according to the definition by the ICS (Haylen et al, 2012)
given above.
• Good response to PTNS. For the purpose of this study, responders will be considered those
participants who have achieved a reduction in the number of micturitions per 24 h by > 30%
• Able and willing to give informed consent
Exclusion criteria
• Unable to comprehend the physiotherapist’s instructions or unable to co-operate
• Pregnancy, or plans of becoming pregnant during the course of the study. The main acupuncture point
that will be used (SP6) has been reported to induce uterine activity (Hecker et al, 2001).
• Presence of a relevant neurological condition (causing neurogenic DO or peripheral neuropathy)
• Previous history of continence surgery
• Women with a pacemaker fitted
• Women with uncorrectable coagulopathies or on anticoagulant medication
• Presence of dermatological lesions (e.g. dermatitis, eczema) in the medial aspect of lower leg and/or feet
• No anticholinergic medication will be allowed during the study period with minimum wash-out
period of 15 days before randomisation
Interventions Percutaneus Stimulation
PTNS performed bilaterally every 4 weeks within the Physiotherapy Department
Transcutaneous Stimulation
TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg
at least 3 times per week
Outcomes Symptom severity measured by OAB-Q
Changes in 24-hour micturition frequency
Mean number of micturition episodes recorded in 3-day bladder chart
Starting date February 2014
Contact information Louise Hardman l.hardman@lwh.nhs.uk
Notes Due to complete: Feb 2016
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NCT02452593
Trial name or title
Methods RCT
Setting: Brazil
Follow-up: 8 weeks’ treatment, 3 months’ follow-up
Participants N = 30
Inclusion criteria
- women with UUI or MUI older than 18 years
Exclusion criteria
• Presence of vaginal or urinary infection
• Not able to understand or sign the informed consent
• Not able to understand or unable to perform the proposed treatment
• Pregnancy or the postpartum period covering the period up to 6 months after delivery
• Women in previous use of chronically used drugs (antidepressants, diuretics, and others) that can
evidently alter the urinary function.
• SUI of pure or mixed incontinence with a predominance of stress component neurogenic bladder
• Use of Botox® in the bladder or pelvic muscles in the last year
• Use of Interstim® or Bion®
• Use of pacemaker or implantable defibrillator
• Current use of TENS in the pelvic region, lower back or legs
• Previous use of percutaneous tibial stimulation
• Drug/experimental devices in the past 4 weeks
• Participation in any clinical research involving or affecting the urinary or renal function in the last 4
weeks
• Pelvic radiotherapy
• Changes in sensibility lower limb
Interventions Transcutaneous electrical stimulation of the tibial nerve at home
Development of an innovative portable equipment, with domestic technology for home application of the
posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Fre-
quency: 20 Hz, Pulse width: 200 us; duration: 15 minutes daily
Active Comparator: “Pelvic Floor Exercises”:
This group will do pelvic muscle training 3 times a day . In dorsal decubitus posture, legs flexed and abductee.
Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and contractions
keeping 4 seconds and relaxing 8 seconds for 10 times
Outcomes Number of participants with UUI
Starting date January 2014
Contact information Magda Ms Aranchip mchipe@hotmail.com
Luciana Dr Paiva luciana.paiva@ufrgs.br
Notes Due to complete August 2015
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NCT02456441
Trial name or title
Methods RCT
Setting: Brazil
Follow-up: unclear
Participants N = 12
Inclusion criteria
• Female
• Aged between 40 and 60 years
• Clinical diagnosis of OAB syndrome non neurogenic type
• Score questionnaire OAB-V8, sum equal to or greater than 8
• Calendar indicating voiding more than 8 micturitions in 24 hours
• Complaints of urinary urgency
Exclusion Criteria
• With a diagnosis of lower UTI
• Signs of leukorrhoea/diagnosis of vaginitis
• Pregnant women
• Diagnosed with cancer of bladder or other pelvic organs
• With a history of pelvic radiotherapy
• With change in the sensitivity of the pelvis and lower limbs region
• With diabetes mellitus
• With known neurologic diseases
• Patients on medications that may affect the autonomic nervous system, including anticholinergics,
alpha-adrenergic antagonists, tricyclic antidepressants, serotonin, antimuscarinic, beta-receptor agonists or
antagonists and antihypertensive agents
• Use of cardiac pacemakers
Interventions A: TENS: 2 self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm
above will be used. Through a chain of 1 Hz, the aim is to correctly identify the tibial nerve. This position is
confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10 Hz, the
pulse width set at 200 “microseconds” and adjusted according to the intensity threshold for each participant,
belowmotor threshold. This current generator also has a device, the VIF (variation in intensity and frequency)
that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30
min
B: Placebo: active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar
to that used in A. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other
10 cm above will be used. The application time 30 min
Outcomes Parasympathetic and sympathetic system values obtained from heart rate variability (HRV) after TENS
application
Starting date March 2014
Contact information None given
Notes Due to complete August 2014
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NCT02511717
Trial name or title
Methods RCT
Setting: Canada
Follow-up: 12 weeks
Participants N = 60
Inclusion criteria
1. Female, > 18 years of age, with the clinical diagnosis of OAB
2. Failure of behavioural measures and pharmacologic therapy to adequately control OAB symptoms
3. Baseline patient perception of bladder condition score of 2 or higher
Exclusion criteria
1. Current or previous percutaneous or sacral neuromodulation therapy
2. Stress predominant urinary incontinence
3. Newly added bladder medication or dose change with the last 2 months (tamsulosin, silodosin,
alfuzosin, terazosin, baclofen, diazepam, amitriptyline, imipramine, DDAVP, tolterodine, oxybutynin,
fesoterodine, darifenacin, solifenacin, trospium, mirabegron)
4. Intravesical botulinum toxin use within the last 1 year
5. Implanted pacemaker or defibrillator
6. History of epilepsy
7. Unable or unwilling to commit to study treatment schedule
8. Pregnant, or possible pregnancy planned for the duration of the study period
9. Active skin disease of the lower legs (dermatitis, cellulitis, eczema, trauma)
10. Documented allergy to patch electrodes or their adhesive
11. Abnormal sensory function of the lower limb
12. Metallic implant within the lower limb
Interventions Sham transcutaneous tibial nerve stimulation: transcutaneous stimulation in a location and with settings not
related to the bladder nerves, 3 x/week for 30 min for 12 weeks. Patch electrodes applied posterior to the
lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be
used, with a frequency of 10 Hz, 200 ms pulse, and the amplitude will be set a 1 mA. This will be done by
the participants at home 3 x/week for 30 min, over 12 weeks
Transcutaneous tibial nerve stimulation. Patch electrodes applied posterior to the medial malleolus, and 5-10
cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting
will be used, with a frequency of 10 Hz, 200 ms pulse, and the amplitude will be titrated up to participant’s
maximum nonpainful tolerance (between 0.5-10 mA). This will be done by the participants at home 3 x/
week for 30 min, over 12 weeks
Outcomes OAB-Q SF
Voiding diary
24-hour pad weights
Physician assessment of treatment benefit
Starting date November 2015
Contact information None given
Notes Due to complete Nov 2017
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NCT02582151
Trial name or title
Methods RCT
Setting: Canada
Follow-up: 3 months
Participants N = 60
Inclusion criteria
• > 18 years of age, with a clinical condition associated with neurogenic bladder dysfunction (multiple
sclerosis, Parkinson’s disease, stroke, dementia, cerebral palsy, spinal cord injury) (27)
• Failure of behavioural measures and/or pharmacologic therapy to adequately control neurogenic
bladder symptoms
Exclusion criteria
• Current or previous percutaneous/transcutaneous tibial nerve stimulation or sacral neuromodulation
therapy
• Stress predominant urinary incontinence
• Newly added bladder medication or dose change with the last 2 months (tamsulosin, silodosin,
alfuzosin, terazosin, baclofen, diazepam, amitriptyline, imipramine, DDAVP, tolterodine, oxybutynin,
fesoterodine, darifenacin, solifenacin, trospium, mirabegron)
• Intravesical botulinum toxin use within the last 1 year
• Implanted pacemaker or defibrillator
• History of epilepsy
• Unable or unwilling to commit to study treatment schedule
• Pregnant, or possible pregnancy planned for the duration of the study period
• Active skin disease of the lower legs (dermatitis, cellulitis, eczema, trauma)
• Documented allergy to patch electrodes or their adhesive
• Metallic implant within the lower limb
Interventions Sham tibial nerve stimulation
Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve
Tibial nerve stimulation
Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve
Device: EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine
Percutaneous patch electrodes are used to deliver low level electrical currents
Outcomes Neurogenic bladder symptom score questionnaire
Qualiveen-Short Form Questionnaire
Participant-reported urinary frequency, urgency, incontinence episodes
24-hour incontinence pad weights
Physician assessment of participant benefit
Starting date December 2015
Contact information Mary McKibbon mary.mckibbon@sjhc.london.on.ca
Notes Due to complete Dec 2016
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NCT02583529
Trial name or title
Methods RCT
Setting: Brazil
Follow-up: 12 weeks
Participants N = 30
Inclusion criteria
• Female, age 40-90
• Clinical diagnosis of PD according to the criteria of the London Brain Bank
• urinary storage symptoms complaints such as urinary urgency (sudden urge, abrupt and compelling, to
urinate, which is difficult to suppress), with or without urge incontinence (urine leakage after emergency),
frequency (number of urinations > 7/day) and nocturia (the number of micturitions > 1/night)
Exclusion criteria
• Damage to the peripheral sacral nerves
• Infection of the lower urinary tract untreated
• Diabetes mellitus
• Chronic pulmonary disease worsened
• Pregnancy and postpartum
• Urinary Incontinence of pure SUI or MUI with predominance of the stress component
• Pacemaker or defibrillator
• Metal prostheses
• Application of botulinum toxin into the bladder and/or pelvic muscles within the last year
• Current TENS treatment in the pelvic region, lower back and/or legs
• Prior urinary incontinence surgery
• Current bladder carcinoma
• Cognitive impairment likely to prevent implementation of the proposed treatment
• Not able to understand/sign informed consent
Interventions Back Tibial Nerve Electrostimulation
The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole
positioned on the inner malleolus and the positive approximately 0.5 cm below the previous, and connected to
a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department
of the HCPA
Placebo ES
Outcomes Hoehn and Yahr Disability Stage of scale
Starting date July 2014
Contact information Tatiane Gomes de Araujo tatinhaga@yahoo.com.br
Notes Due to complete December 2017
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NTR2192
Trial name or title
Methods Study design: RCT
Multicentre or single-centre: not reported
Setting: the Netherlands
Period: planned to be April 2009-October 2010
Details of sample size calculation: not reported
Follow-up: 12 weeks
Participants Inclusion criteria: OAB, defined as urgency and frequency (more than 8 voids per 24 h and the sudden urge
to void can hardly be suppressed); urgency incontinence (urgency leading to urinary leakage occurring at least
3 times weekly); age > 18 years
Exclusion criteria: symptoms existing for less than 6 months; pregnancy; active UTI or recurrent UTI; severe
cardiopulmonary disease; diabetes with peripheral nerve involvement; neurological disorders; flowmetry < 15
mm/s; previous treatment for OAB
Interventions 1. PTNS
2. Bladder training
Outcomes Primary outcomes: ICIQ-UI-SF scores; percentage of 70% improvement on the ICIQ-UI-SF scores
Secondary outcomes: incontinence episodes per week; frequency of micturition per 24 h
Starting date
Contact information
Notes Contacted study author asking for data 06 January 2015
DO: detrusor overactivity
ES: electrical stimulation
ICIQ: International Consultation on Incontinence Questionnaire
ICIQ-UI SF: International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form
MUI: mixed urinary incontinence
OAB: overactive bladder
RCT: randomised controlled trial
SUI: stress urinary incontinence
PTNS: posterior tibial nerve stimulation
TPTNS: transcutaneous posterior tibial nerve stimulation
TEVS: transcutaneous electrical nerve stimulation
UUI: urgency urinary incontinence
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D A T A A N D A N A L Y S E S
Comparison 1. Electrical stimulation (ES) versus no active treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants cured or
improved
2 121 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.34, 2.55]
Comparison 2. Electrical stimulation (ES) versus placebo or sham treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants cured 4 189 Risk Ratio (M-H, Fixed, 95% CI) 2.69 [1.39, 5.21]
2 Number of participants cured or
improved
10 677 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [1.85, 2.77]
3 Number of participants cured or
improved: different ES routes
6 398 Risk Ratio (M-H, Fixed, 95% CI) 3.55 [2.54, 4.96]
3.1 Percutaneous tibial nerve
stimulation
4 304 Risk Ratio (M-H, Fixed, 95% CI) 3.19 [2.22, 4.58]
3.2 Intravaginal 2 94 Risk Ratio (M-H, Fixed, 95% CI) 5.46 [2.33, 12.81]
4 Number of participants satisfied 2 98 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.02, 2.04]
5 Number of participants with
improvement in urgency
urinary incontinence
2 242 Risk Ratio (M-H, Random, 95% CI) 5.03 [0.28, 89.88]
6 Number of participants with
improvement in urinary
frequency
2 236 Risk Ratio (M-H, Fixed, 95% CI) 2.04 [1.43, 2.92]
7 Number of incontinence
episodes per 24 h
2 143 Mean Difference (IV, Fixed, 95% CI) -1.43 [-1.92, -0.95]
8 Number of nocturia episodes 2 245 Mean Difference (IV, Fixed, 95% CI) -0.37 [-0.73, -0.02]
9 Number of micturitions per 24 h 3 285 Mean Difference (IV, Fixed, 95% CI) -1.09 [-1.70, -0.47]
10 Number of participants with
adverse effects
3 450 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.84, 1.83]
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Comparison 3. Electrical stimulation (ES) versus pelvic floor muscle training (PFMT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants cured or
improved
3 195 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [1.19, 2.14]
2 Number of participants satisfied 2 102 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.60, 0.96]
Comparison 4. Electrical stimulation (ES) versus laseropuncture/electro-acupuncture
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of incontinence
episodes per 24 h
2 136 Mean Difference (IV, Fixed, 95% CI) -1.84 [-2.33, -1.35]
Comparison 5. Electrical stimulation (ES) versus drug therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants cured 7 388 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.69, 1.41]
1.1 ES versus tolterodine 3 210 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.46, 1.47]
1.2 ES versus oxybutynin 3 140 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.65, 1.72]
1.3 ES versus propantheline
bromide
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.38, 5.74]
2 Number of participants cured or
improved
8 439 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [1.04, 1.38]
2.1 ES versus tolterodine 3 210 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [1.00, 1.41]
2.2 ES versus oxybutynin 4 191 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.91, 1.52]
2.3 ES versus propantheline
bromide
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.86, 2.44]
3 Number of participants cured or
improved: routes of ES
5 250 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.04, 1.54]
3.1 Transcutaneous posterior
tibial nerve stimulation
1 51 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.74, 1.92]
3.2 Intravaginal/transanal 4 199 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.03, 1.59]
4 Number of participants satisfied 2 94 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.64, 1.23]
4.1 ES versus oxybutynin 2 94 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.64, 1.23]
5 Number of incontinence
episodes per 24 h
5 477 Mean Difference (IV, Random, 95% CI) 0.25 [-1.11, 1.60]
5.1 ES versus tolterodine 1 84 Mean Difference (IV, Random, 95% CI) -0.60 [-1.49, 0.29]
5.2 ES versus oxybutynin 1 43 Mean Difference (IV, Random, 95% CI) 0.90 [-6.45, 8.25]
5.3 ES versus trospium +
solifenacin
1 110 Mean Difference (IV, Random, 95% CI) 2.2 [1.78, 2.62]
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5.4 ES versus oestrogen cream 1 210 Mean Difference (IV, Random, 95% CI) 0.0 [-0.16, 0.16]
5.5 ES versus solifenacin
succinate
1 30 Mean Difference (IV, Random, 95% CI) -0.90 [-2.01, 0.21]
6 Number of urgency episodes per
24h
2 294 Mean Difference (IV, Fixed, 95% CI) 0.62 [0.28, 0.96]
6.1 ES versus tolterodine 1 84 Mean Difference (IV, Fixed, 95% CI) -0.60 [-1.98, 0.78]
6.2 ES versus oestrogen cream 1 210 Mean Difference (IV, Fixed, 95% CI) 0.70 [0.35, 1.05]
7 Number of micturitions per 24 h 6 646 Mean Difference (IV, Fixed, 95% CI) 0.33 [0.15, 0.52]
7.1 ES versus tolterodine 2 116 Mean Difference (IV, Fixed, 95% CI) 0.22 [-1.06, 1.50]
7.2 ES versus oxybutynin 2 80 Mean Difference (IV, Fixed, 95% CI) 0.87 [-0.18, 1.91]
7.3 ES versus solifenacin
succinate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.60 [-2.04, 0.84]
7.4 ES versus oestrogen cream 1 420 Mean Difference (IV, Fixed, 95% CI) 0.33 [0.15, 0.52]
8 Number of nocturia episodes per
night
4 367 Mean Difference (IV, Fixed, 95% CI) -2.07 [-2.27, -1.88]
8.1 ES versus tolterodine 1 84 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.78, 0.38]
8.2 ES versus oxybutynin 1 43 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.35, 0.95]
8.3 ES versus solifenacin
succinate
1 30 Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.06, 0.66]
8.4 ES versus oestrogen cream 1 210 Mean Difference (IV, Fixed, 95% CI) -2.8 [-3.03, -2.57]
9 Number of participants with
adverse effects
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 ES versus oxybutynin 2 79 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 0.84]
9.2 ES versus tolterodine 4 200 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.05, 0.27]
9.3 ES versus solifenacin
succinate
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.60]
Comparison 6. Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus PFMT alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of participants satisfied 2 82 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [1.13, 2.20]
2 Number of incontinence
episodes per 24h
2 119 Mean Difference (IV, Random, 95% CI) -0.60 [-1.84, 0.64]
3 Number of urgency episodes per
24 h
2 248 Mean Difference (IV, Fixed, 95% CI) -2.49 [-2.74, -2.24]
4 Number of micturitions per 24 h 2 63 Mean Difference (IV, Fixed, 95% CI) -0.75 [-1.62, 0.12]
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Comparison 7. Electrical stimulation (ES) plus drug therapy versus drug therapy alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Quality of life 2 248 Std. Mean Difference (IV, Random, 95% CI) -1.50 [-3.72, 0.72]
2 Number of incontinence
episodes per 24h
2 248 Mean Difference (IV, Fixed, 95% CI) -0.53 [-0.63, -0.43]
3 Number of urgency episodes per
24 hours
2 248 Mean Difference (IV, Random, 95% CI) -2.33 [-3.11, -1.54]
4 Number of micturitions per 24
hours
2 250 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.22, 0.21]
Analysis 1.1. Comparison 1 Electrical stimulation (ES) versus no active treatment, Outcome 1 Number of
participants cured or improved.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 1 Electrical stimulation (ES) versus no active treatment
Outcome: 1 Number of participants cured or improved
Study or subgroup Electrical stimulation No active treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Monteiro 2014 12/12 3/12 13.4 % 3.57 [ 1.45, 8.80 ]
Oldham 2013 37/50 22/47 86.6 % 1.58 [ 1.12, 2.23 ]
Total (95% CI) 62 59 100.0 % 1.85 [ 1.34, 2.55 ]
Total events: 49 (Electrical stimulation), 25 (No active treatment)
Heterogeneity: Chi2 = 2.83, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 3.71 (P = 0.00021)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
favours no treatment favours ES
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Analysis 2.1. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 1
Number of participants cured.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 1 Number of participants cured
Study or subgroup Electrical stimulation
Placebo or
sham
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bellette 2009 12/21 6/16 71.6 % 1.52 [ 0.73, 3.17 ]
Wang 2009 5/26 1/23 11.2 % 4.42 [ 0.56, 35.14 ]
Yamanishi 2000a 7/32 1/26 11.6 % 5.69 [ 0.75, 43.32 ]
Wang 2006 4/24 0/21 5.6 % 7.92 [ 0.45, 138.99 ]
Total (95% CI) 103 86 100.0 % 2.69 [ 1.39, 5.21 ]
Total events: 28 (Electrical stimulation), 8 (Placebo or sham treatment)
Heterogeneity: Chi2 = 3.60, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
favours placebo/sham favours ES
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Analysis 2.2. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 2
Number of participants cured or improved.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 2 Number of participants cured or improved
Study or subgroup Electrical stimulation
Placebo or
sham
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bellette 2009 12/21 6/16 7.7 % 1.52 [ 0.73, 3.17 ]
Booth 2013 11/15 5/13 6.0 % 1.91 [ 0.90, 4.05 ]
Finazzi-Agr 2010 12/17 0/18 0.5 % 26.39 [ 1.68, 413.70 ]
Kennelly 2011 43/80 37/83 40.9 % 1.21 [ 0.88, 1.65 ]
Peters 2010 60/110 23/110 25.9 % 2.61 [ 1.75, 3.90 ]
Slovak 2015 5/13 1/6 1.5 % 2.31 [ 0.34, 15.69 ]
Vohra 2002 7/11 0/10 0.6 % 13.75 [ 0.88, 213.65 ]
Wang 2006 14/24 2/21 2.4 % 6.13 [ 1.57, 23.89 ]
Wang 2009 17/26 3/23 3.6 % 5.01 [ 1.68, 14.93 ]
Yamanishi 2000a 26/32 9/28 10.8 % 2.53 [ 1.44, 4.44 ]
Total (95% CI) 349 328 100.0 % 2.26 [ 1.85, 2.77 ]
Total events: 207 (Electrical stimulation), 86 (Placebo or sham treatment)
Heterogeneity: Chi2 = 26.16, df = 9 (P = 0.002); I2 =66%
Test for overall effect: Z = 7.93 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
favours placebo/sham favours ES
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Analysis 2.3. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 3
Number of participants cured or improved: different ES routes.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 3 Number of participants cured or improved: different ES routes
Study or subgroup Electrical stimulation
Placebo or
sham
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Percutaneous tibial nerve stimulation
Booth 2013 9/15 4/13 12.8 % 1.95 [ 0.78, 4.86 ]
Finazzi-Agr 2010 12/17 0/18 1.4 % 26.39 [ 1.68, 413.70 ]
Peters 2010 60/110 23/110 68.4 % 2.61 [ 1.75, 3.90 ]
Vohra 2002 9/11 0/10 1.6 % 17.42 [ 1.14, 265.34 ]
Subtotal (95% CI) 153 151 84.2 % 3.19 [ 2.22, 4.58 ]
Total events: 90 (Electrical stimulation), 27 (Placebo or sham treatment)
Heterogeneity: Chi2 = 5.84, df = 3 (P = 0.12); I2 =49%
Test for overall effect: Z = 6.28 (P < 0.00001)
2 Intravaginal
Wang 2006 14/24 2/21 6.3 % 6.13 [ 1.57, 23.89 ]
Wang 2009 17/26 3/23 9.5 % 5.01 [ 1.68, 14.93 ]
Subtotal (95% CI) 50 44 15.8 % 5.46 [ 2.33, 12.81 ]
Total events: 31 (Electrical stimulation), 5 (Placebo or sham treatment)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000095)
Total (95% CI) 203 195 100.0 % 3.55 [ 2.54, 4.96 ]
Total events: 121 (Electrical stimulation), 32 (Placebo or sham treatment)
Heterogeneity: Chi2 = 8.26, df = 5 (P = 0.14); I2 =39%
Test for overall effect: Z = 7.44 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.29, df = 1 (P = 0.26), I2 =23%
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Analysis 2.4. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 4
Number of participants satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 4 Number of participants satisfied
Study or subgroup Electrical stimulation
Placebo or
sham
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amaro 2006 16/20 13/20 56.7 % 1.23 [ 0.83, 1.82 ]
Yamanishi 2000a 19/32 9/26 43.3 % 1.72 [ 0.94, 3.13 ]
Total (95% CI) 52 46 100.0 % 1.44 [ 1.02, 2.04 ]
Total events: 35 (Electrical stimulation), 22 (Placebo or sham treatment)
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 5
Number of participants with improvement in urgency urinary incontinence.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 5 Number of participants with improvement in urgency urinary incontinence
Study or subgroup Electrical stimulation
Placebo or
sham
treatment Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Finazzi-Agr 2010 12/17 0/18 39.4 % 26.39 [ 1.68, 413.70 ]
Peters 2010 39/103 23/104 60.6 % 1.71 [ 1.11, 2.65 ]
Total (95% CI) 120 122 100.0 % 5.03 [ 0.28, 89.88 ]
Total events: 51 (Electrical stimulation), 23 (Placebo or sham treatment)
Heterogeneity: Tau2 = 3.52; Chi2 = 4.48, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 6
Number of participants with improvement in urinary frequency.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 6 Number of participants with improvement in urinary frequency
Study or subgroup Electrical stimulation
Placebo or
sham
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Booth 2013 11/15 6/13 22.0 % 1.59 [ 0.82, 3.08 ]
Peters 2010 49/103 23/105 78.0 % 2.17 [ 1.44, 3.29 ]
Total (95% CI) 118 118 100.0 % 2.04 [ 1.43, 2.92 ]
Total events: 60 (Electrical stimulation), 29 (Placebo or sham treatment)
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000087)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 7
Number of incontinence episodes per 24 h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 7 Number of incontinence episodes per 24 h
Study or subgroup Electrical stimulation
Placebo or
sham
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Barroso 2002 24 1.3 (1) 12 3 (0.9) 55.5 % -1.70 [ -2.35, -1.05 ]
Kosilov 2013 51 3.7 (1.3) 56 4.8 (2.4) 44.5 % -1.10 [ -1.82, -0.38 ]
Total (95% CI) 75 68 100.0 % -1.43 [ -1.92, -0.95 ]
Heterogeneity: Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 5.82 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 8
Number of nocturia episodes.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 8 Number of nocturia episodes
Study or subgroup Electrical stimulation
Placebo or
sham
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bellette 2009 21 1.14 (1) 16 2.06 (1.2) 24.0 % -0.92 [ -1.65, -0.19 ]
Peters 2010 103 2.4 (1.4) 105 2.6 (1.6) 76.0 % -0.20 [ -0.61, 0.21 ]
Total (95% CI) 124 121 100.0 % -0.37 [ -0.73, -0.02 ]
Heterogeneity: Chi2 = 2.86, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 9
Number of micturitions per 24 h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 9 Number of micturitions per 24 h
Study or subgroup Electrical stimulation
Placebo or
sham
treatment
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Amaro 2006 20 7 (1.78) 20 7.5 (1.78) 31.1 % -0.50 [ -1.60, 0.60 ]
Bellette 2009 21 8.29 (2.8) 16 10.55 (3.1) 10.1 % -2.26 [ -4.19, -0.33 ]
Peters 2010 103 9.8 (2.8) 105 11 (3.1) 58.8 % -1.20 [ -2.00, -0.40 ]
Total (95% CI) 144 141 100.0 % -1.09 [ -1.70, -0.47 ]
Heterogeneity: Chi2 = 2.58, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Electrical stimulation (ES) versus placebo or sham treatment, Outcome 10
Number of participants with adverse effects.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 2 Electrical stimulation (ES) versus placebo or sham treatment
Outcome: 10 Number of participants with adverse effects
Study or subgroup Electrical stimulation
Placebo or
sham
treatment Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kennelly 2011 30/80 29/82 91.5 % 1.06 [ 0.71, 1.59 ]
Peters 2010 6/110 0/110 1.6 % 13.00 [ 0.74, 228.00 ]
Yamanishi 2000a 2/37 2/31 6.9 % 0.84 [ 0.13, 5.61 ]
Total (95% CI) 227 223 100.0 % 1.24 [ 0.84, 1.83 ]
Total events: 38 (Electrical stimulation), 31 (Placebo or sham treatment)
Heterogeneity: Chi2 = 3.30, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Electrical stimulation (ES) versus pelvic floor muscle training (PFMT),
Outcome 1 Number of participants cured or improved.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation (ES) versus pelvic floor muscle training (PFMT)
Outcome: 1 Number of participants cured or improved
Study or subgroup Electrical stimulation PFMT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arruda 2008 14/21 12/21 32.3 % 1.17 [ 0.72, 1.88 ]
Schreiner 2014 34/51 16/50 43.5 % 2.08 [ 1.33, 3.26 ]
Wang 2004 9/18 13/34 24.2 % 1.31 [ 0.70, 2.45 ]
Total (95% CI) 90 105 100.0 % 1.60 [ 1.19, 2.14 ]
Total events: 57 (Electrical stimulation), 41 (PFMT)
Heterogeneity: Chi2 = 3.40, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 3.14 (P = 0.0017)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Electrical stimulation (ES) versus pelvic floor muscle training (PFMT),
Outcome 2 Number of participants satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 3 Electrical stimulation (ES) versus pelvic floor muscle training (PFMT)
Outcome: 2 Number of participants satisfied
Study or subgroup Electrical stimulation PFMT Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arruda 2008 11/21 16/21 38.8 % 0.69 [ 0.43, 1.10 ]
Boaretto 2011 17/22 10/11 32.4 % 0.85 [ 0.63, 1.14 ]
Boaretto 2011 11/16 10/11 28.8 % 0.76 [ 0.52, 1.11 ]
Total (95% CI) 59 43 100.0 % 0.76 [ 0.60, 0.96 ]
Total events: 39 (Electrical stimulation), 36 (PFMT)
Heterogeneity: Chi2 = 0.73, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Electrical stimulation (ES) versus laseropuncture/electro-acupuncture,
Outcome 1 Number of incontinence episodes per 24 h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 4 Electrical stimulation (ES) versus laseropuncture/electro-acupuncture
Outcome: 1 Number of incontinence episodes per 24 h
Study or subgroup ES Lasero/electroacupuncture
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kosilov 2013 51 3.7 (1.3) 63 5.5 (1.4) 96.6 % -1.80 [ -2.30, -1.30 ]
Olmo Carmona 2013 11 1.64 (1.91) 11 4.55 (4.03) 3.4 % -2.91 [ -5.55, -0.27 ]
Total (95% CI) 62 74 100.0 % -1.84 [ -2.33, -1.35 ]
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 7.38 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 1 Number of
participants cured.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 1 Number of participants cured
Study or subgroup Electrical stimulation Drug therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus tolterodine
Franz n 2010 3/33 4/31 10.4 % 0.70 [ 0.17, 2.90 ]
Lin 2004 13/35 10/25 29.5 % 0.93 [ 0.49, 1.77 ]
Peters 2009 1/44 2/42 5.2 % 0.48 [ 0.04, 5.07 ]
Subtotal (95% CI) 112 98 45.1 % 0.82 [ 0.46, 1.47 ]
Total events: 17 (Electrical stimulation), 16 (Drug therapy)
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
2 ES versus oxybutynin
Arruda 2008 11/21 14/22 34.6 % 0.82 [ 0.49, 1.38 ]
Wang 2006 4/24 2/23 5.2 % 1.92 [ 0.39, 9.48 ]
Wang 2009 5/26 3/24 7.9 % 1.54 [ 0.41, 5.76 ]
Subtotal (95% CI) 71 69 47.7 % 1.06 [ 0.65, 1.72 ]
Total events: 20 (Electrical stimulation), 19 (Drug therapy)
Heterogeneity: Chi2 = 1.76, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
3 ES versus propantheline bromide
Smith 1996 4/18 3/20 7.2 % 1.48 [ 0.38, 5.74 ]
Subtotal (95% CI) 18 20 7.2 % 1.48 [ 0.38, 5.74 ]
Total events: 4 (Electrical stimulation), 3 (Drug therapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 201 187 100.0 % 0.98 [ 0.69, 1.41 ]
Total events: 41 (Electrical stimulation), 38 (Drug therapy)
Heterogeneity: Chi2 = 2.53, df = 6 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.80, df = 2 (P = 0.67), I2 =0.0%
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Analysis 5.2. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 2 Number of
participants cured or improved.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 2 Number of participants cured or improved
Study or subgroup Electrical stimulation Drug therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus tolterodine
Franz n 2010 26/33 22/31 18.1 % 1.11 [ 0.83, 1.48 ]
Lin 2004 26/35 19/25 17.7 % 0.98 [ 0.73, 1.31 ]
Peters 2009 35/44 23/42 18.8 % 1.45 [ 1.06, 1.99 ]
Subtotal (95% CI) 112 98 54.7 % 1.18 [ 1.00, 1.41 ]
Total events: 87 (Electrical stimulation), 64 (Drug therapy)
Heterogeneity: Chi2 = 3.47, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.91 (P = 0.056)
2 ES versus oxybutynin
Arruda 2008 11/21 14/22 10.9 % 0.82 [ 0.49, 1.38 ]
Boaretto 2011 11/16 4/6 4.7 % 1.03 [ 0.54, 1.99 ]
Boaretto 2011 17/22 4/7 4.9 % 1.35 [ 0.68, 2.67 ]
Wang 2006 14/24 9/23 7.3 % 1.49 [ 0.81, 2.75 ]
Wang 2009 17/26 12/24 10.0 % 1.31 [ 0.80, 2.13 ]
Subtotal (95% CI) 109 82 37.8 % 1.17 [ 0.91, 1.52 ]
Total events: 70 (Electrical stimulation), 43 (Drug therapy)
Heterogeneity: Chi2 = 2.91, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
3 ES versus propantheline bromide
Smith 1996 13/18 10/20 7.6 % 1.44 [ 0.86, 2.44 ]
Subtotal (95% CI) 18 20 7.6 % 1.44 [ 0.86, 2.44 ]
Total events: 13 (Electrical stimulation), 10 (Drug therapy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
Total (95% CI) 239 200 100.0 % 1.20 [ 1.04, 1.38 ]
Total events: 170 (Electrical stimulation), 117 (Drug therapy)
Heterogeneity: Chi2 = 7.05, df = 8 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
Test for subgroup differences: Chi2 = 0.53, df = 2 (P = 0.77), I2 =0.0%
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Analysis 5.3. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 3 Number of
participants cured or improved: routes of ES.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 3 Number of participants cured or improved: routes of ES
Study or subgroup Electrical stimulation Drug therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Transcutaneous posterior tibial nerve stimulation
Boaretto 2011 17/22 4/7 9.2 % 1.35 [ 0.68, 2.67 ]
Boaretto 2011 11/16 4/6 8.9 % 1.03 [ 0.54, 1.99 ]
Subtotal (95% CI) 38 13 18.1 % 1.20 [ 0.74, 1.92 ]
Total events: 28 (Electrical stimulation), 8 (Drug therapy)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Intravaginal/transanal
Franz n 2010 26/33 22/31 34.5 % 1.11 [ 0.83, 1.48 ]
Smith 1996 13/18 10/20 14.4 % 1.44 [ 0.86, 2.44 ]
Wang 2006 14/24 9/23 14.0 % 1.49 [ 0.81, 2.75 ]
Wang 2009 17/26 12/24 19.0 % 1.31 [ 0.80, 2.13 ]
Subtotal (95% CI) 101 98 81.9 % 1.28 [ 1.03, 1.59 ]
Total events: 70 (Electrical stimulation), 53 (Drug therapy)
Heterogeneity: Chi2 = 1.40, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Total (95% CI) 139 111 100.0 % 1.26 [ 1.04, 1.54 ]
Total events: 98 (Electrical stimulation), 61 (Drug therapy)
Heterogeneity: Chi2 = 1.75, df = 5 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.80), I2 =0.0%
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Analysis 5.4. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 4 Number of
participants satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 4 Number of participants satisfied
Study or subgroup Electrical stimulation Drug therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus oxybutynin
Arruda 2008 11/21 17/22 58.4 % 0.68 [ 0.43, 1.08 ]
Boaretto 2011 17/22 4/6 22.1 % 1.16 [ 0.63, 2.13 ]
Boaretto 2011 11/16 4/7 19.6 % 1.20 [ 0.58, 2.48 ]
Total (95% CI) 59 35 100.0 % 0.89 [ 0.64, 1.23 ]
Total events: 39 (Electrical stimulation), 25 (Drug therapy)
Heterogeneity: Chi2 = 2.70, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 5 Number of
incontinence episodes per 24 h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 5 Number of incontinence episodes per 24 h
Study or subgroup Electrical stimulation Drug therapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ES versus tolterodine
Peters 2009 41 1.2 (1.6) 43 1.8 (2.5) 23.4 % -0.60 [ -1.49, 0.29 ]
Subtotal (95% CI) 41 43 23.4 % -0.60 [ -1.49, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 ES versus oxybutynin
Arruda 2008 21 7.9 (13.7) 22 7 (10.6) 3.0 % 0.90 [ -6.45, 8.25 ]
Subtotal (95% CI) 21 22 3.0 % 0.90 [ -6.45, 8.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 ES versus trospium + solifenacin
Kosilov 2013 51 3.7 (1.3) 59 1.5 (0.9) 25.4 % 2.20 [ 1.78, 2.62 ]
Subtotal (95% CI) 51 59 25.4 % 2.20 [ 1.78, 2.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.16 (P < 0.00001)
4 ES versus oestrogen cream
Abdelbary 2015 105 0.4 (0.6) 105 0.4 (0.6) 26.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 105 105 26.0 % 0.0 [ -0.16, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 1.7 (1.5) 14 2.6 (1.6) 22.2 % -0.90 [ -2.01, 0.21 ]
Subtotal (95% CI) 16 14 22.2 % -0.90 [ -2.01, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
Total (95% CI) 234 243 100.0 % 0.25 [ -1.11, 1.60 ]
Heterogeneity: Tau2 = 1.84; Chi2 = 97.81, df = 4 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 97.81, df = 4 (P = 0.00), I2 =96%
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Analysis 5.6. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 6 Number of urgency
episodes per 24h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 6 Number of urgency episodes per 24h
Study or subgroup Electrical stimulation Drug therapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 3.9 (2.8) 43 4.5 (3.6) 6.1 % -0.60 [ -1.98, 0.78 ]
Subtotal (95% CI) 41 43 6.1 % -0.60 [ -1.98, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
2 ES versus oestrogen cream
Abdelbary 2015 105 4.7 (1.3) 105 4 (1.3) 93.9 % 0.70 [ 0.35, 1.05 ]
Subtotal (95% CI) 105 105 93.9 % 0.70 [ 0.35, 1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.90 (P = 0.000096)
Total (95% CI) 146 148 100.0 % 0.62 [ 0.28, 0.96 ]
Heterogeneity: Chi2 = 3.22, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 3.57 (P = 0.00036)
Test for subgroup differences: Chi2 = 3.22, df = 1 (P = 0.07), I2 =69%
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Analysis 5.7. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 7 Number of
micturitions per 24 h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 7 Number of micturitions per 24 h
Study or subgroup Electrical stimulation Drug therapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 9.8 (3) 43 9.9 (3.8) 1.5 % -0.10 [ -1.56, 1.36 ]
Preyer 2015 16 10.4 (4.1) 16 9.1 (3.6) 0.5 % 1.30 [ -1.37, 3.97 ]
Subtotal (95% CI) 57 59 2.0 % 0.22 [ -1.06, 1.50 ]
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 ES versus oxybutynin
Arruda 2008 21 7.9 (2.3) 22 6.4 (1.6) 2.3 % 1.50 [ 0.31, 2.69 ]
Souto 2014 18 7.9 (3) 19 9.2 (3.8) 0.7 % -1.30 [ -3.50, 0.90 ]
Subtotal (95% CI) 39 41 3.0 % 0.87 [ -0.18, 1.91 ]
Heterogeneity: Chi2 = 4.81, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.62 (P = 0.10)
3 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 9.4 (1.9) 14 10 (2.1) 1.6 % -0.60 [ -2.04, 0.84 ]
Subtotal (95% CI) 16 14 1.6 % -0.60 [ -2.04, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
4 ES versus oestrogen cream
Abdelbary 2015 105 4.7 (0.8) 105 5 (0.9) 62.2 % -0.30 [ -0.53, -0.07 ]
Abdelbary 2015 105 6.6 (1.5) 105 5 (0.8) 31.2 % 1.60 [ 1.27, 1.93 ]
Subtotal (95% CI) 210 210 93.4 % 0.33 [ 0.15, 0.52 ]
Heterogeneity: Chi2 = 87.34, df = 1 (P<0.00001); I2 =99%
Test for overall effect: Z = 3.49 (P = 0.00048)
Total (95% CI) 322 324 100.0 % 0.33 [ 0.15, 0.52 ]
Heterogeneity: Chi2 = 95.60, df = 6 (P<0.00001); I2 =94%
Test for overall effect: Z = 3.60 (P = 0.00032)
Test for subgroup differences: Chi2 = 2.64, df = 3 (P = 0.45), I2 =0.0%
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Analysis 5.8. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 8 Number of nocturia
episodes per night.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 8 Number of nocturia episodes per night
Study or subgroup Electrical stimulation Drug therapy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 ES versus tolterodine
Peters 2009 41 1.7 (1.1) 43 1.9 (1.6) 11.5 % -0.20 [ -0.78, 0.38 ]
Subtotal (95% CI) 41 43 11.5 % -0.20 [ -0.78, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 ES versus oxybutynin
Arruda 2008 21 1.2 (1.3) 22 0.9 (0.8) 9.3 % 0.30 [ -0.35, 0.95 ]
Subtotal (95% CI) 21 22 9.3 % 0.30 [ -0.35, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
3 ES versus solifenacin succinate
Vecchioli-Scaldazza 2013 16 1.7 (0.9) 14 1.9 (1.4) 5.4 % -0.20 [ -1.06, 0.66 ]
Subtotal (95% CI) 16 14 5.4 % -0.20 [ -1.06, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
4 ES versus oestrogen cream
Abdelbary 2015 105 2.2 (0.9) 105 5 (0.8) 73.9 % -2.80 [ -3.03, -2.57 ]
Subtotal (95% CI) 105 105 73.9 % -2.80 [ -3.03, -2.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 23.83 (P < 0.00001)
Total (95% CI) 183 184 100.0 % -2.07 [ -2.27, -1.88 ]
Heterogeneity: Chi2 = 147.47, df = 3 (P<0.00001); I2 =98%
Test for overall effect: Z = 20.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 147.47, df = 3 (P = 0.00), I2 =98%
-4 -2 0 2 4
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Analysis 5.9. Comparison 5 Electrical stimulation (ES) versus drug therapy, Outcome 9 Number of
participants with adverse effects.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 5 Electrical stimulation (ES) versus drug therapy
Outcome: 9 Number of participants with adverse effects
Study or subgroup Electrical stimulation Drug therapy Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ES versus oxybutynin
Svihra 2002 0/9 2/10 25.3 % 0.22 [ 0.01, 4.05 ]
Wise 1993 0/28 7/32 74.7 % 0.08 [ 0.00, 1.27 ]
Subtotal (95% CI) 37 42 100.0 % 0.11 [ 0.01, 0.84 ]
Total events: 0 (Electrical stimulation), 9 (Drug therapy)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
2 ES versus tolterodine
Franz n 2010 0/33 10/30 23.8 % 0.04 [ 0.00, 0.71 ]
Lin 2004 1/35 20/35 43.3 % 0.05 [ 0.01, 0.35 ]
Preyer 2007 1/16 6/15 13.4 % 0.16 [ 0.02, 1.15 ]
Preyer 2015 3/18 9/18 19.5 % 0.33 [ 0.11, 1.03 ]
Subtotal (95% CI) 102 98 100.0 % 0.12 [ 0.05, 0.27 ]
Total events: 5 (Electrical stimulation), 45 (Drug therapy)
Heterogeneity: Chi2 = 4.55, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 5.01 (P < 0.00001)
3 ES versus solifenacin succinate
Chen 2015 0/50 5/50 100.0 % 0.09 [ 0.01, 1.60 ]
Subtotal (95% CI) 50 50 100.0 % 0.09 [ 0.01, 1.60 ]
Total events: 0 (Electrical stimulation), 5 (Drug therapy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.03, df = 2 (P = 0.99), I2 =0.0%
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Analysis 6.1. Comparison 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus
PFMT alone, Outcome 1 Number of participants satisfied.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus PFMT alone
Outcome: 1 Number of participants satisfied
Study or subgroup ES + PFMT PFMT alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gaspard 2014 15/16 11/15 56.3 % 1.28 [ 0.92, 1.78 ]
Schreiner 2010 17/25 9/26 43.7 % 1.96 [ 1.09, 3.55 ]
Total (95% CI) 41 41 100.0 % 1.58 [ 1.13, 2.20 ]
Total events: 32 (ES + PFMT), 20 (PFMT alone)
Heterogeneity: Chi2 = 2.09, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 2.68 (P = 0.0074)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
favours PFMT favours ES + PFMT
Analysis 6.2. Comparison 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus
PFMT alone, Outcome 2 Number of incontinence episodes per 24h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus PFMT alone
Outcome: 2 Number of incontinence episodes per 24h
Study or subgroup ES + PFMT PFMT alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Firra 2013 6 1 (1.47) 6 0.8 (0.97) 38.7 % 0.20 [ -1.21, 1.61 ]
Gaspard 2014 51 3.7 (1.3) 56 4.8 (2.4) 61.3 % -1.10 [ -1.82, -0.38 ]
Total (95% CI) 57 62 100.0 % -0.60 [ -1.84, 0.64 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 2.59, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 6.3. Comparison 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus
PFMT alone, Outcome 3 Number of urgency episodes per 24 h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus PFMT alone
Outcome: 3 Number of urgency episodes per 24 h
Study or subgroup ES + PFMT PFMT alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abdelbary 2015 105 2 (0.8) 105 4.7 (1.3) 74.0 % -2.70 [ -2.99, -2.41 ]
Sancaktar 2010 20 5.7 (0.6) 18 7.6 (0.9) 26.0 % -1.90 [ -2.39, -1.41 ]
Total (95% CI) 125 123 100.0 % -2.49 [ -2.74, -2.24 ]
Heterogeneity: Chi2 = 7.51, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 19.45 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus
PFMT alone, Outcome 4 Number of micturitions per 24 h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 6 Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus PFMT alone
Outcome: 4 Number of micturitions per 24 h
Study or subgroup ES + PFMT PFMT alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Firra 2013 6 8.6 (3.13) 6 7.8 (1.97) 8.7 % 0.80 [ -2.16, 3.76 ]
Schreiner 2010 25 5.9 (1.4) 26 6.8 (1.9) 91.3 % -0.90 [ -1.81, 0.01 ]
Total (95% CI) 31 32 100.0 % -0.75 [ -1.62, 0.12 ]
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 1.69 (P = 0.091)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 7.1. Comparison 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone,
Outcome 1 Quality of life.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone
Outcome: 1 Quality of life
Study or subgroup ES + drug therapy Drug therapy alone
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Abdelbary 2015 105 2 (0.8) 105 6 (2) 50.7 % -2.62 [ -2.99, -2.25 ]
Sancaktar 2010 20 9 (8) 18 11.2 (2.7) 49.3 % -0.35 [ -1.00, 0.29 ]
Total (95% CI) 125 123 100.0 % -1.50 [ -3.72, 0.72 ]
Heterogeneity: Tau2 = 2.49; Chi2 = 35.82, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 7.2. Comparison 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone,
Outcome 2 Number of incontinence episodes per 24h.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone
Outcome: 2 Number of incontinence episodes per 24h
Study or subgroup ES + drug therapy Drug therapy alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abdelbary 2015 105 0.09 (0.28) 105 0.4 (0.6) 62.6 % -0.31 [ -0.44, -0.18 ]
Sancaktar 2010 20 0.9 (0.2) 18 1.8 (0.3) 37.4 % -0.90 [ -1.06, -0.74 ]
Total (95% CI) 125 123 100.0 % -0.53 [ -0.63, -0.43 ]
Heterogeneity: Chi2 = 31.15, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 10.37 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 7.3. Comparison 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone,
Outcome 3 Number of urgency episodes per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone
Outcome: 3 Number of urgency episodes per 24 hours
Study or subgroup ES + drug therapy Drug therapy alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Abdelbary 2015 105 2 (0.8) 105 4.7 (1.3) 53.2 % -2.70 [ -2.99, -2.41 ]
Sancaktar 2010 20 5.7 (0.6) 18 7.6 (0.9) 46.8 % -1.90 [ -2.39, -1.41 ]
Total (95% CI) 125 123 100.0 % -2.33 [ -3.11, -1.54 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 7.51, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
favours ES + drugs favours drugs
Analysis 7.4. Comparison 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone,
Outcome 4 Number of micturitions per 24 hours.
Review: Electrical stimulation with non-implanted electrodes for overactive bladder in adults
Comparison: 7 Electrical stimulation (ES) plus drug therapy versus drug therapy alone
Outcome: 4 Number of micturitions per 24 hours
Study or subgroup ES + drug therapy Drug therapy alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Abdelbary 2015 105 5 (0.8) 105 5 (0.8) 99.4 % 0.0 [ -0.22, 0.22 ]
Souto 2014 21 7.8 (5.43) 19 9.2 (3.41) 0.6 % -1.40 [ -4.18, 1.38 ]
Total (95% CI) 126 124 100.0 % -0.01 [ -0.22, 0.21 ]
Heterogeneity: Chi2 = 0.97, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Description of electrical stimulation interventions
Study Current Current
intensity
Pulse shape&
duration
Frequency
(Hz)
Duty cycle Electrodes Treatment
duration/
supervision
Aaronson
1995
Unclear Unclear Unclear Unclear Unclear Intravaginal Unclear
Abdelbary
2015
30-60 mA ac-
cording to pa-
tient tolerance
(mean 43 mA)
320 ms 20 Unclear Intravaginal Two 30-min
ses-
sions per week
for 12 weeks
Alves 2015 Unclear “Sen-
sory threshold,
acti-
vating superfi-
cial cutaneous
nerve fibers
with larger di-
ameter”
200 µs 10 Unclear Posterior tibial
nerve stimula-
tion
Two 30-min
ses-
sions per week
for 12 weeks
Alves 2015 Unclear “Mo-
tor threshold,
non-painful
contrac-
tion is induced
and the stimu-
lation can sim-
ply make pain
relief in the
same way that
sensory stimu-
lation level
(blocking acti-
vation of the
peripheral or
cental inhibi-
tion)”
200 µs 10 Unclear Posterior tibial
nerve stimula-
tion
Two 30-min
ses-
sions per week
for 12 weeks
Amaro 2006 Bipolar 0-100 mA ac-
cording to par-
ticipant toler-
ance
2 s on, 4 s off Intravaginal Three 20-min
sessions per
week on alter-
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Table 1. Description of electrical stimulation interventions (Continued)
nate days for 7
weeks
Arruda 2008 Biphasic 10-100mAac-
cording to par-
ticipant toler-
ance
1 ms intermit-
tent
10 Unclear Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
Barroso 2002 Biphasic 0-100 mA Asymmetric, 1
s rise time, sus-
tained for 5 s
and resting for
5 s
20 1 s rise time,
sustained
for 5s and rest-
ing for 5 s
Intravaginal Home
use: two 20-
min sessions
per day for 12
weeks
Bellette 2009 Unclear Unclear Unclear Unclear Unclear Transcuta-
neous
posterior tibial
nerve
Two 30-min
sessions
per week for 4
weeks
Berghmans
2002
Biphasic 0-100 mA Rect-
angular 200 µs
stochastic vari-
ation
4-10 Unclear Intravaginal Unclear
Boaretto 2011 Unclear Unclear 200 µs 10 Unclear Transcuta-
neous
posterior tibial
nerve
Twelve 30-
min sessions
Boaretto 2011 Unclear Unclear 500 µs 10 Unclear Intravaginal Twelve 30-
min sessions
Booth 2013 Unclear 0-50 mA 200 µs 10 Unclear Per-
cutaneous tib-
ial nerve stim-
ulation
Two 30-min
sessions
per week for 6
weeks
Bower 1998 Unclear Unclear 200 µs 150 Unclear Transcuta-
neous electri-
cal nerve stim-
ula-
tion - suprapu-
bic placement
Unclear
Bower 1998 Unclear Unclear 200 µs 10 Unclear Transcuta-
neous electri-
cal nerve stim-
ulation - sacral
placement
Unclear
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Table 1. Description of electrical stimulation interventions (Continued)
Brubaker
1997
Bipolar 0-100 mA Bipolar square
wave 0.1 µs
20 2 s on - 4 s off Intravaginal 20 min-
utes daily for 8
weeks
Olmo
Carmona
2013
Unclear 0-10 mA Square wave
320 µs
20 unclear Percutaneous
posterior tibial
nerve stimula-
tion
30 min once
a week for 12
weeks
Chen 2015 Bipolar Accord-
ing to partici-
pant tolerance
Continuous
bipolar square
wave 200 µs
20 Unclear Percutaneous
posterior tibial
nerve stimula-
tion - adhesive
skin electrodes
Unclear
Eftekhar 2014 Unclear Unclear Unclear Unclear Unclear Transcu-
taneous poste-
rior tib-
ial nerve stim-
ulation - “34
gauge
needle placed
5 cm near in-
ternal malleo-
lus”
30-min
sessions
Finazzi-Agrò
2010
Unclear 0-10 mA, ac-
cording to par-
ticipant toler-
ance
200 µs 20 Unclear Per-
cutaneous tib-
ial nerve stim-
ulation
Three 30-min
sessions
per week for 4
weeks
Firra 2013 Unclear Unclear
current, inten-
sity according
to participant
tolerance
Unclear 12.5 5 s on, 10 s off Intravaginal Fourteen 30-
min sessions
Franzén 2010 Unclear Accord-
ing to partici-
pant tolerance
Unclear 5-10 Intravaginal/
transanal
10 sessions: 1-
2 20-min ses-
sions per week
for 5-7 weeks
Gaspard 2014 Biphasic Unclear Biphasic rect-
angular 220 µs
10 20 s on, 4 s off Transcu-
taneous poste-
rior tib-
ial nerve stim-
ulation: exter-
nal electrode 5
cm above me-
One 30-min
session
per week for 9
weeks
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Table 1. Description of electrical stimulation interventions (Continued)
dial malleolus,
1 cm behind
the tibia. The
other electrode
on dorsum of
foot
Gonzalez
2015
Unclear Unclear Unclear Unclear Unclear Transcu-
taneous poste-
rior tib-
ial nerve stim-
ulation
Twice a week
for 6 weeks,
performed by
either physio-
ther-
apist or conti-
nence midwife
Kennelly
2011
Unclear Unclear Unclear Unclear Unclear VERV elec-
trode patches,
placed by the
par-
ticipant - exact
placement un-
clear
One patch per
week for 12
weeks
Kosilov 2013 Diadynamic 20-
40 mA, 50%-
75% intensity
Unclear 20 Unclear Active elec-
trode (50 cm
2 to 70 cm2)
above the pu-
bis, and a pas-
sive
electrode (150
cm2) in lum-
bosacral area
15
procedures ev-
ery other day
Lima 2011 Unclear Unclear Unclear Unclear Unclear Intravaginal Twelve 30-
min sessions
Lima 2011 Unclear Unclear Unclear Unclear Unclear Transcu-
taneous poste-
rior tib-
ial nerve stim-
ulation
Twelve 30-
min sessions
Lin 2004 Unclear 8-70 mA Unclear Unclear Unclear Vaginal/
anorectal
20-30 20-min
sessions
Lo 2003 Unclear Accord-
ing to partici-
pant tolerance
Unclear 0-100 Unclear Inter-
ferential ther-
apy. 2 anterior
flat electrodes
placed over
12 sessions:
first session 15
min, all others
30 min
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Table 1. Description of electrical stimulation interventions (Continued)
obturator fora-
men 1.5 cm
to 2 cm lat-
eral to symph-
ysis, two
posterior elec-
trodes placed
medial to is-
chial tuberosi-
ties either side
of anus
Lobel 1998 Unclear Unclear Unclear Unclear Unclear Intravaginal/
transanal
Once per week
Lobel 1998 Unclear Unclear Unclear Unclear Unclear Intravaginal/
transanal
Twice per
week
Manriquez
2013
Unclear Unclear Unclear Unclear Unclear Transcu-
taneous tibial
nerve stimula-
tion
Twice a week
with at least 48
hour intervals
for 12 weeks
Marques 2008 Biphasic Imme-
diately below
motor thresh-
old
200 µs 10 Unclear Transcuta-
neous electri-
cal nerve stim-
ula-
tion through 1
channel and 2
electrodes
Two 30-min
sessions
per week for 4
weeks
Monga 2011 Unclear Unclear Unclear Unclear Unclear Transdermal
amplitude-
modulated sig-
nal through a
patch applied
to the skin,
controlled by
wireless hand-
held remote
control
Patch worn for
4 weeks
Monteiro
2014
Unclear Below the
threshold that
causes motor
contraction
200 µs 10 Unclear Posterior tibial
nerve stimula-
tion with sur-
face
electrodes.
Negative elec-
trode on me-
30-min twice
weekly over 12
sessions (45
days)
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Table 1. Description of electrical stimulation interventions (Continued)
dial malleolus,
and the pos-
itive electrode
10 cm
above negative
electrode, also
on the medial
side. Rhyth-
mic flexion of
the second toe
dur-
ing the stim-
ulation deter-
mined the cor-
rect position
of the negative
electrode
Oldham 2013 Unclear Pre-
programmed
to increase in-
tensity over 24
s to reach ther-
apeu-
tic level and
switch off au-
tomatically af-
ter 30 min. All
devices same
level of stimu-
lation (average
in-
tensity consid-
ered comfort-
able and capa-
ble of produc-
ing contrac-
tions of pelvic
floor muscles)
Unclear During the 10
s “on time” the
device delivers
10 repeats of a
short high in-
tensity burst of
50Hz stimula-
tion immedi-
ately preceded
by a doublet
(125 Hz), su-
perimposed
on continuous
low frequency
2 Hz stimula-
tion
10 s on, 10 s
off
Intravagi-
nal, single-use
tampon-like
Pelviva device
One
disposable de-
vice per day
for 12 weeks
except during
menstruation
Orhan 2015 Unclear Unclear Unclear Unclear Unclear Percutaneous
posterior tibial
nerve stimula-
tion
Unclear
Peters 2009 Unclear Unclear Unclear Unclear Unclear Percu-
taneous tibial
nerve stimula-
tion: 34-gauge
One 30-min
ses-
sion per week
for 12 weeks
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Table 1. Description of electrical stimulation interventions (Continued)
needle slightly
cephalad to
medial malleo-
lus
Peters 2010 Unclear 0.5-9 mA Unclear 20 Unclear Per-
cutaneous tib-
ial nerve stim-
ulation:
34-gauge nee-
dle inserted at
60º angle 5
cmcephalad to
medial malleo-
lus, slightly
posterior
to tibia. Sur-
face electrode
placed on ip-
silateral calca-
neous
One 30-min
ses-
sion per week
for 12 weeks
Phillips 2012 Unclear Unclear Unclear Unclear Unclear Participant-
managed neu-
romodulation
system patch
Subject
placement ver-
sus investiga-
tor placement
Preyer 2007 Unclear Unclear Unclear Unclear Unclear Peripheral tib-
ial neurostim-
ulation
One 30-min
ses-
sion per week
for 12 weeks
Preyer 2015 Unclear Unclear Unclear Unclear Unclear Percutaneous
posterior tibial
nerve stimula-
tion
One 30-min
session
per week for 3
months
Sancaktar
2010
Unclear 0.5-10mA, ac-
cording to par-
ticipant toler-
ance
200 µs 20 Unclear Stoller afferent
neurostimula-
tion: 34-gauge
nee-
dle inserted at
30° angle 2 cm
to 3 cm supe-
rior-medial as-
pect of tibial
medial malleo-
lus along
posterior tibial
nerve trace
One 30-min
ses-
sion per week
for 12 weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Schmidt 2009 Biphasic Controlled by
participant ac-
cording to tol-
erance
300 µs Asymmetrical,
50
Unclear Intrav-
aginal: probe
with two 26
mm rings 40
mm apart
Unclear
Schreiner
2010
Unclear Unclear 200 µs 10 Unclear Transcu-
taneous tibial
nerve stimula-
tion
One 30 min
ses-
sion per week
for 12 weeks
Schreiner
2014
Unclear Unclear Unclear Unclear Unclear Transcu-
taneous poste-
rior tib-
ial nerve stim-
ulation
Unclear
Seth 2014 Unclear Unclear Unclear Unclear Unclear Transcuta-
neous: discrete
[sic], self-con-
tained,
portable de-
vice adhesive
to the skin
One 30 min
session per day
for 12 weeks
Seth 2014 Unclear Unclear Unclear Unclear Unclear Transcuta-
neous: discrete
[sic], self-con-
tained,
portable de-
vice adhesive
to the skin
One 30-min
ses-
sion per week
for 12 weeks
Shepherd
1984
Unclear Up to 40 v Unclear 10-50 Unclear Max-
imum perineal
stimulation:
Scott electrode
in vagina, large
indifferent
electrode un-
der buttocks
Single 20-min
session
Shepherd
1985
Unclear Unclear Unclear 10 Unclear Intravagi-
nal cushion at-
tached to stim-
ulator worn
around waist
Cushion worn
for 8 out of 24
h, day or night
according
to participant
preference
211Electrical stimulation with non-implanted electrodes for overactive bladder in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Description of electrical stimulation interventions (Continued)
Slovak 2015 Unclear Stim-
ulus intensity
just below that
which would
cause a motor
contraction of
toes/shoulder
muscles
Unclear Unclear Unclear Unilateral
posterior tibial
nerve stimula-
tion with con-
ven-
tional TENS
machine - elec-
trodes placed
above and be-
low the me-
dial malleolus
on the right
ankle
Unclear
Slovak 2015 Unclear Stim-
ulus intensity
just below that
which would
cause a motor
contraction of
toes/shoulder
muscles
Unclear Unclear Unclear Bilateral
posterior tibial
nerve stimula-
tion with con-
ven-
tional TENS
machine - elec-
trodes placed
above and be-
low the me-
dial malleolus
on both ankles
Unclear
Smith 1996 Unclear 5-25 mA Unclear Device uses
2 programmes
simultane-
ously: 12.5 Hz
and 50 Hz
5 s impulse Intravaginal Twice daily for
4 months.
Length of ses-
sion increased
monthly:
15, 30, 45, 60
minutes
Soomro 2001 Unclear Partic-
ipants asked to
control stimu-
lation
to achieve tick-
ling sensation
200 µs 20 Continuous Transcu-
taneous. 2 self-
adhesive pads
applied bilat-
erally over the
perianal region
(S2-S3
dermatome)
Up to 6
hours daily for
6 weeks
Sotelo 2011 Unclear Unclear Unclear Unclear Unclear Transdermal.
Carrier signal
and pulse en-
ve-
lope through
Patch
worn contin-
uously for 7
days
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Table 1. Description of electrical stimulation interventions (Continued)
patch applied
on skin over
spinal nerves
in lower back
Horizon-
tal placement
of electrode
patch near
sacral nerve
Sotelo 2011 Unclear Unclear Unclear Unclear Unclear Transdermal.
Carrier signal
and pulse en-
ve-
lope through
patch applied
on skin over
spinal nerves
in lower back
30° an-
gle placement
of electrode
patch near
sacral nerve
Patch
worn contin-
uously for 7
days
Souto 2014 Unclear Accord-
ing to partici-
pant tolerance
250 µs 10 Unclear Posterior tibial
nerve stimula-
tion. Sur-
face electrode
placed behind
media malleo-
lus and
another placed
10 cm above
first electrode
Two 30 min
ses-
sions per week
for 12 weeks
Spruijt 2003 Biphasic 0-100 mA, ac-
cording to par-
ticipant toler-
ance
100 µs 20 2 s contraction
time, duty cy-
cle 1-2 s
Intravaginal Three 30-min
ses-
sions per week
for 8 weeks. 5
min rest be-
tween each 15
min
Svihra 2002 Square 25 mA. 70%
of intensity of
maximal am-
plitude of reg-
istered
response from
Square im-
pulse 100 µs
1 Unclear Stoller afferent
neurostim-
ulation. Elec-
trodes placed
behind medial
One
30 min session
per week for 5
weeks
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Table 1. Description of electrical stimulation interventions (Continued)
abductor hal-
lucis muscle
ankle of left
lower extrem-
ity, cathode
placed proxi-
mally and an-
ode distally
Vahtera 1997 Unclear Accord-
ing to partici-
pant tolerance
Unclear 10 min of each
frequency, 3
min: 5-10 Hz,
10-50 Hz, 50
Hz
7 s on, 25 s off Intravaginal/
transanal
6 sessions over
two weeks
Vecchioli-
Scaldazza
2013
Unclear Unclear Unclear Unclear Unclear Per-
cutaneous tib-
ial nerve stim-
ulation
Two 30-min
sessions
per week for 6
weeks
Vohra 2002 Unclear 0-10 mA Unclear Unclear Unclear Percutaneous
posterior tibial
nerve stimula-
tion
One 30-min
ses-
sion per week
for 12 weeks
Walsh 2001 Unclear Unclear 200 ms 10 Unclear Transcuta-
neous neu-
rostimulation.
Electrode pads
affixed bilater-
ally to the skin
overlying S3
dermatomes
(junction
of buttock and
upper thigh)
Single session
Wang 2004 Biphasic Minimum 20-
63 mA, maxi-
mum
40-72 mA, ac-
cording to par-
ticipant toler-
ance
Biphasic sym-
metrical 400
µs
10 10 s on, 5 s off Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
Wang 2006 Biphasic Minimum 20-
63 mA, maxi-
mum
40-72 mA, ac-
cording to par-
ticipant toler-
ance
Biphasic sym-
metrical 400
µs
10 10 s on, 5 s off Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
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Table 1. Description of electrical stimulation interventions (Continued)
Wang 2009 Biphasic Minimum 20-
63 mA, maxi-
mum
40-72 mA, ac-
cording to par-
ticipant toler-
ance
Biphasic sym-
metrical 400
µs
10 10 s on, 5 s off Intravaginal Two 20-min
ses-
sions per week
for 12 weeks
Wise 1992 Unclear Unclear Unclear Unclear Unclear Intravaginal One
session per day
(at home) for 6
weeks
Wise 1993 Unclear 0-90 mA, ac-
cording to par-
ticipant toler-
ance
Unclear 20 Unclear Intravaginal One
session per day
(at home) for 6
weeks
Yamanishi
2000
Square 0-60 mA, ac-
cording to par-
ticipant toler-
ance
Square, 1 ms 10 Unclear Intravaginal
(women), sur-
face electrode
or anal plug
(men)
Sur-
face electrode
placed on dor-
sal part of pe-
nis. Anal elec-
trode bullet-
shaped, vagi-
nal plug cylin-
der-formed
with ring-
formed
electrodes
Two 15-min
sessions per
day for 4weeks
Yamanishi
2000
Square 0-60 mA, ac-
cording to par-
ticipant toler-
ance
Square, 1 ms 10 Unclear Intravaginal
(women), sur-
face electrode
or anal plug
(men)
Sur-
face electrode
placed on dor-
sal part of pe-
nis. Anal elec-
trode bullet-
shaped, vagi-
Single session
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Table 1. Description of electrical stimulation interventions (Continued)
nal plug cylin-
der-formed
with ring-
formed
electrodes
Table 2. Electrical stimulation (ES) versus no active treatment
Study Outcome ES (mean (SD/range), N
or n/N; if available)
No active treatment
(mean (SD), N
or n/N; if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
ity of life
Svihra 2002 Improvement in QoL
measured by Incontinence
Quality of Life Question-
naire, Behavioural Urge
Score and International
Prostate Symptom Score
5/9 0/9 RR 11.00 (95% CI 0.70 to
173.66)
Oldham 2013 ICI-Q score1 Median (range), N:
6 (0-17), 64
Median (range), N:
9 (3-18), 60
Not estimable
Secondary outcomes Secondary outcomes
Marques 2008 Daytime frequency NR NR Favours ES
P = 0.0001
Nocturia NR NR Favours ES
P = 0.0186
Monteiro 2014 Participants with noctur-
nal enuresis
45 days’ treatment: 0/12 45 days’ treatment: 2/12 Favours ES
RR 5.00 (95% CI 1.63 to
15.31)12 months’ follow-up: 0/
12
12 months’ follow-up: 2/
12
Participants with nocturia 45 days’ treatment: 5/12 45 days’ treatment: 9/12 RR 2.33 (95% CI 0.78 to
6.94)
12 months’ follow-up: 1/
12
12 months’ follow-up: 6/
12
Favours ES
RR 0.17 (95% CI 0.02 to
1.18)
Participants with increased
daytime frequency
45 days’ treatment: 3/12 45 days’ treatment: 11/12 Favours ES
RR 0.27 (95% CI 0.10 to
0.74)
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Table 2. Electrical stimulation (ES) versus no active treatment (Continued)
12 months’ follow-up: 0/
12
12 months’ follow-up: 9/
12
Favours ES
RR 0.05 (95% CI 0.00 to
0.81)
Results in bold are statistically significant
1Higher score = greater severity
Table 3. Electrical stimulation (ES) versus placebo/sham treatment
Study Outcome ES (mean (SD/range), N
or n/N; if available)
Placebo or sham treat-
ment
(mean (SD), N
or n/N; if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
quality of life
Booth 2013 ICIQ-SF score Median (IQR), N:
2 (0 to -6), 15
0 (-3 to 3), 13 P = 0.132
Participants with
improvement in ICIQ-SF
score
10/15 6/13 RR 1.44 (95% CI 0.73 to
2.87)
Bellette 2009 OAB-Q total score1 83.99 (16.99), 21 66.63 (25.06), 16 Favours ES
MD 17.36 (95% CI 3.09
to 31.63)
Finazzi-Agrò 2010 I-QoL score1 69.9 (65.8-73.3), 17 70.6 (62.2-79.1), 15 No evidence of a differ-
ence
Kennelly 2011 Change in OAB-Q score Median (IQR), N:
8.8 (1.6 to 20.0), 80
Median (IQR), N:
9.2 (-0.8 to 27.2), 83
P = 0.9918
Peters 2010 Change in OAB-Q score 36.7 (21.5), 101 29.2 (20.0), 102 Favours ES
MD 7.50 (1.79, 13.21)
Yamanishi 2000a QoL score2 1.6 (0.7), 37 2.2 (0.9), 31 Favours ES
MD -0.60 (95% CI -0.99
to -0.21)
Secondary outcomes: clinicians’ observations and other quantification of symptoms Secondary outcomes:
symptoms
Yamanishi 2000a Number of pads per day 0.8 (1.2), 37 1.1 (2.0), 31 MD -0.30 (95% CI -1.10
to 0.50)
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Table 3. Electrical stimulation (ES) versus placebo/sham treatment (Continued)
Other outcomes Other outcomes
Amaro 2006 Participants with reduc-
tion in analogue discom-
fort sensation
8/20 5/20 RR 1.60 (95% CI 0.63 to
4.05)
Participants with reduc-
tion in analogue wetness
sensation
6/20 5/20 RR 1.20 (95% CI 0.44 to
3.30)
Pelvic floor muscle
strength (cmH2O)
53.8 (18.6), 20 46.8 (12.5), 20 MD 7.00 (95% CI -2.82
to 16.82)
Yamanishi 2000a Urgency score2 1.7 (0.7), 37 sham ES: 2 (0.8), 31 MD -0.30 (95 CI -0.66 to
0.06)
Results in bold are statistically significant
1Lower score = greater severity
2Higher score = greater severity
Table 4. Electrical stimulation (ES) versus pelvic floor muscle training (PFMT)
Study Outcome ES (mean (SD/range), N or
n/N; if available)
PFMT (mean (SD), N or
n/N; if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
ity of life
Arruda 2008 Participants cured 14/21 12/21 RR 1.17 (95% CI 0.72 to
1.88)
Wang 2004 Participants with improve-
ment in UUI
9/18 13/34 RR 1.62 (95% CI 0.51 to
5.12)
King’s Health Question-
naire score1
180.08 (176.03), 35 50.27 (171.42), 34 Favours ES
MD 129.81 (95% CI 47.
83 to 211.79)
Secondary outcomes: clinicians’ observations and other quantification of symptoms Secondary outcomes:
symptoms
Arruda 2008 Incontinence episodes per
24 hours
7.9 (13.7), 21 7.8 (15.3), 21 MD 0.10 (95% CI -8.68 to
8.88)
Micturitions per 24 hours 7.9 (2.3), 21 71. (2.1), 21 MD 0.80 (95% CI -0.53 to
2.13)
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Table 4. Electrical stimulation (ES) versus pelvic floor muscle training (PFMT) (Continued)
Nocturia episodes per night 1.2 (1.3), 21 1 (1.1), 21 MD 0.20 (95% CI -0.53 to
0.93)
Number of pads per day 0.9 (1.7), 21 0.8 (1.3), 21 MD 0.10 (95% CI -0.82 to
1.02)
1Higher score = greater QoL
Table 5. Electrical stimulation (ES) versus pelvic floor muscle training (PFMT) plus biofeedback
Study Outcome ES (mean (SD/range), N or
n/N; if available)
PFMT plus biofeedback
(mean (SD), N or n/N; if
available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
ity of life
Wang 2004 Participants with improve-
ment in UUI
9/17 17/34 RR 1.06 (95%CI 0.60 to 1.
85)
King’s Health Question-
naire score1
180.08 (176.03), 35 185.86 (176.57), 34 MD -5.78 (95% CI -88.99
to 77.43)
1Higher score = greater QoL
Table 6. Electrical stimulation (ES) versus laseropuncture/electro-acupuncture
Study Outcome ES (mean (SD/range), N
or n/N; if available)
Laseropuncture/elec-
tro-acupuncture (mean
(SD), N or n/N; if avail-
able)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
quality of life
Olmo Carmona 2013 Bladder Self-Assessment
Questionnaire score
5.18 (2.56), 11 7.27 (2.24), 11 Favours ES
MD -2.09 (95% CI -4.
10 to -0.08)
Secondary outcomes: clinicians’ observations and other quantification of symptoms Secondary outcomes:
symptoms
Olmo Carmona 2013 Micturitions per day 8 (1.73), 11 7.73 (1.67), 11 MD 0.27 (95% CI-1.15
to 1.69)
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Table 6. Electrical stimulation (ES) versus laseropuncture/electro-acupuncture (Continued)
Nocturia episodes per
night
1.09 (1.51), 11 2.09 (1.92), 11 MD -1.00 (95% CI -2.
44 to 0.44)
1Higher score = greater severity
Table 7. Electrical stimulation (ES) versus drug therapy
Study Outcome ES (mean (SD/range), N
or n/N; if available)
Comparator
(mean (SD), N or n/N;
if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
quality of life
Aaronson 1995 Participants cured or im-
proved
69% (N not reported) Probanthine 50% (N
not reported)
Not estimable
Chen 2015 I-QoL score1 25.2 (1.0), 50 Solifenacin succinate:
24.2 (1.0), 48
MD 1.00 (95% CI 0.60
to 1.40)
Vecchioli-Scaldazza
2013
OAB-Q score2 2.9 (0.9), 14 Solifenacin succinate: 3.
1 (1.1), 14
MD -0.20 (95% CI -0.
94 to 0.54)
Patient Global Impres-
sion of Improvement
score2
2.1 (0.7), 14 Solifenacin succinate: 2.
9 (1.1), 14
Favours ES
MD -0.80 (95% CI -1.
48 to -0.12)
Participant Perception of
Intensity of Urgency
Scale score2
2.1 (0.9), 14 Solifenacin succinate: 2.
7 (1.2), 14
MD -0.60 (95% CI -1.
39 to 0.19)
Abdelbary 2015 ES Oestrogen cream Favours ES
MD -2.20 (95% CI -2.
71 to -1.69)
Favours ES
MD -2.00 (95% CI -2.
50 to -1.50)
MD 1.60 [0.91, 2.29]
QoL score2 (instrument
not reported)
End of treatment: 2.8 (2)
, 105
3 months: 4 (1.7), 105
6 months: 7.6 (3), 105
End of treatment: 5 (1.
8), 105
3 months: 6 (2), 105
6 months: 6 (2), 105
Secondary outcomes: clinicians’ observations and other quantification of symptoms Secondary outcomes:
symptoms
ES Oestrogen cream
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Table 7. Electrical stimulation (ES) versus drug therapy (Continued)
Abdelbary 2015 Voids per 24 hours End of treatment: 4.7 (0.
8), 105
3 months: 5.0 (1.0), 105
6 months: 6.6 (1.5), 105
End of treatment:
5.0 (0.9), 105
3 months: 5.3 (0.9), 105
6 months: 5.0 (0.8), 105
Favours ES
MD (-0.30 (95% CI -0.
56 to -0.04)
Favours ES
MD -0.30 (95% CI -0.
53 to -0.07)
Favours oestrogen
cream
MD1.60 (95%CI 1.27
to 1.93)
Nocturia episodes per
night
End of treatment: 0.9 (0.
7), 105
3 months: 1.1 (0.9), 105
6 months: 2.2 (0.9), 105
End of treatment: 1.4 (0.
8), 105
3 months: 1.5 (0.8), 105
6 months: 5.0 (0.8), 105
Favours ES
MD -0.50 (95% CI -0.
70 to -0.30)
Favours ES
MD -0.40 (95% CI -0.
63 to -0.17)
MD -2.80 (95% CI -3.
03 to -2.57)
Incontinence episodes End of treatment: 0.1 (0.
3), 105
3 months: 0.1 (0.3), 105
6 months: 0.4 (0.6), 105
End of treatment: 0.4 (0.
6), 105
3 months: 0.5 (0.6), 105
6 months: 0.4 (0.6), 105
Favours ES
MD -0.30 (95% CI -0.
43 to -0.17)
Favours ES
-0.40 (95% CI -0.53 to
-0.27)
0.00 [-0.16, 0.16]
Urgency episodes End of treatment: 2 (0.
7), 105
3 months: 2.7 (1.0), 105
6 months: 4.7 (1.3), 105
End of treatment: 4 (1.
3), 105
3 months: 4.5 (1.5), 105
6 months: 4 (1.3), 105
-3.00 [-3.28, -2.72]
-1.80 [-2.14, -1.46]0.
70 [0.35, 1.05]
Arruda 2008 Number of pads per day 0.9 (1.8), 21 Oxybutynin: 0.9 (1.5),
22
MD0.00 (95%CI -0.96
to 0.96)
Souto 2014 Participants with noc-
turia
2/18 Oxybutynin: 3/19 RR 0.70 (95% CI 0.13
to 3.73)
Results in bold are statistically significant
1Lower score = greater severity
2Higher score = greater severity
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Table 8. Electrical stimulation (ES) plus pelvic floor muscle training (PFMT) versus PFMT alone
Study Outcome ES plus PFMT (mean
(SD/range), N or n/N; if
available)
PFMT (mean (SD), N or
n/N; if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
ity of life
Gaspard 2014 SF-Qualiveen1 Median (IQR), N:
9 weeks: 1.000 (0.656, 1.
719), 16
6 months: 1.313 (0.687, 1.
625), 16.
Median (IQR), N:
9 weeks: 1.375 (0.625, 2.
188)
6 months: 1.500 (0.344, 2.
094), 15
Not estimable
Firra 2013 York Incontinence Percep-
tion Scale2
41.2 (10.2), 6 47 (5.5), 6 MD -0.65 (95% CI -1.83
to 0.52)
Schreiner 2010 Participants with improve-
ment in UUI
19/25 7/26 Favours ES plus PFMT
RR 2.82 (95 CI 1.44 to 5.
52)
ICIQ-SF score1 7.9 (4.5), 25 10.6 (4.4), 26 Favours ES plus PFMT
MD -2.70 (95% CI -5.14
to -0.26)
Secondary outcomes Secondary outcomes
Schreiner 2010 Nocturia episodes per
night
1.3 (1.5), 25 2.4 (1.3), 26 Favours ES plus PFMT
MD -1.10 (95% CI -1.87
to -0.33)
Adverse effects 0/25 0/26 Not estimable
Other outcomes Other outcomes
Firra 2013 Pelvic floor muscle
strength (cmH2O)
27 (16), 6 47.2 (22.7), 6 MD -20.20 (95% CI -42.
42 to 2.02)
Results in bold are statistically significant
1Higher score = greater severity
2Higher score = less severity
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Table 9. Electrical stimulation (ES) plus behavioural therapy versus behavioural therapy alone
Study Outcome ES plus behavioural ther-
apy (mean (SD/range), N
or n/N; if available)
Behavioural
therapy (mean (SD), N or
n/N; if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
ity of life
Gonzalez 2015 OAB-Q score1 100.81 (41.5), 31 127.71 (40.64), 37 Favours ES plus
behavioural therapy
MD -26.90 (95% CI -46.
52 to -7.28)
Incontinence Severity In-
dex score1
5.15 (3.23), 31 7.38 (4.00), 37 Favours ES plus
behavioural therapy
MD -26.90, 95% CI -46.
52 to -7.28
Results in bold are statistically significant
1Higher score = greater severity
Table 10. Electrical stimulation (ES) plus drug therapy versus drug therapy alone
Study Outcome ES plus drugs (mean (SD/
range), N or n/N; if avail-
able)
Drugs (mean (SD), N or
n/N; if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
ity of life
Sancaktar 2010 IIQ-7 score1 ES plus tolterodine: 9.0 (0.
8), 20
Tolterodine: 11.2 (2.7),
18.
Favours ES plus toltero-
dine
MD -2.20 (95% CI -3.50
to -0.90
Abdelbary 2015 ES plus oestrogen cream: Oestrogen cream:
QoL score1 (instrument
not reported)
End of treatment: 2.9 (2.
2), 105.
3 months: 1.6 (0.9), 105.
6 months: 2 (0.8), 105.
End of treatment: 5 (1.8),
105
3 months: 6 (2), 105
6 months: 6 (2), 105
MD-2.10 (95%CI -2.64,
-1.56]
MD -4.40 (95% CI -4.82
to -3.98)
MD -4.00 (95% CI -4.41
to -3.59)
Secondary outcomes Secondary outcomes
Abdelbary 2015 ES plus oestrogen cream: Oestrogen cream:
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Table 10. Electrical stimulation (ES) plus drug therapy versus drug therapy alone (Continued)
Voids per day End of treatment:
5 (0.8), 105.
3 months: 5 (0.8), 105.
6 months: 5 (0.8), 105.
End of treatment:
5.0 (0.9), 105
3 months: 5.3 (0.9), 105
6 months: 5.0 (0.8), 105
MD 0.00 (95% CI -0.23
to 0.23)
MD -0.30 (95% CI -0.53
to -0.07)
MD 0.00 (95% CI -0.22
to 0.22)
Nocturia episodes per
night
End of treatment:
0.5 (0.5), 105
3 months: 1 (0.9), 105
6 months: 1.5 (0.8), 105
End of treatment:
1.4 (0.8), 105
3 months: 1.5 (0.5), 105
6 months: 5 (0.8), 105
MD -0.90 (95% CO -1.
08 to -0.72)
MD -0.50 (95% CI -0.70
to -0.30)
MD -3.50 (95% CI -3.72
to -3.28)
Incontinence episodes per
24 hours
End of treatment: 1.4 (0.
7), 105
3 months: 0.09 (0.28),
105.
6 months: 0.09 (0.28),
105.
End of treatment: 0.4 (0.
6), 105
3 months: 0.5 (0.6), 105
6 months: 0.4 (0.6), 105
MD 1.00 (95% CI 0.82 to
1.18)
MD -0.41 (95% CI -0.54
to -0.28)
MD -0.31 (95% CI -0.44
to -0.18)
Urgency episodes per 24
hours
End of treatment: 1.4 (0.
7), 105
3 months: 1.6 (0.9), 105
6 months: 2 (0.8), 105
End of treatment: 4 (1.3),
105
3 months: 4.5 (1.5), 105
6 months: 4 (1.3), 105
MD -2.60 (95% CI -2.88
to -2.32)
MD -2.90 (95% CI -3.23
to -2.57)
MD -2.00 (95% CI -2.29
to -1.71)
Sancaktar 2010 Adverse effects ES plus tolterodine: 1/20 Tolterodine: 2/18 RR 0.45 (95% CI 0.04 to
4.55)
Results in bold are statistically significant
1Higher score = greater severity
Table 11. Electrical stimulation (ES) versus ES
Study Outcome ES A (mean (SD/range),
N or n/N; if available)
ES B (mean (SD), N or n/
N; if available)
Result
Primary outcomes: cure/improvement of OAB symptoms; OAB-related quality of life Primary outcomes:
quality of life
Alves 2015 ICIQ-OAB score1 Tibial nerve stimulation:
sensory threshold acti-
vating superficial cuta-
neous nerve fibres with
larger diameter: 4.46 (2.
Tibial nerve stimulation:
motor threshold, non-
painful contraction is in-
duced: 4.53 (3.07), 13
MD -0.07 (95% CI -2.21
to 2.07)
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Table 11. Electrical stimulation (ES) versus ES (Continued)
66), 15
Finazzi-Agrò 2005 Success = > 50% reduc-
tion in micturitions/24
hours
OR
If incontinent, success >
50% reduction in UI
episodes/24 hours
ES once a week: 11/17
(4/11 incontinent partici-
pants)
ES 3 times per week: 12/
18 (5/11 incontinent par-
ticipants)
RR 0.97 (95% CI 0.60 to
1.57)
Incontinence partic-
ipants: RR 0.80 (95% CI
0.29 to 2.21)
I-QoL score2 ES once a week (median,
range, N): 77 (35-100),
17
ES 3 times a week (me-
dian, range, N): 78 (33-
100), 18
Not estimable
Lobel 1998 Participants with im-
provement in symptoms
ES once a week: 100% ES twice a week: 100% Not estimable
Participants satis-
fied enough to request no
further treatment
24% (9/37) Not es-
timable, not reported per
treatment group
Secondary outcomes: clinicians’ observations and other quantification of symptoms Secondary outcomes:
symptoms
Finazzi-Agrò 2005 Adverse effects ES once a week: 0/17 ES 3 times per week: 0/18 Not estimable
Subjective improvement
after 6-8 sessions
ES once a week: 17/17 ES 3 times a week: 18/18 Not estimable
Incontinence episodes per
24 hours
ES once a week (median,
range, N): 1 (0-3), 11
ES 3 times a week (me-
dian, range, N): 1 (0-3),
11
Not estimable
Micuturitions per 24
hours
ES once a week (median,
range, N): 8 (5-15), 17
ES 3 times a week (me-
dian, range, N): 8 (6-18),
18
Not estimable
SF-36 score ES once a week (median,
range, N): 62 (24-81), 17
ES 3 times per week (me-
dian, range, N): 62 (25-
80), 18
Not estimable
Alves 2015 UUI episodes per 24
hours
Tibial nerve stimulation:
sensory threshold activat-
ing superficial cutaneous
nerve fibres with larger di-
ameter: 0.33 (0.57), 15
Tibial nerve stimulation:
motor threshold, non-
painful contraction is in-
duced: 0.84 (1.39), 13
MD -0.51 (95% CI -1.32
to 0.30)
Urgency episodes per 24
hours
Tibial nerve stimulation:
sensory threshold activat-
Tibial nerve stimulation:
motor threshold, non-
MD 0.21 (95% CI -0.39
to 0.81)
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Table 11. Electrical stimulation (ES) versus ES (Continued)
ing superficial cutaneous
nerve fibres with larger di-
ameter: 0.79 (0.97), 15
painful contraction is in-
duced: 0.58 (0.65), 13
Micturitions per 24 hours Tibial nerve stimulation:
sensory threshold activat-
ing superficial cutaneous
nerve fibres with larger di-
ameter: 8.33 (2.52), 15
Tibial nerve stimulation:
motor threshold, non-
painful contraction is in-
duced: 7.89 (2.64), 13
MD 0.44 (95% CI -1.48
to 2.36)
Nocturia episodes per
night
Tibial nerve stimulation:
sensory threshold activat-
ing superficial cutaneous
nerve fibres with larger di-
ameter: 1.26 (1.21), 15
Tibial nerve stimulation:
motor threshold, non-
painful contraction is in-
duced: 1.05 (1.01), 13
MD 0.21 (95% CI -0.61
to 1.03)
Bower 1998 Maximumcystometric ca-
pacity
150 Hz: 351 (144), 16 10 Hz: 305 (146), 16 MD 46.00 (95% CI -54.
48 to 146.48)
Volume at first desire to
void
150 Hz: 208.5 (132), 16 10 Hz: 154 (61), 16 MD 54.50 (95% CI -16.
75 to 125.75)
Other outcomes Other outcomes
Boaretto 2011 Participants satisfied 200 µs pulse width: 17/22 500 µs pulse width: 11/16 RR 1.12 (95% CI 0.75 to
1.68)
1Higher score = greater severity
2Lower score = greater severity
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Incontinence Specialised Register
The terms that were used to search the Cochrane Incontinence Specialised Register are given below:
(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND ({INTVENT.PHYS.ELECTSTIM*}) AND ({TOPIC.URINE.INCON*} OR
{TOPIC.URINE.OVERACTIVE*})
All searches were of the keyword field of Reference Manager 2012. Date of last search 10 December 2015.
Other searches
Some of the review authors (OLFG, RE, MOG, AK, JLA) also searched the following databases, details of the searches are below:
PubMed (inception to December 2013) andCENTRAL (2013, Issue 12 ) were searched on 12 December 2013 using the following
search terms:
((Overactive Bladder)OR (OveractiveUrinary Bladder)OR (OveractiveDetrusor)OR (OveractiveDetrusor Function)ORbladderOR
(urinary bladder) OR (unstable bladder) OR (urge incontinence) OR (inhibits bladder) OR (Urinary Reflex Incontinence) OR (Urinary
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Urge Incontinence) OR (Urge Incontinence) OR (Urinary Bladder Disease) OR (Urinary Bladder Diseases) OR (Bladder Diseases) OR
(Bladder Disease)) AND ((Electrical Stimulation) OR (Electrical Stimulations) OR (Electric Stimulations) OR (Electric Stimulation)
OR (Electric Stimulation Therapy)OR (Therapeutic Electrical Stimulation) OR ElectrotherapyOR (Therapeutic Electric Stimulation)
OR (Electrical Stimulation Therapy) OR (Transcutaneous Electrical Stimulation) OR (Percutaneous Electric Nerve Stimulation) OR
(Percutaneous Electrical Nerve Stimulation) OR (Transdermal Electrostimulation) OR (Transcutaneous Electrical Nerve Stimulation)
OR (Transcutaneous Nerve Stimulation) OR (Transcutaneous Electric Stimulation) OR TENS OR Electroanalgesia OR (Analgesic
Cutaneous Electrostimulation))
Embase on OVID SP (from 1980 onwards) (searched on 12 December 2013)
The search strategy that was be used in Embase is given below. The RCT terms (lines 1 and 2) are those recommended by Lefebvre 2011.
The search was limited to those records added to Embase from January 2010 onwards as earlier trials are included in the Specialised
Register search of CENTRAL.
1. (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$
or allocat$ or volunteer$).tw.
2. (crossover-procedure or double-blind procedure or randomised controlled trial or single-blind procedure).sh.
3. 1 or 2
4. urine incontinence/ or mixed incontinence/ or stress incontinence/ or urge incontinence/
5. overactive bladder/
6. (Detrusor$ or bladder$ or incontinen$ or continen$).tw.
7. 4 or 5 or 6
8. (Electric$ Stimulation$ or Electric Stimulation or Electrotherap$ or TENS or Electroanalgesia or electrostimulation$ or nerve
stimulation$).tw.
9. electrostimulation/
10. electrostimulation therapy/
11. transcutaneous nerve stimulation/
12. 8 or 9 or 10 or 11
13. 3 and 7 and 12
14. 2010$.em.
15. 2011$.em.
16. 2012$.em.
17. 2013$.em.
18. 14 or 15 or 16 or 17
19. 13 and 18
LILACS (on the Virtual Health Library/Bireme) (from 1982 to December 2013) (searched on 12 December 2013).
The terms that were used to search LILACS are given below. The RCT terms are those developed by Castro and colleagues (Castro
1997; Castro 1999).
(Detrusor$ OR bladder$ OR incontinen$ OR continen$) [Words]
AND
((Electric$ Stimulation$) OR (Electric Stimulation) OR Electrotherap$ OR TENS OR Electroanalgesia OR electrostimulation$ OR
(nerve stimulation$)) [Words]
(nb for some reason if remove (electric stimulation) it retrieves less articles!!!)
((Pt randomised controlled trial OR Pt controlled clinical trial OR Mh randomised controlled trials OR Mh random allocation OR
Mh
double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical
trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$))
OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR
Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) ORMh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR
Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) ORMh research design) ANDNOT (Ct animal ANDNOT (Ct human and
Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR
Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal))) [Words]
Field = words
Ongoing clinical trials were sought by searching the clinical trials registration sites ClinicalTrials.gov and WHO ICTRP using the
search term: overactive bladder. The date of the most recent search was 12 December 2013.
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WH A T ’ S N E W
Last assessed as up-to-date: 10 December 2015.
Date Event Description
10 February 2017 Amended Minor amendment to results section 3 i) - we moved participant satisfaction under its own heading
as it had got left in with the outcome above it
H I S T O R Y
Protocol first published: Issue 9, 2012
Review first published: Issue 4, 2016
Date Event Description
29 November 2016 New citation required and conclusions have changed For this first update of this review the main outcomes
were reframed to: perception of cure or cure/improve-
ment. The searchwas updated and 12new studies were
included. A brief economic commentary has also been
added. The conclusions have changed
9 September 2015 New citation required and minor changes The protocol has been amended.
9 September 2015 Amended The protocol has been amended.
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: Joao Luiz Amaro (JLA)
Co-ordinating the review: JLA, Regina El Dib (RED), Fiona Stewart (FS)
Undertaking manual searches: Luís Felipe Orsi Gameiro (LFOG)
Screening search results: LFOG, FS, Monica Orsi Gameiro (MOG)
Organising retrieval of papers: LFOG
Screening retrieved papers against inclusion criteria: LFOG, FS, JLA, MOG, and RED
Appraising quality of papers: FS, LFOG, JLA, MOG, and RED
Abstracting data from papers: FS, LFOG, RED
Writing to authors of papers for additional information: FS, LFOG and Anil Kapoor (AK)
Providing additional data about papers: LFOG, MOG, AK, JLA
Obtaining and screening data on unpublished studies: LFOG
Data management for the review: FS, LFOG, JLA, MOG and RED
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Data entry: FS, LFOG and RED
Statistical analysis using RevMan 2014: FS, LFOG, JLA, MOG, and RED
Other statistical analysis not using RevMan 2014: RED and AK
Interpretation of data: FS, LFOG, RED, MOG, AK, JLA
Statistical inferences: FS, LFOG, RED, MOG, AK, JLA
Writing the review: FS, LFOG, RED, MOG, AK, JLA
Guarantor for the review: RED
Reading and checking review before submission: FS, LFOG, RED, MOG, AK, JLA
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Several aspects of the methods specified in the protocol were changed when conducting the review, partly due to practical considerations
but mostly in response to advice from clinicians and methodologists.
Data collection and analysis
Time constraints and the large number of trials identifiedmade it unfeasible to carry out the planned independent double data extraction
and risk of bias assessment; instead, data extraction and risk of bias assessment were checked by a second reviewer.
Comparators
Electrical stimulation versus no active treatment, placebo or sham treatment: between the protocol and review stages it became apparent
that it was not appropriate to treat these three comparators as one comparator. Placebo and sham treatment were considered similar
enough to be grouped as one comparator while no active treatment was treated as an entirely separate comparator.
Comparison 6: ES plus another treatment versus no active treatment, placebo or sham treatment. Between publishing the protocol
and conducting the review it became apparent that this comparison does not help to answer the primary research question of the
effectiveness of electrical stimulation compared to other treatments because we would be unable to isolate the effects of ES from those
of the other treatment under investigation.
Types of outcomes
Data relating to the following outcome, which was not a pre-specified outcome, were reported in the review:
• Number of participants satisfied with treatment
The following pre-specified secondary outcomes were no longer considered to be clinically relevant and were not included in the review.
• Pad tests
• Number of participants with objectively measured incontinence (such as observation of leakage, leakage observed at
urodynamics study)
• Number of participants with detrusor overactivity observed at urodynamic study
• Bladder capacity measured by urodynamic study
Data analysis
We did not use standardised mean difference to combine trials that measured the same outcome with different methods.
We did not identify sufficient data to carry out the planned subgroup analyses:
• trials in people with OAB and/or UUI versus those with OAB, UUI and/or MUI; and
• trials in people with idiopathic OAB versus neurogenic OAB.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Electric Stimulation Therapy [instrumentation; ∗methods]; Electrodes; Pelvic Floor; Randomized Controlled Trials as Topic; Urinary
Bladder, Overactive [∗therapy]; Urinary Incontinence, Urge [∗therapy]
MeSH check words
Adult; Humans
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